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The liver is the second largest organ of the body after the skin, and is divided in two lobes, 
which are surrounded by connective tissue, the Glisson's capsule. The liver contains a 
variety of cell types. The majority of liver cells are parenchymal cells or hepatocytes. 
Hepatocytes require mutual contact to coordinate their physiological functions. Therefore, 
hepatocytes are positioned in plates, forming a radius around a hepatic venule (Fig 1 ). The 
plate of hepatocytes connects at least at two sides to 
sinusoids via the space of Disse. A sinusoid consists 
of endothelial cells, Kupffer cells and stellate or fat­
storing cells, and transports blood from the periphery 
of the liver lobule to the hepatic vein. Sinusoidal 
endothelial cells are a specific type of fenestrated 
�'-----··" endothelial cells, which line the sinusoids of the liver. 
In addition, these endothelial cells are antigen­
presenting cells involved in the immune response. 
Kupffer cells are part of the host defense system, and 
have a strong phagocytotic activity, removing large 
particles in particular. Furthermore, Kupffer cells are 
an important source of inflammatory mediators during 
infection and inflammation. Hepatic stellate cells are 
situated in the space of Oisse. Stellate cells have two 
functions: 1) storage of vitamin A in cytoplasmic lipid 
droplets, 2) production of extracellular matrix, in 
particular collagen type I (1, 2). 
Figure 1. Schematic representation of the liver 
Bile canaliculi are located between adjacent hepatocytes, forming a network within the 
hepatocyte plates. Bile is transported via the canals of Hering and interlobular ducts into the 
extrahepatic bile duct and common bile duct system. This network of branching ducts is 
called the biliary tree. Cholangiocytes, the epithelial cells of the bile duct, modify bile by 
secreting a hydrogen carbonate-rich fluid. They are also involved in bile acid recycling in the 
cholehepatic shunt pathway (1-3). 
The various functions of the liver, executed mostly by hepatocytes, include metabolism of 
(toxic) compounds and drugs, bile production and secretion, (plasma) protein and lipid 
synthesis, metabolic function e.g. gluconeogenesis and subsequent storage of metabolites 
(2). 
Bile formation and the enterohepatic circulation 
Bile is composed mainly of water (80%). Bile contains bile acids, phospholipids, cholesterol, 
glutathione (conjugates) and metabolites like bilirubin. Bile acids are synthesized in the liver 
and actively secreted into the bile canaliculi. Bile acids are conjugated to glycine or taurine in 
the liver for efficient transmembrane transport in the enterohepatic circulation. After passage 
through the small intestine, the majority of bile acids (90%) are efficiently reabsorbed at the 
terminal ileum and the remainder of bile acids is lost via the feces. This loss of bile acids is 
compensated by the de novo synthesis from cholesterol in hepatocytes producing primary 
bile acids. Two pathways for bile acid synthesis exist: 1. the neutral or classical pathway, 2. 
the acidic or alternative pathway, both yielding cholic acid (CA) and chenodeoxycholic acid 
(COCA). The majority of the de novo synthesized bile acids are produced via the neutral 
pathway. Both pathways require specific members of the cytochrome P450 (Cyp) family of 
enzymes for bile acid synthesis. In humans, the bile acid pool consists for almost one half of 
CA, and for one third of COCA. The primary bile acids are converted by bacteria in the 
intestines into the secondary bile acids deoxycholic acid (OCA) and lithocholic acid (LCA; 1, 
2, 4, 5). 
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The enterohepatic circulation is the permanent shuttling of bile acids between the liver and 
the intestine (Fig 2). Hepatocytes take up bile acids (BA) and organic anions (OA) from the 
portal blood at the basolateral (or sinusoidal) membrane via members of two transporter 
families: 1. Na•ttaurocholate cotransporting polypeptide (NTCP), a member of the solute 
carrier family (SLC10), 2. organic anion transporting polypeptides (OATPs), members of the 
solute carrier organic anion transporter family (SLCO). NTCP is a sodium-dependent 
transporter, requiring a sodium gradient for the exchange of one bile acid for two sodium 
ions, and is highly specific for conjugated primary bile acids. OATPs function as sodium­
independent transporters of unconjugated bile acids and organic anions. Inside the 
hepatocyte, bile acids are transferred from the 
basolateral to the canalicular membrane via either 
intracellular trafficking or vesicle-mediated trafficking. 
Bile acid secretion into bile at the canalicular (or apical) 
membrane requires ATP-binding cassette (ABC) 
transporters. The bile salt export pump (BSEP) is the 
major bile acid exporter, which transports univalent bile 
salts. The multidrug resistance-associated protein 
(MRP) type 2 is the primary transporter for organic 
anions like bilirubin glucuronides and glutathione 
conjugates, but is also able to excrete sulphated and 
glucuronidated bile acids. The transport of bile acids 
into bile is very critical for the enterohepatic circulation, 
being the rate-limiting step in bile formation and 
excretion by hepatocytes (4-8). 
11A 
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Figure 2. Enterohepatic circulation 
Bile acid secretion into bile influences the vesicular transport of free cholesterol and 
phosphatidylcholine. Multidrug-resistance (MDR) protein type 3 (Mdr2 in rodents) flips 
phospholipids from the inner to the outer leaflet of the canalicular membrane, and is 
responsible for the delivery of phosphatidylcholine to bile. Cholesterol is excreted into bile by 
the heterodimeric ABC transporter ABCG5 and ABCG8. In this way, mixed micelles are 
formed consisting of bile acids, phosphatidylcholine and cholesterol, which are stored in the 
gallbladder (4-9). 
Bile passes the biliary tree, where exchange of organic anions and proteins by 
cholangiocytes takes place, thus altering the composition of bile. The biliary tree is also the 
first place of bile acid absorption. Cholangiocytes in the bile duct actively absorb bile acids 
and shuttle them back to hepatocytes for re-excretion. This route is known as the 
cholehepatic shunt pathway. Therefore, cholangiocytes express the SLC10 member, apical 
sodium-dependent bile acid transporter (ASST) at the canalicular membrane, and MDR3, t­
ASBT and the heteromeric organic solute transporters (Ost) a and [3 at the basolateral 
membrane. Inside cholangiocytes, transcellular bile acid transport is achieved by the ileal 
bile acid binding protein, IBABP (4, 5, 8, 9). 
After passage through the biliary tree, bile enters the gallbladder. In response to food intake, 
the gallbladder contracts and bile is released into the small intestine. The absorption of bile 
acids in the ileum is accomplished by ASST in the enterocytes. Bile acids are then 
transferred intracellularly to the basolateral area by IBABP for secretion into the portal 
circulation by Osta/[3. In the portal blood, bile acids are bound to albumin and lipoproteins. 
Due to a conformational change of albumin in the proximity of the basolateral membrane of 
hepatocytes are bile acids released from albumin. Finally, hepatocytes extract the bile acids 
from the portal blood via NTCP and OATPs. The majority of conjugated bile acids are 
absorbed during one passage through the liver. Additional bile acid transporters exist that 
come into play when the enterohepatic circulation is not functioning properly. MRP3, like 
NTCP and OATPs, is located in the basolateral membrane of hepatocytes. However, MRP3 
is involved in the reverse transport of bile acids, thus secreting bile acids and organic anions 
9 
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from the hepatocyte into the sinusoids (4, 5). The homeostasis of bile acids, cholesterol and 
triglycerides is regulated by members of the nuclear hormone receptor family such as 
farnesoid X receptor (FXR), liver X receptor (LXR) and pregnane X receptor (PXR). Bile 
acids directly bind to these nuclear receptors, which regulate the activity of hepatic 
transporter proteins and Gyp-enzymes involved in the de novo bile acid synthesis and 
metabolism (sulphation, glucuronidation) of bile acids. FXR is known to regulate bile acid 
synthesis and transport, LXR is mainly involved in cholesterol homeostasis and PXR 
regulates enzymes involved in the conjugation of bile acids. Hence, bile acid binding to FXR 
results in down-regulation of NTCP and ASBT, while BSEP, MRP2, IBABP and Osta/� are 
up-regulated (4, 5, 8). 
Bile has multiple functions. Cholesterol is removed through the de novo synthesis of bile 
acids in the liver, and via the incorporation in mixed micelles. In the intestine bile is, also via 
the mixed micelles, essential for the absorption of lipids, cholesterol and lipid-soluble 
vitamins. In addition, bile acids activate signaling pathways involved in the electrolyte 
homeostasis and apoptosis in the epithelium of intestine and colon. Thus, bile and bile 
constituents are key players in bile formation and in the homeostasis of bile, lipids and 
cholesterol (1, 2, 4-9). 
Cell death 
Disturbances of bile homeostasis can lead to cell injury and cell death, culminating in loss of 
organ (liver) function and eventually organ (liver) failure. Cell death can occur in at least two 
forms: apoptosis and necrosis, although intermediary forms (aponecrosis) and additional 
types of cell death (autophagy, entosis) have been reported. 
Apoptosis, or programmed cell death, is an energy-dependent process, involving a specific 
family of cysteine proteases, the caspases. Apoptotic cell death is characterized by 
chromatin condensation, nuclear fragmentation and cell shrinkage, resulting in the 
fragmentation of the cell into apoptotic bodies. Apoptotic bodies are cleared by surrounding 
phagocytosing cells, thus minimizing inflammation. The caspase-family comprises fourteen 
members, which participate mainly in apoptosis and inflammation. Caspases are present as 
inactive precursor enzymes, the pro-caspases, that become activated via an interaction with 
caspase recruitment domains (CARD), death domains (DD) or death effector domains (OED) 
on various apoptosis-related proteins and death receptors. The pro-domain is cleaved from 
the pro-caspase, resulting in the active form consisting of a small and a large subunit. Based 
on their function in the apoptotic cascade, caspases are divided in two groups, initiator and 
effector caspases. Initiator caspases (caspases 8, 9 and 10) are involved in the initiation of 
apoptotic signaling. The initiator caspases are responsible for the activation of the effector 
caspases 3, 6 and 7, operating at the final stage of apoptosis. Effector caspases cleave 
essential cellular proteins involved in signal transduction, RNA synthesis, DNA-repair and 
structure, which ultimately results in the morphological modifications that characterize 
apoptotic cells. Apoptosis can be induced by a variety of agents, such as cytokines, 
oxidative stress, growth factor withdrawal or DNA damage, all resulting in the activation of 
caspases (10-15). 
A distinction is made between the intrinsic pathway, resulting from an apoptotic trigger inside 
the cell, and the extrinsic pathway mediated by death receptor activation at the cell surface. 
Intrinsic pathway 
The intrinsic pathway of apoptosis is also known as a stress pathway (Fig 3). A stress event 
can trigger the mitochondrial permeability transition (MPT), which is characterized by the 
loss of potential between the mitochondrial inner and outer membrane (intermembrane 
space), mitochondrial swelling and outer mitochondrial membrane rupture. As a 
consequence, the damaged mitochondria release a variety of pro-apoptotic proteins from the 
intermembrane space, like cytochrome c, second mitochondria-derived activator of caspases 
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(Smac)/direct inhibitor of apoptosis protein (IAP) binding protein with low pl (Diablo), 
Omi/high temperature requirement A2 (HtrA2) and apoptosis inducing factor (AIF). 
Cytochrome c binds to apoptotic protease activating factor 1 (Apaf-1 ), thereby facilitating the 
binding of {d)ATP to Apaf-1. Then, pro-caspase-9 is recruited by the CARD motif of Apaf-1, 
and simultaneously Apaf-1 assembles into a complex called the apoptosome, which consists 
of Apaf-1, cytochrome c, (d)ATP and procaspase-9. Inside the apoptosome, caspase-9 is 
activated via Apaf-1-regulated homodimerization, and cytochrome c is a critical cofactor in 
this process. Subsequently, caspase-9 activates the effector caspases pro-caspase-3 and -
7. Although the apoptosome activates caspases, studies have shown that the apoptosome is 
an amplifier, rather than a crucial initiator, of apoptosis (11, 13, 16-22). 
Extrinsic pathway 
The extrinsic or death receptor pathway of apoptosis is initiated by the ligation of death 
receptors (DR) at the cell membrane (Fig 3). Death receptors belong to the tumor necrosis 
factor/nerve growth factor (TNF/NGF) receptor super family, including TNF-R1, Fas and 
TNF-related apoptosis inducing ligand {TRAIL)-R1/DR4 and R2/DR5 In general, upon ligand 
binding, the death receptor monomers oligomerize at the cell surface, providing a docking 
platform at the cytoplasmic side, which facilitates the recruitment of adaptor proteins like 
Fas-associated death domain (FADD). An interaction is established via the death domains 
(DD) of the death receptors and the adaptor proteins, and subsequently, pro-caspase-8 
and/or -10 are recruited to the death effector domain (OED) of FADD. The resulting complex, 
consisting of death receptors, FADD and pro-caspases is called the death inducing signaling 
complex {DISC). DISC formation results in the enzymatic activation of procaspase-8, and 
apoptosis is induced either via direct activation of caspase-3 (type I cells) or via a pathway 
involving the mitochondria (type II cells). In type II cells, like hepatocytes, active caspase-8 
cleaves Bid, a pro-apoptotic member of the Bcl-2 family. Truncated-Bid (t-Bid) translocates 
to the mitochondria inducing the formation of pores in the mitochondrial outer membrane, 
hence stimulating the release of cytochrome c, the formation of the apoptosome and 
subsequently the induction of apoptosis (10, 23-25). 
Intrinsic pathway 
hepatocyte 
Figure 3. Intrinsic and extrinsic signaling of apoptosis 
Extrinsic pathway 
apoptosis , ••• - . apoptosome 
An exception to this common pathway is TNF-R1, which recruits the TNF receptor 1-
associated protein, TRADD. TRADD performs a twofold function; apoptosis is induced by an 
interaction with FADD via the ODs, but TRADD also represses apoptosis by recruiting 
secondary adaptor proteins like receptor interacting protein (RIP) and TNF receptor­
associated factor (TRAF) 2 and 5. The binding of RIP to TRADD activates kinases that 
eventually cause degradation of IKB resulting in the release from, and activation of the 
transcription factor nuclear factor (NF)-KB that regulates the expression of many anti­
apoptotic genes. In hepatocytes, the net effect caused by the ligand TNFa favors cell 
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survival rather than cell death. In contrast, the death receptors Fas and TRAIL-R1 and R2 
which only recruit FADD, but not TRADD, do not or hardly activate NF-KB and thus always 
induce cell death. Some cell types also express a second TNF receptor, TNF-R2, which 
lacks the death domain and is therefore unable to bind adaptor proteins and induce signaling 
pathways. The liver is known to highly express the death receptors Fas, TRAIL-R1 and R2 
and TNF-R1. Hepatocytes, cholangiocytes, activated stellate cells and endothelial cells 
express Fas, hepatocytes and endothelial cells express TNF-R1 and hepatocytes also 
express TRAIL-R1 and R2 ( 10, 23, 26). 
In contrast to apoptotic cell death, necrotic cell death is a passive process, which via 
mitochondrial and cellular swelling results in plasma membrane rupture and subsequent 
release of the cellular content into the extracellular environment and circulation. Thus, an 
inflammatory response is triggered. Compared to apoptosis this mode of cell death is rather 
disorganized, and necrotic cells are not eliminated by phagocytosis. Usually, liver injury 
occurs as a combination of apoptosis and necrosis since these two mechanisms of cell 
death share common pathways involving the mitochondria (21, 22, 27). 
Reactive oxygen species 
Reactive oxygen species (ROS) comprise free radicals (HO·), peroxides (e.g. H202) and 
oxygen ions such as superoxide anions (02 ·-). Under normal conditions, the majority of ROS 
in a cell are formed during oxidative phosphorylation in the mitochondria. Upon cellular 
stress, the levels of ROS can be enhanced dramatically, exceeding the capacity of the cell to 
detoxify ROS. This situation is known as oxidative stress and results in cellular damage. A 
variety of conditions can lead to increased ROS generation and oxidative stress, like ageing, 
compromised antioxidant status, metabolism of xenobiotics (e.g. acetaminophen), alcohol 
metabolism and inflammation. Hepatocytes contain various defense mechanisms against 
oxidative stress (Fig 4), including superoxide dismutases (SODs). The SOD family consists 
of mitochondrial manganese (Mn)-SOD, cytoplasmic copper, zinc (Cu, Zn)-SOD and 
extracellular (EC)-SOD. SOD family members catalyze the reduction of superoxide anions to 
hydrogen peroxide, which is subsequently converted into water by either catalase or 
glutathione peroxidase. In addition to water, catalase releases an oxygen molecule during 
the conversion of hydrogen peroxide. Glutathione peroxidase oxidizes glutathione, while 
reducing hydrogen peroxide into water. In contrast to the conversion into water, hydrogen 
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Figure 4. Generation and metabolism of reactive oxygen species 
hydroxyl radicals. Cells 
contain many other 
antioxidant systems, such as 
reduced glutathione (GSH), 
vitamins (particularly vitamin 
E) and uric acid. Pro-oxidant 
systems involve nicotinamide 
adenine di nucleotide 
phosphate (NADPH) oxidase, 
which generates superoxide 
anions while oxidizing 
NADPH and xanthine 
oxidase. 
Since reactive oxygen species are generated in both acute and chronic liver diseases like 
(non)-alcoholic steatohepatitls ((N)ASH) and chronic cholestasis, ROS have been implicated 
to be key players in hepatocyte cell death in these disorders. One of the aims of this thesis 
was to determine the involvement of ROS in bile acid-induced cell death (28-36). 
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Signal transduction pathways 
Signal transduction pathways, including phosphoinositide-3 kinase (Pl3K), mitogen-activated 
protein kinases (MAPK), Src tyrosine kinases, NF-KB activating pathways, Bcl-2 family 
members and calcium signaling regulate cell death and survival in hepatocytes. This thesis 
analyzed the role of selected signal transduction pathways in hepatocyte cell death, which 
are summarized below. 
Phosphoinositide-3 kinase family 
The Pl3K family comprises a large group of structurally related enzymes that phosphorylate 
inositol lipids at specific sites. Members of the Pl3K family are involved in a broad range of 
cellular functions such as cell survival, cell growth and proliferation, insulin-induced 
responses and cellular trafficking. The Pl3K enzymes are arranged in three classes (I, I I and 
Ill) based on their substrate specificity, and each class is involved in particular functions. 
Class I is sub-divided into IA and 18. Members of the class IA family play a role in cell 
survival and proliferation, and 18 subtypes participate in allergy and inflammation. Class II 
enzymes are responsible for lipid binding and protein interactions, and class Ill members are 
involved in intracellular trafficking. Protein kinases, phospholipases and G-proteins are 
downstream targets of Pl3K enzymes. An important Pl3K class I-effector in cell survival is 
Akt or protein kinase B (PKB), a serine/threonine kinase. Akt activation requires 
phosphorylation at Thr308 and Ser473, which occurs at the plasma membrane. Activated 
Akt protects from apoptosis via phosphorylation and inhibition of the pro-apoptotic Bcl-2 
family member Bad, and the initiator caspase-9, and by enhanced degradation of IKB kinase 
(IKK), and subsequent activation of NF-KB. Another Akt target is the mammalian target of 
rapamycin (mTOR), which is a key player in transcription, translation, cytoskeletal 
arrangement and protein degradation. The important role of Akt in cell survival has been 
demonstrated: a constitutively active form of Akt inhibited apoptosis induced by various 
agents, like UV radiation, DNA damage and cytokines, whereas an inactive form of Akt 
promoted cell death (27, 37-47). 
Mitogen-activated protein kinases 
MAPK members are involved in cell differentiation, proliferation, apoptosis and cell survival. 
All members become activated by a sequence of phosphorylation events, starting with a 
MAPK kinase kinase (MAPKKK), followed by a MAPK kinase (MAPKK) and finally the MAPK 
is activated via twofold phosphorylation at a threonine and tyrosine residue. The MAPK 
family consists of five groups: a) extracellular signal regulated kinase (ERK) 1 and 2; b) Jun 
N-terminal kinase (JNK) 1, 2 and 3; c) p38 a, B, y, 6; d) ERK3 and 4; e) ERK5 (27, 48, 50-
51 ). 
ERK1/2 is activated by growth factors, cytokines and phorbol esters, and is an important 
regulator of cell proliferation, while only a minor role of ERK1/2 is implicated in apoptosis. 
Main targets of activated ERK1/2 are other kinases, transcription factors, e.g. NF-KB, 
cytoskeletal proteins and the anti-apoptotic Bcl-2 family member Bcl-2. The exact outcome 
of the activation of ERK1/2 depends on the length and strength of ERK1/2 activation (27, 48-
51 ). 
JNK activity is induced by various stress stimuli such as UV irradiation, cytokines, oxidative 
stress or growth factors. JNK participates in the stress response, inflammation and apoptosis 
by stimulating c-Jun-dependent transcription and phosphorylation of downstream targets, 
including other kinases and apoptosis-modulating proteins like Itch (52, 53). 
Most stimuli like environmental stress and cytokines, which activate JNK, also activate p38. 
The activity of p38 is crucial for the regulation of the immune system and inflammation, thus 
explaining the involvement of p38 in asthma and autoimmune diseases. Targets of p38 are 
transcription factors, genes coding for inflammatory cytokines and downstream kinases (27, 
48-51 ). 
ERK3 and 4 are so-called atypical MAPK members, they lack the threonine and tyrosine 
residues which become phosphorylated by upstream kinases. In contrast, ERK3 and 4 are 
activated via auto-phosphorylation (48). 
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Growth factors activate ERK5, which is essential for angiogenesis (48). 
Src tyrosine kinase family 
The Src family consists of 9 members, all of them containing specific Src homology (SH) 
domains and a tyrosine kinase domain. Src kinases phosphorylate specific target proteins 
(e.g. Pl3-kinase) at a tyrosine residue. Tyrosine phosphorylation of proteins is involved in 
numerous signal transduction mechanisms. Therefore, Src kinases are implicated in many 
cellular processes, including gene transcription, apoptosis and differentiation. Recently, Src 
family members were shown to be important in cytotoxicity induced by oxidative stress, Fas 
ligand (Fasl) and bile acids, since specific inhibition of Src kinases reduced hepatocyte cell 
death induced by these stimuli (32, 54-60). 
NF-KB signaling 
The NF-KB subunit family is a key player in cell survival, inflammation and stress, and 
contains five members; p65 (RelA), RelB, c-Rel, p50/p105 (NF-KB1 ), and p52/p100 (NF­
KB2). NF-KB members are present in the cytoplasm of cells as inactive homo- or 
heterodimers. The most common heterodimer is composed of a p65 and p50 subunit. NF-KB 
proteins can be activated by various signal transduction pathways of which the classical or 
canonical pathway and the alternative or non-canonical route are best described. The 
classical pathway can be triggered by a variety of cell surface receptors such as TNF­
receptors and Toll-like receptors, while the alternative pathway only becomes activated by 
specific receptors, for instance lymphotoxin B (11 ,  27, 61 -63). 
Since TNF-R1 activates the classical pathway, this signal transduction pathway will be 
described in more detail. In the classical pathway, inactive NF-KB is bound to one of the 
inhibitory IKB isoforms. Upon receptor activation, IKB becomes phosphorylated via 
sequential activation of adapter proteins like IKK�, and as a consequence IKB is released 
from the p65 subunit of NF-KB. On the p65 subunit, a nuclear localization sequence is 
exposed and NF-KB translocates to the nucleus. In the nucleus, NF-KB induces transcription 
via the interaction with KB binding sites in the regulatory sequences of target genes (62, 63). 
Many signal transduction molecules, including JNK, Pl3K/Akt and protein kinase C (PKG) 
modulate NF-KB activation. NF-KB effector genes include cytokines, superoxide dismutase 
(SOD), inducible nitric oxide synthase (iNOS) and anti-apoptotic members of the Bcl-2 
family. The Bcl-2 family consists of pro-apoptotic members (e.g. Bad, Bax and Bak), as well 
as anti-apoptotic members (e.g. Bcl-2, Bel-xi and Bfl-1 or A 1 ). NF-KB specifically induces the 
expression of the anti-apoptotic proteins Bcl-2, Bel-xi and A 1/Bfl-1 (1 1 ,  27, 61-68). 
Liver diseases 
Bile acids, reactive oxygen species and cytokines are key players in liver diseases. 
Bile acids are involved in acute and chronic cholestatic liver disorders. Cholestasis is 
described as impaired bile flow, and symptoms are jaundice, pruritus and fatigue. The 
disease is initiated by a genetic, drug-induced, immunologic or mechanical insult to the bile 
ducts or hepatocytes. Progression of cholestasis occurs via hepatocytes, inflammatory cells 
(Kupffer cells, neutrophils) and stellate cells, due to the release of cytokines and ROS, and 
deposition of extracellular matrix. Cholestasis develops via fibrosis into cirrhosis and 
eventually end-stage liver failure (34, 69, 70). The most common genetic liver disorders 
associated with cholestasis are progressive familial intrahepatic cholestasis (PFIC) type 1, 2 
and 3. These hereditary diseases result in impaired bile flow due to mutations in transporter 
proteins (putatively) involved in bile formation. PFIC type 1 or Byler's disease is caused by 
mutations in the FIC1 gene. FIC1 is an ATP-dependent protein pump at the canalicular 
membrane of hepatocytes and cholangiocytes. FIC1 is direct or indirect involved in the bile 
formation, since defects in FIC1 result in impaired transport of bile acids in the liver and the 
intestine. Mutations in the BSEP gene cause PFIC type 2 or Byler syndrome. Different BSEP 
mutations lead to different outcomes, varying from disturbed BSEP translocation to the 
canalicular membrane, abrogated bile acid transport by BSEP or no effect on either transport 
or trafficking. PFIC type 3 or MDR3 deficiency is characterized by the absence of MDR3, 
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and thus the lack of phospholipids in bile. Bile acids are no longer captured in mixed 
micelles, and the toxic bile acids can induce severe injury (4, 5, 69, 70). 
Drug-induced cholestasis can also be related to BSEP. Certain drugs, such as cyclosporine 
A and rifampicin, inhibit BSEP, which results in bile acid accumulation and liver injury. Other 
drugs known to induce cholestasis include oral contraceptives, penicillin and anabolic 
steroids. Cholestasis related to the immune system can be caused by bacterial or viral 
infections, and is very often associated with sepsis or allograft rejection. Inflammation is also 
the cause of bile duct destruction in the auto-immune disorder primary biliary cirrhosis 
(PBC). Mechanical obstruction of the bile ducts may be due to gall stones or tumors. 
However, in some cholestatic disorders like biliary atresia and primary sclerosing cholangitis 
(PSC) the bile ducts are damaged due to a yet unidentified reason (4, 5, 69-72). 
In cholestatic patients and animal models of cholestasis like bile duct ligation (BDL) or 
cholate-feeding, the bile acid retention in hepatocytes affects several transporters involved in 
the enterohepatic circulation. NTCP and OATP1 at the basolateral membrane and MRP2 at 
the canalicular membrane are down-regulated, while MRP3 is up-regulated ,  and BSEP is 
unaffected. Furthermore, the glycine-conjugates of hydrophobic bile acids trigger hepatocyte 
apoptosis and necrosis in cholestasis. Increasing bile acid levels also induce proliferation of 
cholangiocytes, which via the release of pro-inflammatory cytokines results in the death of 
the cholangiocytes (4, 5, 9, 73-75). 
Ursodeoxycholic acid (UDCA) is a dihydroxy bile salt which is used in the treatment of 
chronic cholestatic liver diseases. The hepatoprotective mechanism of UDCA is 
accomplished via upregulation of the basolateral bile acid transporters and stimulation of bile 
acid secretion of hepatocytes. In addition, activation of anti-apoptotic pathways by UDCA or 
its taurine conjugate TUDCA has been described. In cholangiocytes, UDCA and TUDCA 
inhibit the bile acid-induced proliferation and loss of cholangiocytes. However, cholestatic 
disorders do not always respond to UDCA-treatment, and often surgery is required to drain 
or eliminate the obstruction. As a final option, when complications occur, a liver 
transplantation is required (75-81 ). 
Reactive oxygen species are generated in both non-alcoholic fatty liver disease (NAFLD) 
and alcoholic liver diseases. NAFLD comprises a group of diseases varying from triglyceride 
accumulation in hepatocytes (steatosis), via hepatic steatosis accompanied by inflammation 
(steatohepatitis), into excessive accumulation of connective tissue (fibrosis) and finally to 
cirrhosis and liver failure. Steatosis or fatty liver is associated with the metabolic syndrome, 
insulin resistance, drugs and nutritional factors. Non-alcoholic steatohepatitis (NASH) is 
becoming a serious problem in countries with a Western life style, due to obesity, excessive 
caloric intake and lack of exercise. NASH is believed to develop in two sequential steps. 
First, accumulation of fat in hepatocytes leads to increased mitochondrial and peroxisomal B­
oxidation, resulting in ROS generation and oxidative stress. Second, fat accumulation results 
in inflammation, increased production of cytokines like TNFa and cell death. NASH 
progresses into fibrosis in approximately 20% of the patients. The most effective treatment in 
fatty liver diseases is weight loss, thus removing the condition that causes the disease. 
Medications with a beneficial effect are the anti-diabetic drug metformin and in some cases 
UDCA. Alcoholic liver diseases resemble NASH,  although the type and pattern of fat 
accumulation is different. The injury in alcoholic liver diseases is caused by the metabolism 
of alcohol (ethanol), which generates ROS and reactive metabolites like acetaldehyde. 
Acetaldehyde is a pro-fibrogenic factor. Apoptosis appears to be the dominant mode of cell 
death. Indeed, in patients with alcoholic hepatitis, marked numbers of apoptotic hepatocytes 
were detected (82-84 ). 
Cytokines participate in all liver diseases, but play a predominant role in acute liver diseases 
like acute hepatitis and acute liver failure (ALF). Acute liver injury induces the rapid 
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generation of pro-inflammatory cytokines and reactive oxygen species which results in 
hepatocyte cell death, mainly apoptosis. This inflammation-induced apoptosis of hepatocytes 
and loss of functional liver cells plays an important role in the augmentation of liver injury 
and ultimately liver failure. Hepatitis is most often the result of an infection with the hepatitis 
B, C, D or E virus, while an important trigger for acute liver failure is drug-induced toxicity 
(e.g. acetaminophen overdose) or mushroom poisoning (85-86). 
From this overview it becomes clear that the majority of chronic liver diseases progress into 
cirrhosis and end-stage liver failure, demanding a liver transplantation as only possible 
treatment. Since chronic liver diseases are characterized by the progressive loss of 
hepatocytes, the functional liver cells, it is important to investigate the signaling pathways 
involved in cell survival and death in these conditions. This will allow the identification of 
potential targets for intervention. In addition, the effects of existing drugs on signal 
transduction pathways involved in hepatocyte survival needs to be explored. In this thesis, 
two of these drugs, metformin and leflunomide were investigated in detail. 
Metformin 
Metformin is a drug used in the treatment of Diabetes Mellitus type I I ,  where it improves 
insulin sensitivity. Metformin reduced aminotransferase levels and decreased liver size in 
patients with NASH and in animal models for steatosis. Moreover, metformin treatment 
improved hepatocyte viability in fatty livers. However, the protective mechanism of metformin 
in patients or experimental animals with diabetes or fatty livers is unknown. Metformin is 
known to stimulate the activity of AMP-activated protein kinase (AMPK) family members a1 
and a2. AMPK is involved in energy homeostasis, and becomes activated upon a rise in 
cellular AMP or changes in the AMP/ATP ratio. Furthermore, AMPK can be activated by 
stimuli not changing the AMP/ATP ratio, like oxidative stress, hypoxia, hyperosmotic stress 
or pharmacological compounds. AMPK activity represses signaling via mTOR, a 
downstream target of Akt and Pl3K. Based on studies describing protective effects of 
metformin in NAFLD, we investigated the hepatoprotective effect of metformin in this thesis 
using two different in vitro models for liver damage: 1) the toxic, hydrophobic bile acid 
glycochenodeoxycholic acid (GCDCA), as a model for acute bile acid toxicity, resulting in 
both apoptosis and necrosis; 2) the cytokine TNFa in combination with the transcriptional 
inhibitor actinomycin D (to inhibit NF-KB activation), a model for acute liver failure, which is 
characterized by apoptosis (87-98). 
Leflunomide 
Leflunomide (N-[(4-trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide) is a well­
known anti-inflammatory agent, as therapy for autoimmune diseases, particularly rheumatoid 
arthritis. Furthermore, leflunomide is used in the prevention of rejection after organ 
transplantation, and in the treatment of Crohn's disease and cancer. After administration, the 
prodrug leflunomide, is almost completely metabolized (>95%) to its active compound A77 
1726 or teriflunomide (2-cyano-3-oxo-N-[(4-trifluoromethyl)phenyl]butyramide). Proposed 
molecular mechanisms explaining the anti-inflammatory, anti-proliferative and 
immunosuppressive effects of leflunomide are inhibition of protein tyrosine kinases, e.g. 
kinases of the Src family, blocking dihydroorotate dehydrogenase (DHODH) involved in 
pyrimidine synthesis and progression through the cell cycle, inhibition of MAP kinases, 
including JNK and reduced production of pro-inflammatory cytokines via inhibition of NF-KB. 
In experimental models, leflunomide was protecting liver cells against injury induced by 
acetaminophen, concanavalin A (model for hepatitis), bile duct ligation and 
ischaemia/reperfusion. The protective mechanisms observed were inhibition of cytochrome c 
release from the mitochondria and caspase activities, reduced plasma cytokine 
concentrations and aminotransferase levels. In this thesis we studied the potential protective 
mechanisms of leflunomide in three different in vitro models of cell death: 1) GCDCA, 2) 
TN Fa and actinomycin D, 3) the superoxide anion donor menadione as a model of oxidative 
stress-induced apoptosis (99-110). 
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Scope of the thesis 
The aim of this thesis was to unravel the mechanisms of hepatocyte cell death induced by 
factors present in liver diseases: bile acids, inflammatory mediators and oxidative stress. For 
this purpose, we used three different in vitro models of hepatocyte injury, representing 
various inducers of cell death relevant for liver diseases: bile acid-induced toxicity, as model 
for cholestatic diseases; 2. cytokine induced injury, representing acute hepatitis and acute 
liver failure; 3. reactive oxygen species, representative for many chronic liver diseases 
accompanied by oxidative stress, such as alcoholic and non-alcoholic steatohepatitis. 
Furthermore, we investigated the effect and mechanism of action of various potential drugs 
against liver diseases. In chapter 2, we examined the protective role of the anti-diabetic 
drug metformin against hepatocyte cell death. Metformin was shown to protect primary rat 
hepatocytes against bile acid-induced apoptosis. The protective effect was dependent on the 
Pl3K/Akt-signaling pathway. In chapter 3, the cytoprotective effects of leflunomide, an anti­
inflammatory compound, are described. Leflunomide protects hepatocytes against bile acid­
induced apoptosis and necrosis, but the drug does not protect against cytokine or oxidative 
stress-induced cell death. In addition, we studied the mechanism involved in the protection 
of leflunomide. In Chapter 4 we studied the involvement of reactive oxygen species in bile 
acid-induced hepatocyte cell death. We report that reactive oxygen species are not required 
for bile acid-induced hepatocyte apoptosis, but Src-kinase family members are critically 
involved in bile acid-induced cell death. Chapter 5 describes the role of the stress­
responsive protein H0-1 in in vivo and in vitro models of liver injury. The protective effect of 
H0-1 and carbon monoxide, one of its products, against superoxide anion-induced 
hepatocyte death were examined. Chapter 6 describes an in vitro approach to study 
cholestasis. We examined the isolation and culture of cholestatic hepatocytes in detail and 
demonstrate that cholestatic hepatocytes retain their in vivo phenotype during in vitro 
experiments. Thus, we provide a tool to study the signaling pathways occurring in 
hepatocytes during cholestatic liver diseases in detail. 
In conclusion, this thesis reports about the prevention and mechanisms of hepatocyte cell 
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Background: Metformin is used in the treatment of Diabetes Mellitus type II and improves 
liver function in patients with steatosis. Metformin activates AMP-activated protein kinase 
(AMPK), the cellular energy sensor that is sensitive to changes in the AMP/ATP-ratio. AMPK 
is an inhibitor of mammalian target of rapamycin (mTOR). Both AMPK and mTOR are able 
to modulate cell death. Aim: to evaluate the effects of metformin on hepatocyte cell death. 
Methods: Apoptotic cell death was induced in primary rat hepatocytes using either the bile 
acid glycochenodeoxycholic acid (GCDCA) or tumor necrosis factor (TNF) a in combination 
with actinomycin D (ActD). Metformin (0.1-2 mmol/L) was added 10 minutes prior to the 
apoptotic stimuli, unless stated otherwise. AMPK, mTOR and phosphoinositide-3 kinase 
(Pl3K)/Akt were inhibited using pharmacological inhibitors. Apoptosis and necrosis were 
quantified by caspase activation,  acridine orange staining and Sytox green staining 
respectively. 
Results: Metformin dose-dependently reduces GCDCA-induced apoptosis, even when 
added 2 hours after GCDCA, without increasing necrotic cell death. Metformin does not 
protect against TNFa/ActD-induced apoptosis. The protective effect of metformin is 
dependent on an intact Pl3-kinase/Akt pathway, but does not require AMPK/mTOR­
signaling. Metformin does not inhibit NF-KB activation. 
Conclusion: Metformin protects against bile acid-induced apoptosis, but not TNFa/ActD­
induced apoptosis. If these results can be confirmed in in vivo models, metformin could be 
considered in the treatment of chronic liver diseases accompanied  by inflammation. 
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2.2 Introduction 
In chronic liver diseases, like chronic cholestasis, hepatocytes are exposed to increased 
levels of bile acids, toxic metabolites and oxidative stress, causing cell death. In acute liver 
diseases, such as acute viral hepatitis, cell death is caused by pro-inflammatory and pro­
apoptotic cytokines and reactive oxygen species. Cell death can occur as apoptosis or 
necrosis. Apoptosis or programmed cell death is an energy dependent process, involving the 
caspase-family of cysteine proteases. Apoptosis is characterized by cell shrinkage, nuclear 
condensation and formation of apoptotic bodies. On the contrary, necrosis is a passive 
process, involving plasma membrane rupture and release of cellular content into the 
extracellular environment and systemic circulation, causing inflammation (1-8). 
Metformin is a drug used in the treatment of Diabetes Mellitus type II, where it improves 
insulin sensitivity. Recently, metformin was shown to have beneficial effects in fatty liver 
diseases: metformin was found to reduce leptin secretion (9). Furthermore, metformin 
reduced aminotransferase levels and decreased liver size in patients with non-alcoholic 
steatohepatitis (NASH) and animal models for steatosis. Moreover, metformin treatment 
improved hepatocyte viability in fatty livers (10-13). Metformin is known to stimulate AMP­
activated protein kinase (AMPK) activity in whole liver, in human and rat primary 
hepatocytes, and in a rat hepatoma cell line (14-16). Among the 5 members of the AMPK 
family, AMPK-a1 and -a2 are activated by metformin (14, 17). AMPK consists of a catalytic a 
subunit and two regulatory subunits (P, y; 14, 18). AMPK is involved in energy homeostasis, 
and becomes activated upon a rise in the cellular AMP concentration or changes in the 
AMP/ATP-ratio. Furthermore, AMPK can be activated by stimuli not changing the AMP/ATP­
ratio, like hyperosmotic stress, hypoxia, oxidative stress or pharmacological compounds. 
AMPK activity is dependent on the phosphorylation of Thr172 in the a subunit (16, 18-24). 
Activation of AMPK using the cell permeable adenosine analogue 5-aminoimidazole-4-
carboxamide 1-P-D-ribofuranoside (AICAR) was shown to be pro-apoptotic in liver cells, via 
activation of Jun N-terminal kinase (JNK) and caspase-3 (25). In a rat hepatoma cell line 
AMPK activity stimulated apoptosis, and in pancreatic f3-cells both metformin and AICAR 
induced apoptosis. On the contrary, in astrocytes and endothelial cells, activation of AMPK 
reduced apoptosis (26). Moreover, in DLD-1 cells, Ark5, another AMPK family member, was 
protective against Fas-mediated cell death. Ark5 directly inhibited one of the effector 
caspases, caspase-6, and Ark5 activity was shown to be controlled by Akt, a key regulator in 
survival signaling (15, 19, 27-30). In whole liver, AMPK activity represses signaling via the 
mammalian target of rapamycin (mTOR), a downstream target of Akt and phosphoinositide-3 
kinase (Pl3K). mTOR is a key player in transcription, translation, cytoskeletal arrangement, 
and protein degradation (18, 20, 29, 31-36). Akt was found to suppress apoptosis in various 
cell types, including liver cells. In a rat hepatoma cell line, constitutive activation of Pl3K 
blocks glycochenodeoxycholic acid (GCDCA)-induced apoptosis. In primary rat hepatocytes, 
the protection of tauroursodeoxycholic acid (TUDCA) against GCDCA-induced apoptosis 
was abolished when the Pl3K/Akt survival pathway was inhibited (5, 37-41). In addition to 
Pl3K/Akt, there are several important survival pathways in hepatocytes, such as the 
transcription factor nuclear factor-KB (NF-KB) and the mitogen-activated protein kinases 
(MAPK; 42). Activation of NF-KB leads to the induction of survival genes and subsequently 
inhibition of apoptosis. In cholestatic livers, NF-KB is activated, and reduces liver injury (43). 
GCDCA-induced apoptosis was also reduced by NF-KB activation in primary rat hepatocytes 
(44). Furthermore, inhibition of both the Pl3K pathway and one of the anti-apoptotic MAPK 
members p38 or extracellular signal regulated kinase (ERK) 1/2 enhanced bile acid induced 
cell death in rat hepatocytes (45). 
Considering the controversy about the role of metformin in apoptosis and the apparent 
beneficial effect in the treatment of steatohepatitis, we investigated the effect of metformin in 
2 different in vitro models of hepatocyte cell death. We studied the effects of metformin on 
hepatocyte survival pathways, and examined if downstream targets of metformin modulate 
hepatocyte cell death. We describe a hepatoprotective action of metformin against bile acid-
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induced apoptosis which is independent of AMPK activation, but dependent on an intact 
Pl3K/Akt signaling pathway. 
2.3 Materials and Methods 
Animals 
Specified pathogen-free male Wistar rats (200-250 g) were purchased from Charles River 
Laboratories Inc (Wilmington, MA, USA). Rats were housed under standard laboratory 
conditions with free access to standard laboratory chow and water. Prior to isolation, rats 
were fasted overnight. Experiments were performed following the guidelines of the local 
Committee for Care and Use of laboratory animals. 
Rat hepatocyte isolation 
Hepatocytes were isolated from rats by a two step collagenase perfusion as described 
before (46). Cell viability was greater than 85% as determined by Trypan Blue exclusion. 
After isolation, 112,500 cells per cm2 were plated on Vitrogen® (Cohesion Technologies Inc., 
Palo Alto, CA, USA) coated plates in William's E medium (lnvitrogen, Breda, The 
Netherlands) supplemented with 50 µg/mL gentamycin (lnvitrogen) and penicillin­
streptomycin-fungizone (Lonza, Verviers, Belgium). During the attachment period (4 hrs) 50 
nmol/L dexamethasone (Dept. of Pharmacy, UMCG, Groningen, The Netherlands) and 5% 
fetal calf serum (lnvitrogen) were added to the medium. Cells were cultured in a humidified 
incubator at 37°C and 5% CO2. 
Experimental design 
Experiments were started 4 hrs after isolation of hepatocytes. Cell death was induced by bile 
acids or cytokines. Monolayer cultures were exposed to 50 µmol/L GCDCA (Calbiochem, La 
Jolla, CA, USA) for 4 hrs or the indicated time period ,  or hepatocytes were exposed for 16 
hrs to 20 ng/ml recombinant murine tumor necrosis factor a (mTNFa, R&D Systems, 
Abingdon, United Kingdom) in combination with 200 ng/ml actinomycin D (ActD, Roche 
Diagnostics, Almere, The Netherlands) or a cytokine mixture (CM) consisting of 20 ng/ml 
mTNFa, 10 ng/ml recombinant human interleukin-113 (hlL-113, R&D Systems), 10 ng/ml 
recombinant rat interferon-y (rlFNy, R&D Systems) and 10 µg/ml lipopolysaccharide (LPS, 
Escherichia coli, serotype 0127:BB, Sigma-Aldrich, St. Louis, MO, USA). 1, 1-
dimethylbiguanide hydrochloride (metformin, Sigma-Aldrich) was used at a concentration 
range from 0.1-2 mmol/L. Signal transduction pathways were specifically blocked using 0.1 
µmol/L of the AMPK inhibitor 5'-iodotubercidin (Calbiochem), 0.5 µmol/L of the mTOR 
inhibitor rapamycin (Calbiochem) or 50 µmol/L of the Pl3K inhibitor L Y294002 (Calbiochem). 
All inhibitors were added 30 minutes prior to bile acids or cytokines. Each experimental 
condition was performed in triplicate wells. Each experiment was performed at least three 
times, using hepatocytes from different isolations. 
Cells were harvested at the indicated time points after the addition of the apoptotic stimuli, 
and washed three times with ice cold phosphate-buffered saline (PBS) before the addition of 
hypotonic cell lysis buffer (protein analysis, caspase-3 assay), 2x concentrated sample 
buffer (Western blot analysis) or Tri-reagent (RNA isolation, Sigma-Aldrich) as described 
previously ( 45 ). 
Caspase enzyme activity assays 
Caspase-3 like activity was assayed as described previously (45). The arbitrary fluorescence 
unit (AFU) was corrected for the amount of protein in the cell lysate. Caspase-6 like activity 
was assayed according to the manufacturer's instructions (Biovision, Mountain View, CA, 
USA). 
Sytox green and acridine orange nuclear staining 
To determine necrotic cell death, hepatocytes were incubated for 15 minutes with Sytox 
green (1 :40,000, lnvitrogen) nucleic acid stain. Sytox can only enter cells with compromised 
plasma membranes. Hepatocytes exposed to 5 mmol/L hydrogen peroxide (H202, Merck 
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Chemicals Ltd, Nottingham, UK) for 6 hrs served as positive control for necrosis. Apoptotic 
nuclei were visualized with acridine orange (1 :5,000, Sigma-Aldrich) as described previously 
(46). Fluorescent nuclei were visualized using an Olympus CKX41 microscope at 450-490 
nm. Necrosis and apoptosis were quantified by counting fluorescent nuclei (necrotic or 
apoptotic cells) and the total number of cells in  3 randomly chosen high power fields. 
Western blot analysis 
Western blot analysis of cell lysates was performed by SOS-PAGE followed by semi dry­
blotting to transfer the proteins to Hybond ECL n itrocellulose membrane (Amersham 
Biosciences, Piscataway, NJ , USA). Ponceau S 0.1 % w/v (Sigma-Aldrich) staining was 
used to confirm electrophoretic transfer. Activation of AMPK was detected using the 
polyclonal antibody against phosphorylated AMPKa (Thr 172, lnvitrogen) at a dilution of 
1 :500. Hepatocytes exposed to 250 µmol/L AICAR (Biomol Research Laboratories Inc, 
Plymouth Meeting, PA, USA) for 60 minutes served as positive control for phosphorylation 
and activation of AMPK. After Western blot analysis, blots were stripped as described 
previously (46) and incubated with a monoclonal antibody against �-actin (Sigma-Aldrich, 
dilution 1: 10000). 
The blots were analyzed in a ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA). Protein 
band intensities were quantified by Quantity One software (Bio-Rad). 
RNA isolation and quantitative polymerase chain reaction (PCR) 
RNA isolation was performed as described previously (47). RNA concentration was 
determined with the Ribogreen RNA quantitation reagent and kit (lnvitrogen). Reverse 
transcription (RT) PCR was carried out on 2.5 µg of total RNA using random primers in a 
total volume of 50 µL using Moloney murine leukemia virus (M-MLV) reverse transcriptase 
system according to the manufacturer's instruction (Sigma-Aldrich). 
Quantitative PCR was performed on 4 µL 20-times diluted complementary DNA in a final 
volume of 20 µL (47). Fluorescence was measured using the ABI PRISM 7700 Sequence 
Detector version 1.7 software (Applied Biosystems, Nieuwerkerk a/d IJssel, The 
Netherlands) starting with 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C 
and 1 minute at 60°C. Details of primers and probes are listed in Table 1. Each sample was 
analyzed in duplicate. 18S mRNA levels were used as endogenous control. 
Table 1. Sequences of primers and probes used for quantitative PCR analysis 
18S Sense 5'-CGG CTA CCA CAT CCA AGG A-3' 
rat Antisense 5'-CCA ATT ACA GGG CCT CGA AA-3' 
Probe 5'FAM-CGCGCAAA TT ACCCACTCCCGA-TAMRA3' 
iNOS Sense 5'-GTG CTA ATG CGG AAG GTC ATG-3' 
rat Antisense 5'-CGA CTT TCC TGT CTC AGT AGC AAA-3' 
Probe 5'FAM-CCC GCG TCA GAG CCA CAG TCC T-TAMRA3' 
Bcl-x, Sense 5'-TTG TGG ATC TCT ACG GGA ACA AT-3' 
rat Antisense 5'-GTC AGG AAC CAG CGG TTG AA-3' 
Probe 5'FAM-CTC CTG GCC TTT CCG GCT CTC G-TAMRA3' 
Statistical analysis 
All numerical results are reported as the mean of at least 3 independent experiments ± 
standard error of the mean. For each experiment, the results were analyzed using the 
Kruskal-Wallis test to verify the significance. If P<0.05 for the Kruskal-Wallis test, a Mann­
Whitney U test was used to determine the significance of differences between experimental 
groups. A P-value smaller than 0.05 was considered to be statistically significant. 
2.4 Results 
Metformin dose-dependently reduces bile acid induced apoptosis 
To examine whether metformin is hepatoprotective, two different models for apoptosis were 
used: bile acid (GCDCA)-induced apoptosis and TNFa/ActD-induced apoptosis. GCDCA­
induced caspase-3 activity peaks at 4 hrs (45), while for TNFa/ActD-induced apoptosis, 
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caspase-3 activity is maximal between 12-16 hrs (data not shown). Therefore, these time 
points were chosen to study the effects of metformin. Metformin inhibited GCDCA-induced 
caspase-3 activity dose-dependently from 24 % inhibition at 0.1 mmol/L to an almost 
complete block (84% inhibition) at a concentration of 2 mmol/L (Fig 1A). In contrast, 1 
mmol/L metformin, a concentration which reduces GCDCA-induced caspase-3 activity for 
63%, had no effect on TNFa/ActD-induced caspase-3 activity (Fig 18). Metformin (0.1-2 
mmol/L) alone did not induce caspase-3 activity. However, higher concentrations (5 mmol/L 
and higher) were toxic to hepatocytes (data not shown). Acridine orange staining confirmed 
the results obtained with the caspase-3 assay. Condensed nuclei are visible in 47% of 
GCDCA-treated hepatocytes (Fig 1 C), whereas in combination with metformin this number 
of apoptotic cells is reduced by 50% to 23%. However, metformin hardly affects TNFa/ActD­
induced nuclear condensation (Fig 1 C). Apoptotic cells were not observed in control or 
metformin-exposed hepatocytes. Next, the effects of metformin on GCDCA-induced 
caspase-6 activity were studied. Metformin (1 mmol/L) decreased GCDCA-induced caspase-
6 activity by 46 % (Fig 1 D). 
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Figure 1. Metformln dose-dependently reduces 
bile acid- nduced caspase-3 and caspase-6 
act,vity, but not TNFaiActD-induced apoptosis. 
Pr•mary rat hepatocytes were exposed to 
metformin prior to (A, D) GCDCA or (B) 
TNFa/ActD. Caspase-3 l'ke activity ,s shown as 
fold induction compared to control, control 
values were set at one. (C) Metform1n prevents 
---==--- GCDCA (4 hrs) induced nuclear condensat,on 
as demonstrated by acridlne orange staining. 
but has no effect on TNFalActD ( 16  hrs) 
induced nuclear condensation. Percentages 
represent condensed nuclei. Magnification 20X. 
(D) Caspase-6 like activity is measured in 
pr mary rat hepatocytes and is shown as fo d 
induction compared to control; contr� values 
were set at one Stat1stica1 analysis: • p<0.05 or 
+ p<O 01 compared to control. # p<0.05 
compared to GCDCA-trealed cells 
To demonstrate that metformin inhibits and does not delay bile acid induced apoptosis, a 
time course study was performed. At the indicated time points, from four to nine hrs after 
addition of GCDCA, metformin (added 10 min before GCDCA) inhibited GCDCA-induced 
caspase-3 activity (Fig 2A). After 24 hrs, levels of caspase-3 activity of GCDCA and GCDCA 
plus metformin treated cells were both comparable to control cells. Acridine orange staining 
was performed to ensure that the peak of caspase-3 activity of hepatocytes treated with 
GCDCA plus metformin was not between any of the time points studied. Both after 4 and 24 
hr exposure, metformin reduced the GCDCA-induced nuclear condensation by 72 % (Fig 
2B). 
i1 : 1�1 ------· ---'---·---·�.:. _____ _
Figure 2. Metform:n does not delay bile ackt-induced apoplosis. Primary rat 
hepatocytes were exposed to GCDCA without or in combjnat,on with metformin 
for 4, 6, 9 and 24 hrs MetformIn was added 10 minutes before GCDCA Control 
cells are rat hepatocytes not treated with GCDCA or metformm At the indicated 
time points, cells were analyzed for (A) caspase-3 1ke actlvty or (B) nuclear 
condensation as ndicated by acndine orange staining and expressed as % of 
condensed nuc el Magnilicahon 20X Statlstical analysis + p<0.01 compared to 
control. #  p<0.05 or • p<0.01 compared to GCDCA-treated cells (same t me-point). 
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Metformin does not block the uptake of GCDCA at the cell membrane 
Next, we examined whether metformin only protects cells when added before GCDCA, or 
also after bile acid exposure. Metformin was added either 10 minutes before, simultaneously 
with,  or 1, 2 or 3 hrs after addition of the bile acid. Metformin significantly decreased GCDCA 
induced caspase-3 activity when added up to 2 hrs after GCDCA (Fig 3). No difference in 
reduction of caspase-3 activity between a pre-incubation of 10 minutes with metformin or 
addition at the same time as GCDCA was detected (data not shown). 
40 
control 
Figure 3. Mettormin protects 
primary rat hepatocytes against 
apoptosis when added after 
GCDCA Hepatocytes were 
treated without (control) or with 
GCDCA for 4 hrs. Metformin was 
added with GCDCA or 1 .  2 and 3 
hrs after addition of GCDCA. 
Caspase-3 like activity was 
measured and is shown as fold 
induction compared to control; 
control values were set at one. 
---.-•• -,---,-,.-,.-.,.....:....c......_2-,..-.-•• -,---3-,.,-.-•• -,- Statistical analysis: + p<0.01 
GCOCA 
compared to control. # p<0.05 or • -----------==:::....---------- p<0.01 compared to GCDCA· 
treated cells 
Furthermore, equal uptake of fluorescent bile acids in hepatocytes treated with or without 
metformin was observed (data not shown). These results indicate that the protective effect of 
metformin is not due to reduced uptake of GCDCA into hepatocytes. 
Metformin reduces apoptosis without increasing necrotic cell death 
Subsequently, we studied whether the reduction in apoptotic cell death by metformin results 
in a shift towards necrotic cell death. At the peak of caspase-3 activity, 4 hrs after exposure 
to GCDCA the percentage of necrotic cells was determined. GCDCA caused necrosis in 
11 % of the cells, whereas 7% of the hepatocytes exposed to GCDCA and metformin were 
necrotic (Fig 4). Also after 16 hrs, there was no significant difference between cultures 
treated with GCDCA or GCDCA plus metformin (1 mmol/L, data not shown). No significant 
necrosis was observed in control cultures or cultures treated with metformin (Fig 4 ). 
Figure 4. Metformln reduces apoptosis 
without increasing necrotic cell death. 
Cells w11<e exposed to GCOCA for 4-16 
hrs. Metformin was added before 
addition of GCDCA Cells st,mu.ated 
with H202 (5 mmolll. 6 hrs) were used 
as positive control Sytox green nuclear 
staining was used to determine necrotic 
cell death Representative images 4 hrs 
after stimulat1on are shown. 
percentages indk:ate necrotic ce�s 
Upper panel phase contrast and 
fluorescence. Lower panel 












The anti-apoptotic effects of metformin are dependent on Pl3K/Akt signaling, but not 
on AMPK/mTOR signaling 
Previous results showed the involvement of the Pl3K survival pathway in the protective 
effect of TUDCA against GCDCA-induced apoptosis (45). Thus, we investigated whether the 
Pl3K pathway is also involved in the anti-apoptotic effects of metformin using the specific 
Pl3K inhibitor, L Y294002. Metformin reduced the GCDCA-induced caspase-3 like activity 
with 69% (Fig 5A). This protective effect of metformin against apoptosis was completely 
abolished when the Pl3K pathway was blocked (Fig 5A). A significant increase in GCDCA­
induced apoptosis was observed when the Pl3K pathway was inhibited in hepatocytes (data 
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not shown) as described previously (45). Next, the involvement of the AMPK/mTOR pathway 
was examined. AMPK was inhibited using a pharmacological inhibitor (5'-iodotubercidin) and 
mTOR was blocked by the specific inhibitor rapamycin (Fig 58). As shown in figure 58, 
blocking either AMPK or mTOR had no effect on the anti-apoptotic actions of metformin. 
Both inhibitors did not change GCDCA-induced caspase-3 activity (data not shown). 
Hepatocytes treated with the inhibitors alone or in combination with metformin showed 
caspase-3 values similar to control cells (data not shown). Interestingly, Western blot 
analysis demonstrated that hepatocytes treated for 1 hr with either GCDCA or metformin 
caused a slight induction (2-fold) of phosphorylated AMPKa compared to control cells (Fig 
SC). Cells exposed to both GCDCA and metformin showed a further 2-fold increase of 
AMPKa phosphorylation compared to control hepatocytes, while cells treated with AICAR 
induced a 30-fold increase of AMPKa phosphorylation. 
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Figure 5. The protective effect of metformtn involves the Pl3K/Akt 
pathway, bul not lhe AMPK/mTOR palhway Primary rat hepalocyles 
were exposed lo GCDCA and melformln for 4 hrs wilh or wilhoul (A) 
LY294002 or (B) 5"-lodoluberc·d n or rapamycm. Caspase-3 aclivily is 
presented as fold induction compared to control; control values were 
set at one Statistical anarysis: • p<0 05 or + p<0.01 compared to 
control. # p<0 05 compared lo GCDCA-lrealed cells. • p<0 05 
compared lo GCDCA plus melformin-lrealed eel s. (C) Western b'ol 
analysis for AMPK phosphorylation on cell lysales (45 µI). Lane 1 
control hepalocyles; lane 2: GCDCA treated cells (50 µmoVL, 1 hr); 
lane 3: GCDCA plus melformln (1 mmol/L) lane 4: melformin (1 
mmoVL); lane 5: positive control: hepalocyles exposed lo AICAR (250 GCOCA+ - µmolll, 1 hr). Western blots were quanbfied and band intensities of 
phaspho'Y ated AMPKa were expressed as ratio of the 1ntens1ty of f!-act1n prote111 levels Data is presented as mean of at least three independent 
expenments +/. S.E M. Control values were set at one A representative Western blot Is shown. 
Metformin induces Bel-xi expression 
Members of the Bel-2 family are key regulators of apoptosis. Previous studies revealed a 
role of the anti-apoptotic Bcl-2 family member, Bel-xi, in the protection of rat hepatocytes 
against superoxide anion induced apoptosis (unpublished data). Thus, the involvement of 
Bel-xi in GCDCA-induced apoptosis was studied. GCDCA did not change Bel-xi gene 
expression compared to control cells (Fig 6). Metformin caused a slight increase of Bel-xi 
gene expression, which was further enhanced in hepatocytes exposed to both GCDCA and 
metformin (Fig 6). 
comrol 
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Figure 6. Metformin increases Bc.l·xl mRNA expression, which is 
further enhanced In combination wilh GCDCA qPCR analysis for Bel­
xi using cDNA of primary rat hepatocytes stimulated for 4 hrs with 
GCDCA (50 µmol/L) and/or melformln ( 1 mmoVL). 
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Metformin is not an inhibitor of NF-KB 
Since inhibition of NF-KB sensitizes hepatocytes to TNFa-induced cell death (39), it is 
important to determine the effect of metformin on NF-KB activation, prior to its use in 
inflammatory (TNFa-mediated) liver diseases. Therefore, we studied the involvement of NF­
KB signaling in the protective effect of metformin. Previous studies demonstrated strong NF­
KB-dependent cytokine-induced expression of inducible nitric oxide synthase (iNOS) in 
hepatocytes (39). Cytokine mixture induces a 200-fold relative induction of iNOS expression 
compared to control cells (Fig 7 A), which was not affected by metformin. As expected, the 
transcriptional inhibitor actinomycin D completely blocked cytokine-induced iNOS expression 
(Fig 7A). Metformin alone did not induce iNOS expression (data not shown). The qPCR 
results were confirmed using the caspase-3 assay. TNFa alone, or in combination with 1 
mmol/L metformin did not induce caspase-3 activation (Fig 7B). In contrast, caspase-3 
activity was strongly induced in hepatocytes exposed to TNFa in combination with 
actinomycin D. 
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Figura 7. Metformin does not inhibit NF-KB activalion (A) Metform1n does not reduce cytokine mixture-induced iNOS mRNA expression qPCR 
analysis for iNOS using cDNA of primary rat hepatocytes exposed for 4 hrs to cytokine mixture with or without 1 mmol/L metform n The 
transcriptional inhibitor actinomycin D (200 ng/ml) served as positive control for NF-KB inhibition. (B) Metformin does not sensitize hepatocytes to 
TNFo-lnduced apoptosis Caspase-3 like activity was measured in primary rat hepatocytes exposed to TNFo (20 ng/ml, 16 hrs) with or without 
metformln (1 mmol/L) or actinomycin D (200 ng/ml, positive control for induction of TNFa-induced caspase-3 activity). Caspase-3 activity is shown 
as fold induction compared to control: control values were set at one. Statistical analysis: Fig 7A: • p<0.05 or + p<0 01 compared to control # 
p<0.01 compared to cytokine mixture-treated cells. • p<0.01 compared to cytokine mixture plus metformin-treated cells. Fig 78 • p<0.05 
compared to control. # p<0.05 compared to TNFa-treated cells. • p<0.05 compared to TNFa plus mettormin-treated cells. 
2.5 Discussion 
In this study we investigated the hepatoprotective actions of metformin in models of TNFa­
and bile acid-induced apoptosis in primary rat hepatocytes. Other studies described that 
metformin improves the viability of hepatocytes in fatty livers and reduced serum levels of 
ALT and AST in NASH (1 1-1 3). We show that metformin is protective against bile acid­
induced cell death, but metformin has no effect on TNFa-induced apoptosis. Metformin 
reduces, but does not delay, GCDCA-induced caspase activity and nuclear condensation. 
The opposite effects of metformin in these two models of hepatocyte apoptosis is most likely 
due to the involvement of different signaling pathways in cytokine and bile acid induced 
apoptosis. Cytokines like TNFa exert their effects via death receptors at the cell membrane, 
while bile acids need to be taken up by the bile acid transporter, Na+/taurocholate 
cotransporting polypeptide (Ntcp; 1 ,  4, 7). Furthermore, bile acid-induced apoptosis has 
been shown to involve activation of the Fas pathway via epidermal growth factor (EGF)­
receptor phosphorylation (48). TNFa is known to activate the transcription factor NF-KB, 
while we have previously demonstrated that GCDCA has no effect on NF-KB signaling (44). 
To elucidate the mechanism of the protective effect of metformin, we first excluded the 
possibility that metformin is protective by inhibiting GCDCA uptake at the cell membrane. 
The results obtained with the fluorescent bile acids clearly demonstrated that metformin has 
no effect on bile acid uptake. Furthermore, metformin was able to reduce apoptosis when 
added up to 2 hrs after bile acid exposure. These data suggest that metformin does not 
interfere with bile acid uptake, but rather activates survival pathways very rapidly. In this 
respect, the protective effect of metformin resembles the protective effect of TUDCA. 
TUDCA also protected against GCDCA-induced cell death when added up to 2 hrs after the 
bile acid (45). We confirm previous findings (45), that caspase-3 activation is still minimal 2 
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hours after GCDCA exposure,  and apoptosis can be prevented ,  while beyond this time point 
the apoptotic machinery cannot be reversed anymore. 
Previously, we demonstrated that under particular conditions the mode of cell death can shift 
from apoptosis to necrosis (46). In this study, metformin does not cause a switch from 
apoptotic to necrotic cell death. The percentage of necrotic cells is similar for GCDCA and 
GCDCA plus metformin treated hepatocytes. Furthermore, metformin does not significantly 
reduce GCDCA-induced necrosis. These results demonstrate that metformin only protects 
against apoptotic cell death. 
Since the AMPK/mTOR pathway is an important downstream target of metformin, we 
investigated the involvement of these pathways in the protective effect of metformin. Our 
results demonstrate that the AMPK/mTOR signaling pathway is not involved in the anti­
apoptotic actions of metformin (20, 21, 29, 49). Both known inhibitors for AMPK and mTOR, 
5'-iodotubercidin and rapamycin, had no effect on the reduction in GCDCA-induced 
apoptosis caused by metformin. Interestingly, GCDCA slightly increased the phosphorylation 
and activation of AMPK, although AMPK does not appear to be involved in the protective 
effect of metformin. The mechanism of this effect and its relevance remains to be elucidated. 
Since AMPK is not involved in the protective actions of metformin, the drug must exert its 
anti-apoptotic actions via other pathways. Our results demonstrate that the protective effect 
of metformin against GCDCA-induced apoptosis is dependent on an intact Pl3K pathway. 
These data are in accordance with other reports emphasizing the importance of Pl3K/Akt in 
the protection against bile acid-induced apoptosis (5, 37, 38, 40, 41, 45). However, our data 
imply that members of the MAP kinase family are not involved in the anti-apoptotic signaling 
of metformin, since inhibitors of the anti-apoptotic MAP kinases ERK1/2 and p38 do not 
affect the protective effect of metformin (data not shown). 
Our results demonstrate the induction of Bel-xi mRNA by metformin. Surprisingly, Bel-xi 
mRNA expression was further enhanced in combination with GCDCA, while Bel-xi 
expression levels were unaffected by the bile acid alone. Several reports have described 
NF-KB-controlled Bel-xi expression in different cell types (50, 51 ). However, in primary rat 
hepatocytes cytokine induction of the anti-apoptotic protein Bel-xi was not observed, while 
the anti-apoptotic Bcl-2 family member A1/Bfl-1 was induced by cytokines (39). Studies have 
reported both induction and down-regulation of NF-KB activity upon bile acid treatment (52-
55). In human fetal hepatocytes, chenodeoxycholic acid (COCA) and its taurine, but not 
glycine, conjugate induced NF-KB activation (55). Another report describes the dose­
dependent activation of NF-KB by GCDCA in hepatocytes. However, in this study GCDCA 
concentrations up to 400 µmol/L were used (52). In contrast, GCDCA at 500 µmol/L inhibited 
NF-KB activity in primary rat hepatocytes (53). We and others have previously reported that 
GCDCA at a concentration of 50 µmo!/L does not activate NF-KB in primary rat hepatocytes 
(44, 55). Thus, we can only speculate why metformin in combination with GCDCA further 
induces Bel-xi expression. The possibility that GCDCA sensitizes hepatocytes to NF-KB 
activation can be excluded, since metformin, either alone or in combination with GCDCA, did 
not induce the expression of the NF-KB-dependent gene iNOS. One study reported caspase­
regulated Bel-xi expression, via caspases downstream of ERK1/2. Using the specific ERK1/2 
inhibitor U0126, Bel-xi expression was reduced and apoptosis was induced. This U0126-
induced down-regulation of Bel-xi was reversed by the pancaspase inhibitor Z-VAD-FMK 
(56). Although a different cell type was used, caspase-dependent Bel-xi expression could 
explain our results: in our model GCDCA-induced caspase activity is reduced by metformin 
and this could result in an additional increase in Bel-xi expression. 
Our data clearly show that metformin does not inhibit NF-KB activity. Hepatocytes are not 
sensitized  to TNFa-induced apoptosis by metformin, and metformin does not affect cytokine 
induced NF-KB-dependent gene transcription. Our data are in contrast with several reports 
describing inhibition of NF-KB by metformin via AMPK (57, 58). However, these studies are 
not performed in hepatocytes but in endothelial cells, which could explain the discrepancy. 
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Furthermore, these reports showed the involvement of AMPK in metformin signaling, while in 
our study AMPK is not involved in the anti-apoptotic actions of metformin. 
In summary, we have shown that metformin, at concentrations similar to the clinical situation, 
is protecting primary rat hepatocytes against GCDCA-induced apoptosis, while metformin 
has no effect on TNFa/ActD-induced apoptosis. The Pl3K/Akt survival pathway is necessary 
for the anti-apoptotic effects of metformin. The protection is independent of the AMPK/mTOR 
signaling pathway. Furthermore, metformin induces the expression of the anti-apoptotic Bcl-
2 family member Bel-xi. In addition, we have demonstrated that metformin does not inhibit 
NF-KB activity and hence does not sensitize hepatocytes to TNFa-induced apoptosis. 
Therefore, if our data can be confirmed in in vivo models, metformin could be useful in the 
treatment of chronic liver diseases, in which an inflammatory component is present. 
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Background: Leflunomide is used in the treatment of autoimmune diseases as anti­
inflammatory agent. Leflunomide and its active metabolite A77 1726 modulate mitogen­
activated protein kinases (MAPK), Src kinases, the phosphoinositide-3 kinase (Pl3K)/Akt­
pathway and nuclear factor (NF)-KB activation. Both cell protective and cytotoxic effects of 
leflunomide have been described. Aim: Since leflunomide affects pathways involved in 
hepatocyte cell survival, we examined the effects of A77 1726 on hepatocyte cell death. 
Methods: Primary rat hepatocytes were exposed to the bile acid glycochenodeoxycholic acid 
(GCDCA), the superoxide anion donor menadione, or tumor necrosis factor (TNF) a in 
combination with A77 1 726. Activation of MAPK members was determined by Western blot 
analysis. Apoptosis and necrosis were analyzed by acridine orange staining and caspase 
activity, and Sytox Green staining, respectively. 
Results: A77 1726 dose-dependently reduces GCDCA-induced apoptosis and necrosis, but 
not menadione- or TNFa/ActD-induced apoptosis. The hepatoprotective effect of A77 1726 
does not involve ERK1/2, p38 or Pl3K/Akt activation and is mimicked by Src inhibition. A77 
1726 does not inhibit NF-KB activation. 
Conclusion: A77 1726 inhibits bile acid-induced cell death and does not sensitize primary rat 
hepatocytes to TNFa. In vivo studies are necessary to confirm the observed protective 
effects of A77 1726 in animal models for chronic liver injury, since our in vitro experiments 
suggest that A77 1726 might be useful as therapy for chronic liver diseases accompanied by 
elevated bile acid levels and inflammation. 
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3.2 Introduction 
Chronic cholestatic liver diseases result in cell death of hepatocytes via elevated levels of 
toxic metabolites, bile acids and reactive oxygen species. In acute liver injury, like acute viral 
hepatitis, hepatocyte cell death is mainly a consequence of pro-inflammatory cytokines and 
oxidative stress. Cell death often occurs as a combination of apoptosis and necrosis. 
Apoptosis or programmed cell death is an energy consuming process, which involves 
caspases, a family of cysteine proteases. Apoptosis is characterized by chromatin 
condensation, nuclear fragmentation and cell shrinkage, leading to the formation of apoptotic 
bodies. In contrast, necrotic cell death is a passive process, which via mitochondrial and 
cellular swelling results in plasma membrane leakage and subsequent release of cellular 
content into the extracellular environment and circulation, thus triggering inflammation ( 1 -8). 
Leflunomide (N-[(4-trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide) or Arava® is a 
well-known anti-inflammatory drug, used in the treatment of autoimmune diseases, 
particularly rheumatoid arthritis. Furthermore, leflunomide is used in the protection against 
rejection after organ transplantation, and in the treatment of Crohn's disease and cancer. 
After administration, the prodrug leflunomide, is almost completely metabolized (>95%) to its 
active compound A77 1726 or teriflunomide (2-cyano-3-oxo-N-[(4-
trifluoromethyl)phenyl]butyramide; 9-14). Proposed molecular mechanisms explaining the 
anti-inflammatory, anti-proliferative and immunosuppressive effects of leflunomide are 
inhibition of protein tyrosine kinases, e.g kinases of the Src family, blocking dihydroorotate 
dehydrogenase (DHODH) involved in pyrimidine synthesis and progression through the cell 
cycle, inhibition of mitogen activated protein kinase (MAPK) members, including the pro­
apoptotic Jun N-terminal kinase (JNK), and reduced production of pro-inflammatory 
cytokines via inhibitory effects on the transcription factor nuclear factor- B (NF- B; 9, 1 4-
1 8). Leflunomide was shown to protect against acetaminophen (APAP)-induced cell death in 
human hepatocytes (9) and diminished APAP-mediated liver injury in mice (19). The 
protective mechanisms included inhibition of cytochrome c release from the mitochondria, 
and reduced activation of both the pro-apoptotic MAPK family member JNK1/2 and the pro­
apoptotic protein, Bcl-2 (9, 19). In primary human hepatocytes (20) and erythroleukemia 
cells (21) A77 1 726 reduced activation of p38 and JNK1/2. The Aki survival pathway and 
extracellular signal regulated kinase (ERK) 1/2 were activated upon leflunomide treatment in 
these cells (21 ). Variable effects of leflunomide on NF-KB activation have been reported: 1 )  
leflunomide did not affect NF-KB signalling in primary human hepatocytes and 
erythroleukemia cells (20, 21 ); 2) leflunomide suppressed NF-KB activation in Jurkat, 
myeloid, cervical epithelial and glioma cells (15, 16), and in an in vivo study of concanavalin 
A (Con A)-induced hepatitis in mice (1 0). The cytoprotective effect of leflunomide is 
illustrated by the reduction of Con A-induced aminotransferase levels in the serum, caspase 
activities, plasma cytokine concentrations, and p38 activity in mice (10), a significant 
improvement of bile duct ligation (BDL)-induced liver injury (22) and reduced hepatocyte 
damage after ischemia/reperfusion (1/R) injury (11 ). In contrast, in rat thymocytes apoptosis 
was induced by A77 1726 (23). The synthetic analogue of A77 1726, called LFM-A12 (a­
cyano-l3-hydroxy-l3-methyl-N-[4-(trifluoromethoxy)phenyl]-propenamide), induced apoptosis 
in breast cancer cells in vitro (24). Thus, both cell protective as well as cytotoxic effects of 
leflunomide have been described. 
Considering this discrepancy in actions of leflunomide, and the variable effects on signal 
transduction pathways that are also involved in hepatocyte survival, including MAPK 
members, Src-family members, NF-KB signalling and the phosphoinositide-3 kinase 
(Pl3K)/Akt survival pathway, we investigated the effects of the prodrug and its active 
metabolite A77 1726 on hepatocyte cell death. The effect of leflunomide in 3 different in vitro 
models was examined. We report a cytoprotective effect of A77 1726 against bile acid­
induced hepatocyte cell death, which is independent of the anti-apoptotic MAPK members, 
p38 and ERK1/2 and the Pl3K/Akt signalling pathway. Furthermore, no effect of A77 1 726 
on NF-KB activation in hepatocytes was observed. 
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3.3 Materials and Methods 
Animals 
Specified pathogen-free male Wistar rats (200-250 g) were purchased from Charles River 
Laboratories Inc. (Wilmington, MA, USA). Rats were housed under standard laboratory 
conditions with free access to standard laboratory chow and water. Prior to isolation, rats 
were fasted overnight. Experiments were performed following the guidelines of the local 
Committee for Care and Use of laboratory animals. 
Rat hepatocyte isolation 
Hepatocytes were isolated from rats by a two step collagenase perfusion as described 
before (25). Cell viability was greater than 85% as determined by Trypan Blue exclusion. 
After isolation, 112,500 cells per cm2 were plated on Vitrogen® (Cohesion Technologies Inc. , 
Palo Alto, CA, USA) coated plates in William's E medium (lnvitrogen, Breda, The 
Netherlands) supplemented with 50 µg/mL gentamycin (lnvitrogen) and penicillin­
streptomycin-fungizone (Lonza, Verviers, Belgium). During the attachment period (4 hrs) 50 
nmol/L dexamethasone (Dept. of Pharmacy UMCG, Groningen, The Netherlands) and 5% 
fetal calf serum (lnvitrogen) were added to the medium. Cells were cultured in a humidified 
incubator at 3rc and 5% CO2. 
Experimental design 
Experiments were started immediately after the 4 hrs hepatocyte attachment period. 
Monolayer cultures were exposed to 50 µmol/L glycochenodeoxycholic acid (GCDCA, 
Calbiochem, La Jolla, CA, USA) for 4 hrs. Alternatively, hepatocytes were treated for 12 hrs 
with 50 µmol/L of the superoxide anion donor, menadione (2-methyl-1,4-naphthoquinone, 
Sigma-Aldrich, St. Louis, MO, USA) or for 16 hrs with 20 ng/ml recombinant murine tumor 
necrosis factor a (mTNFa, R&D Systems, Abingdon, United Kingdom) in combination with 
200 ng/ml of the transcriptional inhibitor actinomycin D (ActD, Roche Diagnostics, Almere, 
The Netherlands) or for 4 hrs with a cytokine mixture (CM) consisting of 20 ng/ml mTNFa, 10 
ng/ml recombinant human interleukin-113 (hlL-113, R&D Systems), 10 ng/ml recombinant rat 
interferon-y (rlFN y, R&D Systems) and 10 µg/ml lipopolysaccharide (LPS, Escherichia coli, 
serotype 0127:BB, Sigma-Aldrich). Leflunomide (Sigma-Aldrich) and its active metabolite, 
A77 1726 (also known as teriflunomide, Calbiochem) were used at concentrations ranging 
from 1-50 µmol/L. MAPK members were specifically blocked using 10 µmol/L of the cell 
permeable p38 kinase inhibitor SB203580 (Calbiochem), 10 µmol/L of U0126 (Promega, 
Madison, WI, USA), the inhibitor of the ERK1/2 signalling cascade or 5 µmol/L of the 
JNK1/2-inhibitor SP600125 (lnvitrogen). The Src-family of tyrosine kinases were inhibited 
using 10 µmol/L SU6656 (Calbiochem) The Pl3K pathway was inhibited using L Y294002 (50 
µmol/L, Calbiochem). All inhibitors were added 30 minutes prior to GCDCA. Each 
experimental condition was performed in triplicate. 
Cells were harvested at the indicated time points after the addition of the apoptotic stimuli, 
and washed three times with ice cold phosphate-buffered saline (PBS) before the addition of 
hypotonic cell lysis buffer (protein analysis, caspase-3/-6 assay), Tri-reagent (RNA isolation, 
Sigma-Aldrich) or 2x concentrated sample buffer (Western blot analysis) as described 
previously (26). 
Each experiment was performed at least three times, using hepatocytes from different 
isolations. 
Caspase enzyme activity assays 
Caspase-3 like activity was assayed as described previously (26). The arbitrary fluorescence 
unit (AFU) was corrected for the amount of protein in the cell lysate. Caspase-6 like activity 
was assayed according to the manufacturer's instructions (Biovision, Mountain View, CA, 
USA) 
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Sytox green and acridine orange nuclear stainings 
To determine necrotic cell death, hepatocytes were incubated for 1 5  minutes with Sytox 
green (lnvitrogen) nucleic acid stain. Sytox binds DNA, but can only enter cells with leaky 
plasma membranes, characteristic of necrotic cell death. Sytox cannot cross the membranes 
of viable cells or apoptotic bodies. Hepatocytes exposed to 5 mmolll hydrogen peroxide 
(H2O2, Merck Chemicals Ltd, Nottingham, UK) for 6 hrs served as positive control for 
necrosis. Apoptotic nuclei were visualized with acridine orange (Sigma-Aldrich) as described 
previously (25). Fluorescent nuclei were visualized using an Olympus CKX41 microscope at 
450-490 nm. 
Western blot analysis 
Western blot analysis of cell lysates treated for 1 hr with GCDCA and/or A77 1726 was 
performed by SOS-PAGE followed by semi dry-blotting to transfer the proteins to Hybond 
ECL nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA). Ponceau S 
(Sigma-Aldrich) staining (0.1 % w/v) was used to monitor electrophoretic transfer. Activation 
of the MAP kinases JNK, p38 or ERK1 /2 was detected using polyclonal antibodies against 
phosphorylated JNK (lnvitrogen), phosphorylated p38 (Cell Signaling Technology, Inc, 
Danvers, MA, USA) or the monoclonal antibody against phosphorylated ERK1/2 (New 
England Biolabs, Leusden, The Netherlands) at a dilution of 1 :500. After Western blot 
analysis, blots were stripped as described previously (25) and incubated with polyclonal 
antibodies against total JNK, p38 (Cell Signaling Technology, Inc) or ERK1/2 (Santa Cruz 
Biotechnology, Inc, Heidelberg, Germany) respectively (dilution 1 : 1 000). Western blots were 
quantified and band intensities of phosphorylated protein were expressed as ratio of the 
intensity of the corresponding total protein. 
RNA isolation and quantitative polymerase chain reaction (PCR) 
RNA isolation was performed as described previously (27). RNA concentration was 
determined with the Ribogreen RNA quantitation reagent and kit (lnvitrogen). Reverse 
transcription PCR (RT-PCR) was carried out on 2.5 µg of total RNA using random primers in 
a total volume of 50 µL using the moloney murine leukemia virus (M-MLV) reverse 
transcriptase system (Sigma-Aldrich) according to the manufacturer's instruction. 
Quantitative PCR was performed on 4 µL of 20-times diluted complementary DNA in a final 
volume of 20 µL (27). Fluorescence was measured using the ABI PRISM 7700 Sequence 
Detector version 1 .7 software (Applied Biosystems, Nieuwerkerk aid IJssel, The 
Netherlands) starting with 10 minutes at 95°C, followed by 40 cycles of 1 5  seconds at 95°C 
and 1 minute at 60°C. Details of primers and probes are listed in Table 1. Each sample was 
analyzed in duplicate. 18S mRNA levels were used as endogenous control. 
Table 1. Sequences of primers and probes used for quantitative PCR analysis 
18S Sense 5'-CGG CTA CCA CAT CCA AGG A-3' 
rat Antisense 5'-CCA ATT ACA GGG CCT CGA AA-3' 
Probe 5'FAM-CGCGCAAA TT ACCCACTCCCGA-TAMRA3' 
!Nos Sense 5'-GTG CTA ATG CGG AAG GTC ATG-3' 
rat Antisense 5'-CGA CTT TCC TGT CTC AGT AGC AAA-3' 
Probe 5'FAM-CCC GCG TCA GAG CCA CAG TCC T-TAMRA3' 
Statistical analysis 
All numerical results are reported as the mean of at least 3 independent experiments ± 
standard error of the mean. A Mann-Whitney test was used to determine the significance of 





A77 1 726, the active metabolite of leflunomide, dose-dependently reduces bile acid­
induced apoptosis 
The effects of the drug leflunomide and its active metabolite, A77 1726, were examined in an 
in vitro model of acute bile acid toxicity: GCDCA-induced apoptosis. Leflunomide, did not 
change GCDCA-induced caspase-3 activity at concentrations up to 50 µmol/L (Fig 1A). In 
contrast, A77 1726 dose-dependently reduced GCDCA-induced caspase-3 activity in the 
concentration range of 1 µmol/L (27.5% reduction) to 50 µmol/L (79.2% inhibition; Fig 1 B). 
A77 1726 alone did not induce caspase-3 activity (data not shown). Since A77 1726 at a 
concentration of 25 µmol/L inhibited GCDCA-induced caspase-3 activity comparable to 50 
µmol/L A77 1726, 73.7% and 79.2% respectively, we decided to use the lower concentration 
(25 µmol/L) of A77 1726 to study the protective effects in more detail. At this concentration, 
A77 1726 (25 µmol/L) also decreased GCDCA-induced caspase-6 activity (51.1 %; Fig 1 C). 
These results were confirmed by acridine orange staining. Hepatocytes exposed to GCDCA 
for 4 hrs demonstrate apoptotic nuclei in 52.6% of the cells (Fig 1 D), whereas in combination 
with A77 1726 the percentage of condensed nuclei is reduced to 33.7 %. In control or A77 
1726-treated hepatocytes apoptotic cells were nearly absent. 
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Figure 1. The active metabol te of leflunomlde. A77 1 726 reduces bile acid 
induced apoptosls. Primary rat hepatocytes were exposed to (A) 
leflunom,de or 1B) A77 1726 added 30 minutes prior to GCDCA (50 µmol/L. 
4 hrs) Caspase-3 like activity was measured, and is shown as fold 
induction compared to controt values· control values were set at one. (C) 
A77 1 726 also reduces GCOCA induced caspase-6 act v1ty. Caspase-6 hke act1v1ty was measured 1n primary rat hepatocytes exposed to GCDCA 
with or without A77 1726. Caspase-6 like act1V1ty 1s shown as fo d induction compared to control, control values were set at one. (0) A77 1726 
prevents GCDCA (4 hrs) nduced nuclear condensation as indicated by acnd1ne orange staining and expressed as ,.o of condensed nuclei. 
Magnification 20X. Statistical analysis • p<0 05 or + p<0 01 compared to control cells # p<0.05 or p<0.01 compared to GCDCA treated ce Is. 
A77 1 726 does not protect against cytokine or oxidative stress induced apoptosis 
Since these results indicate that A77 1726 protects hepatocytes against bile acid-induced 
apoptosis, we decided to study the effects of A77 1726 also in other models of liver cell 
toxicity. Two models were examined, an in vitro model for acute liver failure induced by 
TNFa in combination with ActD, and receptor-independent oxidative stress-induced cell 
death, elicited by the superoxide anion donor menadione. A77 1726 (25 µmol/L) did not 
change TNFa/ActD-induced caspase-3 activity (Fig 2A). In contrast, menadione-induced 
caspase-3 activity was even further increased, although not significantly, by A77 1726 (Fig 
28). 
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Figure 2. A77 1726 does not protect hepatocytes against cytokine- or oxidative stress-induced apoptosis Primary rat hepatocytes were exposed 
to A77 1 726 added 30 minutes prior to (A) TNFa/ActD (20 nglml, 200 nglml, 16 hrs) or (B) menadione (50 µmol/L, 12 hrs) Caspase-3 like activity 
was measured, and is shown as fold induction compared to control values, control values were set at one Statistical analysis • p<0.05 or + 
p<0.01 compared to control 
A77 1 726 blocks apoptotic cell death without inducing necrotic cell death 
Next, we studied whether the reduction in apoptosis by A 77 1726 resulted in a shift to 
necrosis. The percentages of necrotic cells were determined both at the peak of caspase-3 
activity (4 hrs) as well as after overnight exposure. Hepatocytes exposed to GCDCA for 4 
hrs resulted in necrosis in 12% of the cells, while 6% of the cells treated with GCDCA and 
A77 1726 were necrotic (Fig 3). After overnight exposure, A77 1726 also significantly 
lowered GCDCA-induced necrosis {data not shown). In control cultures or hepatocytes 











Figure 3. A77 1 726 reduces necrotic 
cell death Cells were treated without 
(control) or with GCDCA (50 µmol/L) for 
4-16 hrs A 77 1 726 was added 30 
minutes before GCDCA. Sytox green 
nuclear staining was used to determine 
positive control 
>95% 
necrotic cell death Cells stimulated with 
H202 (5 mmoUL, 6 hrs) were used as 
positive control Representative images 
4 hrs after stimulation are shown Upper 
panel: combined phase contrast and 
fluorescence. Lower panel 
fluorescence. Magnification 20X 
Statistical analysis # p<0.05 compared 
to GCDCA-treated cells. 
A77 1 726 is protective after addition of bile acids 
Subsequently, we examined whether A77 1726 also protects hepatocytes when added after 
GCDCA exposure. A 77 1726 was added either 30 minutes prior to, simultaneously with or 1, 
2 or 3 hrs after addition of the bile acid. A77 1726 significantly reduced GCDCA-induced 
,. caspase-3 activity when added up to 1 
+ hr after GCDCA (Fig 4). At all three 
l 
2 1n •'* , ....... 
time points of A77 1726 addition, pre­
incubation, simultaneously with or one 
hr after bile acid, around 65% 
reduction in caspase-3 activity was 
observed. When added 2 or 3 hrs after 
GCDCA, A77 1726 still decreased 
GCDCA-induced caspase-3 activity, 
although not significantly (Fig 4). 
Figure 4. A77 1726 protects against apoptosis when added after GCDCA. Rat hepatocytes were treated without (control) or with GCDCA (50 
µmol/L) for 4 hrs. A77 1726 (25 µmol/L) was added 30 minutes prior to GCDCA, simultaneously with the bile acid or 1, 2 and 3 hrs after addition 
of GCDCA. Caspase·3 like activity was measured, and is shown as fold induction compared to control values, control values were set at one 
Statistical analysis: + p<0.01 compared to control # p<0.05 compared to GCDCA treated cells. 
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Our results suggest that A77 1726 does not have a major inhibitory effect on GCDCA-uptake 
by bile acid transporters like ntcp. 
The hepatoprotective effect of A77 1 726 does not require ERK1/2 and p38 MAPK 
activation, is independent of the PIK/Akt survival pathway and is mimicked by Src­
inhibition 
The involvement of the anti-apoptotic members of the MAPK family, ERK1/2 and p38, in the 
protection of A77 1726 was examined using the specific inhibitors U0126 and SB203580, 
respectively. The reduction in GCDCA-induced caspase-3 like activity caused by A77 1726 
was partially reversed by treatment with U0126 or SB203580 (Fig 5A), but this reversal was 
not statistically significant. Both inhibitors alone had no effect on GCDCA-induced caspase-3 
activity (data not shown) as described previously (26). Subsequently, we studied the 
involvement of ERK1/2 and p38 activation in the protective mechanism of A77 1726 by 
Western blot analysis. Similar levels of phosphorylated ERK1/2 (Fig 5B) were detected in 
GCDCA and/or A77 1726-treated hepatocytes compared to control cells. Phosphorylated 
p38 (Fig 5C) appeared to be slightly increased in hepatocytes treated with GCDCA and/or 
A77 1726 compared to control cells, but no significant difference between exposure to 
GCDCA or GCDCA in combination with A77 1726 was observed. Together, these results 
suggest that both ERK1/2 and p38 MAP kinase are not required for the protective effect of 
A77 1726. A '] 
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Figure 5. The protection of A77 1726 does not involve ERK1/2 and p38 MAPK members ncr the Pl3K/Akt survival pathway. Pr mary rat 
hepalocytes were exposed to GCDCA and A77 1726 for 4 hrs with (A) the ERK1/2 inhibitor U0126 (10 µmol/L), the p38 inhibitor 5B203580 (10 
µmol/L), the JNK inhibitor SP600125 (5 µmoVL) or (E) the Pl3-kinase inhibitor L Y294002 (50 µmol/L) and (F) the Src inhibitor SU6656 (10 
µmol/L). Caspase-3 like activity was measured, and 1s  shown as fold induction compared to control; control values were set at  one. Statishcar 
analysis: • p<0 05 or + p<0 01 compared to control. # p<0.05 compared to GCDCA treated eel s Western blot analysis for (B) phosphorylated 
and total ERK1/2, (C) phosphorylated and total p38 and (D) phosphorylated and total JNK1/2 on hepatocytes treated without (control) or with 
GCDCA (50 µmol/L, 1 hr) in combination wilh A77 1726 (25 µmol/L). Western blots were quantified and band intensities of phosphorylated protein 
were expressed as ratio of the intensity of the corresponding total protein. Data is presented as mean of at least three independent expe,,ments 
+/. S E.M. Control values were set at one. A representative Western blot is shown. 
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The MAPK member J NK is pro-apoptotic in bile acid-induced apoptosis, and inhibition of 
JNK phosphorylation and activation using the inhibitor SP600125 reduced GCDCA-induced 
caspase activity and apoptosis (Fig 5A). Since A77 1726 mimicked the effect of the J NK1/2 
inhibitor SP600125 on GCDCA-induced apoptosis, we next determined whether A 77 1726 
acts as JNK-inhibitor. The levels of phosphorylated JNK1 and 2 were equal in hepatocytes 
treated with GCDCA, A77 1726 or both (Fig 5D). 
Next, we investigated whether the Pl3K/Akt survival pathway is involved in the anti-apoptotic 
actions of A77 1726. As shown in figure 5E, inhibition of the Pl3K pathway using LY294002 
had no effect on the protection by A77 1726 against GCDCA-induced apoptosis. As 
described previously (26), GCDCA-induced caspase-3 activity was significantly increased 
when the Pl3K pathway was inhibited (data not shown). Finally, we showed that the effect of 
A77 1726 was mimicked by the Src inhibitor SU6656 (Fig. 5F). 
A77 1 726 does not inhibit NF-KB activation 
Since it has been reported that A77 1726 inhibits TNFa-mediated NF-KB activation in 
inflammatory and immune cells (15, 16), we examined the role of NF-KB signalling in the 
anti-apoptotic actions of A77 1726. First, the effects of A77 1726 on the NF-KB-dependent 
cytokine-induced inducible nitric oxide synthase (iNOS) expression were studied. 
Hepatocytes exposed to cytokine mixture showed a 270-fold relative induction of iNOS 
expression compared with control cells (Fig 6A). In contrast to actinomycin D, which 
completely prevents cytokine-induced iNOS expression, A77 1726 did not affect iNOS 
expression (Fig 6A). Next, we confirmed the qPCR results by determining apoptosis. Both 
hepatocytes treated with TNFa or TNFa plus A77 1726 show only base-line caspase-3 
activity levels similar to control cells (Fig 68), indicating that A77 1726 does not sensitize 
hepatocytes to TNFa-induced cell death. In contrast, actinomycin D in combination with 
TN Fa strongly induced caspase-3 activity. 
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Figure 6. A77 1726 does nol Inhibit TNFo-induced NF-KB activation. qPCR analysis far iNOS using cDNA al primary rat hepalacytes exposed far 
4 hrs lo cytokine mixlure with or withaul A77 1726. The transcriptional inhiMor actinornycin D (200 nglml) served as posnive control for NF-KB 
inhibition (A) Statistical analysis: + p<0.01 compared ta control. • p<0 01 compared to cells stimulated with cytokine mixture or # p<0.01 
compared to cells treated with cytokine mixture + actinomycin D. (B} A77 1 726 does not sensitize hepatocytes to TNFa-induced apoptosis 
Caspase-3 like actJvIty was measured in primary rat hepatacytes exposed ta TNFo (16 hrs) with or without A77 1726 or aclinamycin D (positive 
control for TNFa-sens1tizaUon). Caspasa.3 activity is shown as fold induction compared to control values, control values were set at one 
Statistical analysis • p<0.05 compared to control • p<0.05 compared ta TNFo stimulated cells or # p<0.05 compared ta TNFo/ActD treated cells. 
3.5 Discussion 
Leflunomide (Arava®) is a drug that is used in the treatment of autoimmune disorders and 
rheumatoid arthritis. It has anti-inflammatory and anti-proliferative actions and its reported 
mechanisms of action involve signal transduction pathways that are also relevant in 
hepatocyte survival and apoptosis. Therefore, we examined the effects of leflunomide and its 
active metabolite, A77 1726, in models of bile acid, oxidative stress and TNFa-induced liver 
injury in primary rat hepatocytes. Previous studies reported that leflunomide ameliorated liver 
damage in hepatocytes and animal models of cholestasis including Con A-induced hepatitis, 
drug-induced cytotoxicity and I/R injury (9-11, 19, 22). In the present study, we show that 
leflunomide does not affect GCDCA-induced apoptosis, while its active metabolite A77 1726 
is protective against cell death induced by GCDCA. We examined the effects of both 
compounds at similar concentrations (µmolar range) confirming previous reports that A77 
1726 has a 100-fold higher cytoprotective activity than the pro-drug leflunomide (9). 
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Leflunomide is metabolized in the gastrointestinal wall, the liver and plasma. The metabolism 
of leflunomide to A77 1726 was analyzed in in vitro experiments using rat plasma, whole 
blood and liver microsomes. In plasma or whole blood a t112 for leflunomide of 36 and 59 
minutes respectively was observed, while in liver microsomes only 5 to 6 % was metabolized 
in 30 minutes. However, in the presence of NADPH the t1 12 i ncreased to 40 minutes (28). 
Thus, apart from the variation in cytoprotective potency between leflunomide and A77 1726, 
the lack of protection by the prodrug leflunomide may be caused by insufficient metabolism 
into A77 1 726 within the time frame of our experiments. 
A77 1726 reduced several parameters of apoptosis, including caspase-3 and caspase-6 
activity, nuclear fragmentation, as well as the number of necrotic cells. A77 1 726 only 
prevented bile acid-induced cell death, and did not protect hepatocytes against TNFa/ActD 
or menadione-induced apoptosis, although in these models of cell death caspase activation 
and mitochondria-derived signals are also of major i mportance in the execution of apoptosis. 
A likely explanation is that these inducers of cell death activate different intracellular signal 
transduction pathways involved in cell death and/or cell survival. TNFa is known to activate 
the transcription factor NF-KB, while GCDCA and menadione do not affect NF-KB activity 
(25, 29). Bile acids require uptake by specific transporters, e.g. ntcp and Fas/EGF-receptor 
mediated events (30, 31) to exert their effects (26), while TN Fa signalling is initiated by 
activation of the TNF-receptor at the cell membrane and apoptosis induced by reactive 
oxygen species (superoxide anions) is receptor-independent. Differences in the mechanism 
of cell death are also demonstrated by the fact that the anti-apoptotic bile acid 
tauroursodeoxycholic acid (TUDCA) inhibits GCDCA-induced apoptosis, but not superoxide 
anion or TNFa-induced apoptosis (25). In fact, both A77 1 726 and TUDCA increase 
menadione-induced caspase-3 activity, although not significantly. This slight increase in 
superoxide anion-induced hepatocyte apoptosis was not further explored. 
A77 1726 was still effective when added 1 hour after GCDCA exposure and apoptosis 
tended to be lower when A77 1726 was added between 1 and 3 hours after GCDCA 
exposure. This implies that the protective effect of A77 1726 is probably not due to reduced 
bile acid uptake. Surprisingly, the protection of A77 1 726 was equal when added before, 
simultaneous with or 1 hr after the bile acid. Since bile acid induced caspase-3 activity peaks 
at 3-4 hours (26) our results indicate that A77 1 726 can prevent bile acid induced apoptosis 
at a relatively late stage and that A77 1 726 rapidly activates survival pathways. Numerous 
studies have implicated the involvement of Pl3K/Akt, Src kinases and MAPK members in the 
regulation of apoptosis and cell survival. Since these kinases can be activated very rapidly, 
their role in the protective effect of A77 1 726 was examined. Our results do not support an 
important role for p38 and ERK1/2 or Pl3K/Akt in the anti-apoptotic actions of A77 1726, 
since inhibition of these kinases did not reverse the protective effect of A77 1726. 
Furthermore, A77 1 726 did not change the phosphorylation and hence the activity of these 
kinases, either in the absence or presence of bile acids. These results are in contrast to 
other studies, describing inhibitory effects of A77 1 726 on p38 activation (10, 20, 21), and 
stimulation of ERK1/2 and Akt activity (21). The effects on p38 have been observed in 
various cell types. Using a mouse model of hepatitis (10) p38 activation in whole liver 
sections was determined. In this setting, the effects of other liver cell types, like Kupffer cells 
that may regulate protein kinase phosphorylation are included, while in our in vitro 
experiments one cell type, primary rat hepatocytes, was studied. The d ifferent findings using 
primary human (20) or rat hepatocytes compared to whole liver sections can be explained by 
the involvement of cytokines that are released by non-parenchymal cell types, notably 
Kupffer cells. A77 1726 is able to inhibit p38-activation induced by IL-1 , however, in our 
model, p38 was not significantly induced by GCDCA compared to control cells and A77 1726 
has no effect on p38. In accordance with a previous study in primary human hepatocytes, 
A77 1726 alone had no effect on the phosphorylation of the MAPK family members ERK1/2 
and p38. In contrast, in two human erythroleukemia cell lines leflunomide not only inhibited 
p38 activity, but stimulated ERK1 /2 activation (21 ). Furthermore, at variance with our 
observations, in these cell lines phosphorylation of Akt was induced by leflunomide. These 
46 
The active metabolite of leflunom1de, All 1 726, protects rat hepatocytes against bile acid-induced apoptosis 
differences can be attributed to the use of different cell types and/or the difference between 
primary cells and (transformed) cell lines. 
In contrast to other studies (9, 14, 15, 19-21) A77 1726 did not change the activation of the 
pro-apoptotic MAPK member JNK in our study. In synoviocytes, A77 1726 slightly increased 
cytokine-induced J NK activation (14), while in Jurkat cells (15), hepatocytes (9, 20) and liver 
sections (19) phosphorylated JNK was reduced by A77 1726 or leflunomide. 
Our results clearly show that A77 1726 does not inhibit NF-KB activity. Rat hepatocytes are 
not sensitized to TNFa-induced apoptosis by A77 1726, and A77 1726 does not influence 
cytokine-induced NF-KB-dependent gene transcription. These data are in line with other 
studies reporting no effect of A77 1726 or leflunomide on NF-KB activity (20, 21 ), but are in 
contrast with several reports describing inhibition of NF-KB by leflunomide or its metabolite 
(10, 16). In both primary human (20) and rat hepatocytes, A77 1726 does not affect NF-KB 
activation, while NF-KB-activity induced by a variety of stimuli is inhibited in Jurkat, myeloid, 
epithelial and glioma cells (15, 16). Also, in a mouse model of autoimmune hepatitis, 
leflunomide inhibited NF-KB in whole liver (10). These contradictory observations appear to 
be cell type specific. Our observation that leflunomide nor its metabolite A77 1726 inhibit NF-
B activity is very important, since it implies that leflunomide does not sensitize hepatocytes 
to TNF-induced apoptosis and hence, could be considered for the treatment of cholestatic 
liver diseases in the presence of inflammation. 
None of the investigated signal transduction pathways appeared to be responsible for the 
hepatoprotective effect of A77 1726 against GCDCA-induced cell death. Therefore, we can 
only speculate about the signalling pathways that are involved in this protective effect. One 
possibility comprises the Src-family of tyrosine kinases. Leflunomide was shown to block the 
activity of the Src members Lek and Fyn in T-cells (16-18). Recent papers reported the 
involvement of the Src kinase family members, Yes, Fyn and Lek in oxidative stress­
mediated cytotoxicity and Yes in bile acid-induced cell death (32, 33). Specific inhibition of 
Yes by SU6656 blocked tauro-lithocholic acid-3 sulfate (TLCS)-induced apoptosis (33). In 
our study, we observed a similar effect of SU6656 on GCDCA induced apoptosis. Since 
inhibition of Yes using SU6656 and exposure to A77 1726 result in similar hepatoprotective 
effects, and since A 77 1726 does not affect the MAPK family members, nor the Pl3K 
pathway or NF-KB pathway, we speculate that the Src-kinase Yes could be a potential target 
for A77 1726. 
In summary, we have shown that A77 1726 protecs hepatocytes against bile acid-induced 
cell death, while A77 1726 has no effect on TNFa/ActD- or superoxide anion-induced 
apoptosis. The anti-apoptotic MAPK family members, p38 and ERK1/2, and the Pl3K/Akt 
survival pathway are not involved in the protective effect of A77 1726. Activation of the pro­
apoptotic MAPK member JNK is not modulated by A77 1726. Furthermore, in primary rat 
hepatocytes A77 1726 does not sensitize hepatocytes to TNFa-induced apoptosis. In vivo 
experiments are necessary to confirm our in vitro observations, and to support or reject our 
data which indicate that A 77 1726 could be useful as therapy for chronic cholestatic liver 
diseases accompanied by inflammation. 
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Background: Bile acids, reactive oxygen species (ROS) and inflammatory cytokines are 
crucial regulators of cell death in liver diseases. It has been hypothesized that bile acid­
induced generation of ROS contributes to bile acid-induced hepatocyte death. Aim: to 
investigate the role of ROS in bile acid-induced cell death. 
Methods: Primary rat hepatocytes were exposed to the bile acids glycochenodeoxycholic 
acid (GCDCA) or taurolithocholic acid-3 sulfate (TLCS) in the absence or presence of ROS 
scavengers or antioxidants. Heme oxygenase (HO)-1 mRNA levels were analyzed by qPCR. 
Total glutathione levels were determined, and apoptosis and necrosis were quantified by 
acridine orange and Sytox green staining, respectively. 
Results: Bile acid-induced cell death is not reduced by ROS-scavengers or antioxidants. Bile 
acids do not induce the oxidative stress responsive gene HO-1 and do not deplete 
glutathione levels. The Src-kinase inhibitor, SU6656, reduces GCDCA-induced apoptosis 
and necrosis. Inhibition of NADPH oxidase reduces bile acid-induced apoptosis, but 
increases necrosis. 
Conclusion: Bile acid induced toxicity is not mediated via generation of ROS and bile acids 
do not modulate indicators of oxidative stress. Src-kinases play an important role in bile acid­
induced cell death. NADPH oxidase inhibition does not reduce cell death but induces a shift 
from apoptosis to necrosis. 
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4.2 Introduction 
A common feature of both acute and chronic liver diseases is the excessive death of 
hepatocytes, leading to loss of liver function and eventually liver failure. Several mediators of 
hepatocyte death have been proposed, including pro-inflammatory and pro-apoptotic 
cytokines like tumor necrosis factor (TNF) a and Fas ligand (Fasl}, reactive oxygen species 
(ROS), bile acids and toxic metabolites (1 -3). The exact contribution of each of these 
mediators to hepatocyte cell death in the various liver diseases remains to be elucidated. 
Cell death often occurs as a mixture of apoptosis and necrosis. Apoptosis or programmed 
cell death is a tightly regulated process, involving the caspase-family of cysteine proteases. 
The energy-dependent apoptotic pathway results in cell shrinkage and formation of apoptotic 
bodies, which are cleared very efficiently by surrounding cells (4-7). Necrosis, a passive 
mode of cell death, leads to plasma membrane rupture, and subsequent release of cellular 
content in the extracellular environment and circulation and an increased inflammatory 
response (7, 8). 
Reactive oxygen species comprise a variety of free radicals and peroxides. Under normal 
conditions, ROS are formed during oxygen-dependent metabolism. Upon cellular stress or 
during the metabolism of xenobiotics, e.g. alcohol, the endogenous generation of ROS can 
be significantly enhanced (9- 1 1 ). In addition, in inflammatory conditions there is exposure to 
exogenous ROS, generated by inflammatory cells. Cells contain many other pro-oxidant 
systems, such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidases ( 1 1 -1 3) 
and xanthine oxidase. NADPH-oxidase generates superoxide anions while oxidizing NADPH 
(1 1 ,  1 4). Hepatocytes contain a variety of defence mechanisms against oxidative stress. The 
enzyme superoxide dismutase (SOD) catalyzes the reduction of superoxide anions to 
hydrogen peroxide (H202), which is subsequently converted into water and oxygen by either 
catalase or glutathione peroxidases (1 2, 1 3, 1 5, 1 6). Glutathione peroxidase oxidizes the 
antioxidant glutathione, while reducing hydrogen peroxide into water. In contrast to its 
conversion into water, hydrogen peroxide can also react with ferrous ions, resulting in the 
production of highly reactive hydroxyl radicals ( 13). In addition to enzymatic antioxidants, 
cells contain many other antioxidants such as vitamins, glutathione and bilirubin ( 12, 1 3, 1 7). 
ROS are generated in both acute and chronic liver injury, and increased ROS generation 
has been implicated in hepatocyte cell death. Indeed, antioxidant therapy has been shown to 
be effective in liver injury known to be associated with oxidative stress, e.g. alcoholic liver 
injury (1 8). It has been hypothesized that cholestasis and exposure to bile acids also cause 
generation of ROS and oxidative stress, resulting in hepatocyte death and liver injury. The 
bile acid glycochenodeoxycholic acid (GCDCA) at concentrations of 50-100 µmol/L was 
shown to generate ROS in isolated mitochondria and hepatocytes (1 9-23). In contrast, only 
one paper described that GCDCA (50 µmol/L) did not increase ROS generation, while higher 
concentrations of the bile acid (200 and 400 µmol/L) clearly induced ROS in primary rat 
hepatocytes (9). Additional studies have described the generation of ROS after bile acid 
exposure: tauro-lithocholic acid-3 sulfate (TLCS), taurochenodeoxycholate (TCDC; 1 9, 24-
26), taurodeoxycholic acid (TOCA; 27) and deoxycholic acid (DCA; 27, 28) promoted 
oxidative stress in either freshly isolated (25, 27, 28) or 24-hour cultured ( 19, 24, 26) rat 
hepatocytes. The ROS production could be reduced by a variety of antioxidants (1 9, 25-27), 
which also decreased bile acid-induced caspase activation (26) or cell death (1 9, 25). The 
anti-apoptotic bile acid ursodeoxycholic acid (UDCA) lowered bile acid-induced ROS 
generation and apoptosis in primary rat hepatocytes (22, 28). Likewise, GCDCA-induced 
ROS generation was reduced by antioxidants (1 9-21 ) and antioxidants lowered the levels of 
apoptosis (21 ). However, some studies described no effect of antioxidants on lipid 
peroxidation (29), or even a complete reduction in lipid peroxidation by antioxidants without 
a reduction in liver damage (25, 30). Recently, the importance of members of the Src 
tyrosine kinase family and NADPH oxidases in oxidative stress, Fas and bile acid-induced 
cytotoxicity was reported ( 14, 26, 31 -35). The Src kinase family consists of 9 members, all of 
them containing the Src-specific homology domains SH2 and SH3 and a tyrosine kinase 
53 
Chapter 4 
domain (36). Oxidative stress results in activation of the Src family members Fyn, Yes and 
Lek, while hydrophobic bile acids only activate Yes in cultured hepatocytes (31, 32). The Src 
inhibitor SU6656, which specifically inhibits the Src kinases Fyn ,  Yes, Lek and Src (37), 
blocked bile acid-induced Yes activation (32). In addition, antioxidants that reduced bile acid­
induced ROS generation, also inhibited Yes phosphorylation (32). Membrane-associated 
NADPH oxidase isoforms have been postulated to act up-stream of Yes activation: bile acids 
activate NADPH oxidases, resulting in ROS generation, Yes activation and ultimately 
apoptosis (26). 
In this study, the involvement of ROS in bile acid-induced cell death was examined using 2 
different bile acids. We demonstrate that neither hydrogen peroxide nor superoxide anions 
are involved in GCDCA- or TLCS-induced cell death, while the Src-family of kinases is 
implied in bile acid-induced apoptotic and necrotic signaling. In addition, our results suggest 
that inhibition of NAPDH oxidase shifts GCDCA-induced cell death from apoptosis to 
necrosis. 
4.3 Materials and Methods 
Animals 
Specified pathogen-free male Wistar rats (200-250 g) were purchased from Charles River 
Laboratories Inc (Wilmington, MA, USA). Rats were housed under standard laboratory 
conditions with free access to standard laboratory chow and water. Prior to isolation, rats 
were fasted overnight. Experiments were performed following the guidelines of the local 
Committee for Care and Use of laboratory animals. 
Rat hepatocyte isolation 
Hepatocytes were isolated from rats by a two step collagenase perfusion as described 
before (10). Cell viability was greater than 85% as determined by trypan blue exclusion. After 
isolation, 112,500 cells per cm2 were plated on Vitrogen® (Cohesion Technologies Inc., Palo 
Alto, CA, USA) coated plates in William's E medium (lnvitrogen ,  Breda, The Netherlands) 
supplemented with 50 µg/mL gentamycin ( lnvitrogen) and penicillin-streptomycin-fungizone 
(Lonza, Verviers, Belgium). During the attachment period (4 hrs) 50 nmol/L dexamethasone 
(Dept. of Pharmacy, UMCG, Groningen,  The Netherlands) and 5% fetal calf serum 
(lnvitrogen) were added to the medium. Cells were cultured in a humidified incubator at 37°C 
and 5% CO2. 
Experimental design 
Experiments were started after the attachment period of 4 hrs. Monolayer cultures were 
exposed to 50 µmol/L GCDCA (Calbiochem, La Jolla, CA, USA) for 4 hrs or to 100 µmol/L 
TLCS (Sigma-Aldrich ,  St. Louis, MO, USA) for 6 hrs. In some experiments, hepatocytes 
were treated with the superoxide anion donor, menadione (2-methyl-1,4-naphthoquinone, 50 
µmol/L, Sigma-Aldrich) or a cytokine mixture (CM) consisting of 20 ng/ml recombinant 
murine TNFa (R&D Systems, Abingdon, United Kingdom), 10 ng/ml recombinant human 
interleukin-113 (hlL-113, R&D Systems), 10 ng/ml recombinant rat interferon-y (rlFN y, R&D 
Systems) and 10 µg/ml lipopolysaccharide (LPS, Escherichia coli, serotype 0127:88, Sigma­
Aldrich). The involvement of reactive oxygen species was studied using 100 U/ml superoxide 
dismutase-polyethylene glycol from bovine erythrocytes (PEG-SOD, Sigma-Aldrich), 500 
U/ml catalase-polyethylene glycol (PEG-CAT, Sigma-Aldrich), 5 mmol/L of the antioxidant 
and glutathione precursor N-acetyl-L-cysteine (NAC, Sigma-Aldrich) or 5 mmol/L glutathione 
monoethyl ester (GSH-MEE, Merck Chemicals Ltd, Nottingham, UK), the cell permeable 
derivative of glutathione. Diphenylene iodonium (DPI, Biomol Research Laboratories Inc, 
Plymouth Meeting, PA, USA) was used at 2.5 µmol/L to block NADPH oxidase and nitric 
oxide synthase (NOS, ref 306). 10 µmol/L SU6656 (Merck) was used to inhibit the Src 
kinase family members Fyn, Yes, Lek and Src (37), and 1 µmol/L herbimycin A 
Streptomyces Sp. (Merck) was used to block a variety of protein tyrosine kinases including 
Src, heat shock proteins, and nuclear factor-KB (NF-KB) activation (38). All inhibitors were 
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added 30 minutes prior to bile acids. Each experimental condition was performed in 
triplicate. 
Cells were harvested at the indicated time points after the addition of the apoptotic stimuli, 
and washed three times with ice cold phosphate-buffered saline (PBS) before the addition of 
hypotonic cell lysis buffer (protein analysis, caspase-3 assay), sample buffer 2x (Western 
blot analysis) or Tri-reagent (RNA isolation, Sigma-Aldrich) as described previously (39). 
Each experiment was performed at least three times, using hepatocytes from different 
isolations. 
Caspase enzyme activity assay 
Caspase-3 like activity was assayed as described previously (39). The arbitrary fluorescence 
unit (AFU) was corrected for the amount of protein in the cell lysate. 
Sytox green and acridine orange nuclear staining 
To determine necrotic cell death, hepatocytes were incubated with Sytox green (lnvitrogen, 
1 :40000) nucleic acid stain. Sytox can only enter cells with compromised plasma 
membranes, and cannot cross the membranes of viable cells or apoptotic bodies. Apoptotic 
nuclei were visualized with acridine orange (Sigma-Aldrich, 1 :5000) as described previously 
(10). Fluorescent nuclei were visualized using an Olympus CKX41 microscope at 450-490 
nm. Necrosis and apoptosis were quantified by counting fluorescent nuclei (necrotic or 
apoptotic cells) and the total number of cells in 3 randomly chosen high power fields. 
Western Blot analysis 
Western blot analysis of cell lysates was performed by SOS-PAGE followed by semi dry­
blotting to transfer the proteins to Hybond ECL nitrocellulose membrane (Amersham 
Biosciences, Piscataway, NJ, USA). Ponceau S 0.1 % w/v (Sigma-Aldrich) staining was 
used to confirm electrophoretic transfer. Protein expression of heme-oxygenase-1 (HO-1) 
was detected using a monoclonal antibody against HO-1 (Stressgen, Sanbio BV, Uden, The 
Netherlands) at a dilution of 1 :500. After Western blot analysis, blots were stripped as 
described previously (10) and incubated with a monoclonal antibody against GAPDH 
(Calbiochem, dilution 1 :5000). The blots were analyzed in a ChemiDoc XRS system (Bio­
Rad, Hercules, CA, USA). Protein band intensities were quantified by Quantity One software 
(Bio-Rad). 
RNA isolation and quantitative polymerase chain reaction (PCR) 
RNA isolation, reverse transcription PCR and quantitative PCR (qPCR) were performed as 
described previously (40). Details of primers and probes are listed in Table 1. Each sample 
was analyzed in duplicate. 1 BS mRNA levels were used as endogenous control. 
Table 1. Sequences of primers and probes used for quantitative PCR analysis 
185 Sense 5'-CGG CTA CCA CAT CCA AGG A-3' 
rat Antisense 5'-CCA ATT ACA GGG CCT CGA AA-3' 
Probe S'FAM-CGCGCAAA TT ACCCACTCCCGA-TAMRA3' 
INOS Sense 5'-GTG CTA ATG CGG AAG GTC ATG-3' 
rat Antisense 5'-CGA CTT TCC TGT CTC AGT AGC AAA-3' 
Probe S'FAM-CCC GCG TCA GAG CCA CAG TCC T-TAMRA3' 
H0-1 Sense 5'-CAC AGG GTG ACA GAA GAG GCT AA-3' 
rat Anti sense 5'-CTG GTC TTT GTG TTC CTC TGT CAG-3' 
Probe S'FAM-CAG CTC CTC AAA CAG CTC AAT GTT GAG C-TAMRA3' 
Glutathione determination 
Total glutathione (reduced glutathione and glutathione disulfide, GSSG) was measured in 
cell lysates by the enzymatic recycling procedure as described by Griffith (41) using 
glutathione reductase from yeast (Roche Diagnostics Nederland BV, A/mere, The 
Netherlands), GSSG (Sigma-Aldrich), NADPH (Roche Diagnostics) and 5,5'-dithiobis-(2-
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nitrobenzoic acid) (DTNB, Roche Diagnostics). Samples were analyzed on a 30°C Uvikon 
spectrophotometer for 1 O minutes at 412 nm. Each sample was analyzed in duplicate. 
Values were normalized over the protein amount in the lysates. 
Statistical analysis 
All numerical results are reported as the mean of at least 3 independent experiments ± 
standard error of the mean. For each experiment, the results were analysed using the 
Kruskal-Wallis test to verify the significance. If P<0.05 for the Kruskal-Wallis test, a Mann­
Whitney U test was used to determine the significance of differences between experimental 
groups. A P-value smaller than 0.05 was considered to be statistically significant. 
4.4 Results 
Reactive oxygen species are not involved in bile acid induced cell death 
Caspase-3 activity peaked at 3-4 hours after addition of GCDCA as shown previously (42). 
GCDCA-induced caspase-3 activity was not affected by either the cell permeable enzyme 
superoxide dismutase (SOD) or catalase (Fig 1 A), nor did the cell permeable glutathione 
derivative glutathione monoethyl ester (GSH-MEE) change GCDCA-induced caspase-3 
activity. Caspase-3 activity was slightly reduced by the antioxidant N-acetyl-L-cysteine, 
however this effect was not significant (Fig 1A). The antioxidants alone did not induce 
caspase-3 activity (data not shown). Reactive oxygen species have been implicated in 
TLCS-induced cell death ( 19, 24, 26). In our hands, all three compounds examined, 
superoxide dismutase, catalase and glutathione-monoethylester, slightly reduced TLCS­
induced caspase-3 acitivity (Fig 1B). However, this decrease was not statistically significant 
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shown as fold induction compared to control, control values were set at one. Superoxide dismutase and catalase do not affect GCDCA-induced 
nuclear condensation (C) or tD) necrotic cell death (C) Apoptotic nuclei were determined by acndtne orange staining 4 hrs after GCOCA· 
exposure and expressed as 0o of total nuclei Magnification 10X. (0) Sytox green nuclear stairnng was used to monitor necrosis Upper panel 
combined phase contrast and fluorescence Lower panel fluorescence Magnification 10X Statistical analysis· • p<0 01 compared 10 control 
The results from the caspase-3 activity assay (Fig 1 A) were confirmed by acridine orange 
staining, visualizing condensed, apoptotic nuclei .  Hepatocytes exposed for 4 hrs to GCDCA 
demonstrate apoptotic nuclei in 52% of the cells (Fig 1 C). In combination with PEG-SOD or 
PEG-catalase the percentage of condensed nuclei remained 48% and 47% respectively. In 
control conditions, apoptotic cells were hardly present (Fig 1 C). Next, the effects of PEG­
catalase and PEG-SOD on GCDCA-induced necrosis were analyzed. Necrosis was 
observed in 16% of the cells treated with GCDCA for 4 hrs (Fig 1 D) and this percentage was 
not significantly changed by either PEG-SOD or PEG-catalase: 16% and 12% necrotic cells, 
respectively. Control hepatocytes or hepatocytes exposed to PEG-SOD or PEG-catalase did 
not display necrosis (Fig 1 D, data not shown). 
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To test the effectiveness of the antioxidants PEG-SOD and PEG-catalase, we determined 
the effect of PEG-SOD on menadione-induced apoptosis and PEG-catalase on hydrogen 
peroxide-induced necrosis. PEG-SOD completely abolished menadione-induced apoptosis 
(data not shown) as described previously (10) and PEG-catalase completely prevented 
hydrogen peroxide induced necrosis (data not shown). 
Bile acid exposure does not exert oxidative stress on hepatocytes 
To determine whether GCDCA exerts oxidative stress on hepatocytes, we measured 
expression of the oxidative stress responsive gene HO-1 and total glutathione levels. As 
shown in figure 2A, exposure to GCDCA or TLCS did not change HO-1 mRNA expression 
compared to control hepatocytes. In contrast, exposure to the superoxide anion donor, 
menadione results in a 20-fold induction of HO-1 expression compared to control cells (Fig 
2A). Western blot analysis confirmed that HO-1 is not induced by GCDCA (Fig 2B) and 
quantification of HO-1 protein levels, standardized on GAPDH intensities, revealed relative 
amounts of 1.00 and 0.91 for control and GCDCA-treated hepatocytes respectively (Fig 2B). 
The total gluthathione level of hepatocytes exposed to GCDCA was not significantly lower 
compared to control hepatocytes (Fig 2C). 
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Figure 2. The oxidative stress responsive gene H0-1 is not induced by bile acids. qPCR analysis for H0-1 using cDNA of primary rat 
hepatocytes exposed for 4 hrs to 50 µmol/L GCDCA or 6 hrs to 100 µmol/L TLCS (AJ. The superoxide anion donor, menadione (SO µmol/L, 4 hrs) 
served as positive control for H0-1 induction (B) Western blot analysis of H0-1 prote n expression 1n cell lysates (45 µI) of primary rat 
hepatocyles treated without (control) or with GCDCA (SO µmol/L, 4 hrs). Western blots were quantified and band intensities of H0-1 protein were 
expressed as ratio of the intensity of GAPDH protein Data is presented as mean of at least three independent experiments +/- S E M. Control 
values were set at one. A representative Western blot is shown. (C) GCDCA does not affect total glutath,one 'eve s Total glutathione (mmol/mg 
protein) was measured and is shown as percentage of control; control values were set at 100%. 
Bile acid induced apoptosis involves NADPH oxidase and the Src family of kinases, 
but inhibiting NAPDH oxidase shifts GCDCA-induced cell death from apoptosis into 
necrosis 
Subsequently, the involvement of the Src kinase and NADPH oxidase signaling pathways in 
bile acid-induced cell death were studied. Exposure of hepatocytes to the NADPH-oxidase 
inhibitor DPI prior to GCDCA, strongly reduced caspase-3 activity (Fig 3A). Similarly, 
treatment with the specific Src-kinase inhibitor SU6656 decreases GCDCA-induced 
caspase-3 activity by about 67% (Fig 3A). In contrast, the protein tyrosine kinase inhibitor 
herbimycin A only slightly lowered caspase-3 activity upon GCDCA exposure, but this effect 
was not significant (Fig 3A). The inhibitors alone did not induce caspase-3 activity (data not 
shown). The effects of DPI, SU6656 and herbimycin A were also investigated on TLCS­
induced apoptosis. DPI almost completely inhibited TLCS-induced caspase-3 activity (Fig 
3B), while SU6656 caused a small but non-significant reduction. Herbimycin A even further 
enhanced TLCS-induced caspase-3 activity, although not statistically significant (Fig 3B). 
Again, acridine orange staining was performed to verify the results obtained with the 
caspase-3 activity assay (Fig 3A). GCDCA exposure for 4 hrs resulted in nuclear 
condensation in 52% of the hepatocytes (Fig 3C). DPI and SU6656 reduced the percentage 
of condensed nuclei to 22% and 15% respectively, whereas herbimycin A (50%) had no 
effect on GCDCA-induced nuclear condensation. Apoptosis was barely present in control 
hepatocytes (Fig 3C) or cells treated with only the inhibitors (data not shown). Next, we 
determined the effects of these inhibitors on necrotic cell death. GCDCA-treatment induced 
necrosis in 16% of the hepatocytes after 4 hrs ( Fig 3D), which was further increased after 
overnight exposure to 37% (Fig 3E). At 4 hrs, GCDCA-induced necrosis was not affected by 
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DPI (18% necrotic hepatocytes, Fig 3D). In contrast, overnight exposure of hepatocytes to 
DPI and GCDCA significantly induced necrotic cell death to 83% (Fig 3E). SU6656 reduced 
GCDCA-induced necrosis to less than 10% at both time points (Fig 3D, data not shown). 
Exposure to herbimycin A slightly but not significantly increased GCDCA-induced necrosis al 
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We observed that DPI protected against apoptosis, but strongly increased necrotic cell 
death. Since DPI is also known to inhibit NOS, in addition to NADPH oxidase, we examined 
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Reactive oxygen species are not essential for bile acid-induced cell death 
4.5 Discussion 
We investigated the involvement of reactive oxygen species in bile acid-induced injury in 
primary rat hepatocytes since previous studies described contradictory findings (9, 19, 21, 
23-27, 43). In our studies we show that ROS are not essential for bile acid induced cell 
death, since various scavengers of ROS and antioxidants do not reduce GCDCA or TLCS 
induced apoptosis or necrosis. In addition, parameters of exposure to oxidative stress, such 
as heme oxygenase-1 induction and glutathione depletion, did not change in bile acid 
exposed hepatocytes. These results are in accordance with a previous study (9) showing 
that GCDCA, used at the same concentration as in our experiments, does not induce ROS 
generation. GCDCA did generate ROS at higher concentrations (� 200 µmol/L), but these 
concentrations result predominantly in necrotic rather than apoptotic cell death. This study 
(9) and our results are in contrast to many other reports describing a rapid and sustained 
ROS production in response to GCDCA exposure (19-23). These conflicting data cannot be 
explained by the use of different cell types. The induction of ROS has been shown in both 
freshly isolated rat hepatocytes (21, 23), cultured primary rat hepatocytes (19) and isolated 
mitochondria from human (22) and rat (20). Although a few studies (20, 23) used 2-fold 
higher concentrations of GCDCA as used in our study, ROS generation induced by 50 
µmol/L of bile acid has been described (19, 2 1). An interesting previous observation in this 
regard is that inhibition of caspase-8 completely abrogated GCDCA-induced apoptosis, but 
only partially reduced ROS generation (21 ), indicating no or only a weak correlation between 
ROS generation and apoptosis. 
A possible explanation for these contradictory results is that bile acids at concentrations 
below 100 µmol/L generate low levels of ROS, as has been shown in many studies, that are 
insufficient to induce oxidative stress accompanied by HO-1 induction and glutathione 
depletion and are not causally involved in apoptotic cell death. At these concentrations, bile 
acids activate apoptotic signaling pathways involving Src kinase family members like Yes. At 
very high concentrations of bile acids (above 200 µmol/L), high levels of ROS may be 
generated, accompanied by oxidative stress and necrotic rather than apoptotic cell death. 
Our findings are supported by patient studies (29, 30) in which antioxidant treatment did not 
reduce lipid peroxidation or reduce liver injury. 
The Src-kinase signal transduction pathway has been implicated in bile acid-induced cell 
death and it has been hypothesized that bile acid-induced generation of ROS activate Src­
kinase family members. The inhibitor SU6656, which predominantly inhibits the Yes family 
member, significantly reduced GCDCA-induced apoptosis, whereas the protein tyrosine 
kinase inhibitor herbimycin A had no significant inhibitory effect on GCDCA-induced 
apoptosis. In contrast, both compounds had no significant effect on TLCS-induced 
apoptosis. This distinction is in line with previous papers describing the involvement of 
different signaling pathways in GCDCA- and TLCS-induced cell death. An inhibitory effect of 
SU6656 on TLCS-induced apoptosis has been described (32). In our study SU6656 tended 
to decrease TLCS-induced apoptosis, but this reduction did not reach significance. 
It has been hypothesized that bile acids activate the membrane-associated enzyme NADPH­
oxidase. Activated NADPH-oxidase generates ROS and this ROS, via Yes activation, 
induces apoptosis (26). In our study, inhibition of NADPH oxidase using DPI significantly 
reduced GCDCA and TLCS-induced apoptosis, as described before (26). However, although 
necrotic cell death was not affected by DPI 4 hours after exposure to GCDCA, it was 
significantly increased after overnight treatment of hepatocytes to GCDCA in combination 
with DPI, demonstrating a shift in cell death from apoptosis towards necrosis. A shift from 
apoptotic to necrotic cell death has been observed before using a model system involving 
superoxide anions and the nitric oxide donor SNAP (10). The DPl-induced increase in 
necrotic cell death has not been noted before and leads to the conclusion that inhibition of 
NADPH oxidase does not protect against bile acid induced apoptosis. Together with our 
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observations on the effect of ROS scavengers and parameters of oxidative stress, we can 
conclude that ROS generation is not responsible for bile acid induced apoptotic cell death. 
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Chapter 5 
5.1 Abstract 
Background: Most chronic liver diseases are accompanied by oxidative stress, which may 
induce apoptosis in hepatocytes and liver injury. Oxidative stress induces heme oxygenase-
1 (HO-1) expression. This stress-responsive cytoprotective protein is responsible for heme 
degradation into carbon monoxide (CO), free iron and biliverdin. CO is an important 
intracellular messenger; however, the exact mechanisms responsible for its cytoprotective 
effect are not elucidated yet. Aim: To investigate whether HO-1 and CO protect primary 
hepatocytes against oxidative stress-induced apoptosis. 
Methods: In vivo, bile duct ligation was used as model of chronic liver disease. In vitro, 
primary hepatocytes were exposed to the superoxide anion-donor menadione in a normal 
and a CO containing atmosphere. Apoptosis was determined by measuring caspase-9,-6,-3 
activity and PARP cleavage, and necrosis by Sytox Green staining. 
Results: HO-1 is induced in chronic cholestatic liver diseases. Superoxide anions induce 
HO-1 activity time and dose-dependently. HO-1 overexpression inhibits superoxide anion­
induced apoptosis. CO blocks superoxide anion-induced JNK-phosphorylation, caspase-9, -
6, -3 activation and abolishes apoptosis, but does not increase necrosis. 
Conclusion: HO-1 and CO protect primary hepatocytes against superoxide anion-induced 
apoptosis partially via inhibition of JNK-activity. CO could represent an important candidate 
for treatment of liver diseases. 
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5.2 Introduction 
Chronic liver diseases, such as non-alcoholic steatohepatitis (NASH), chronic cholestasis 
and alcoholic and chronic viral hepatitis, are almost invariably accompanied by exposure to 
reactive oxygen species (ROS; 1-3). ROS can contribute to hepatocyte cell death and liver 
injury by either apoptosis or necrosis. 
Caspases (4, 5) represent the central executioners of apoptosis (6, 7). Apoptosis is an active 
process characterized by cell shrinkage, chromatin condensation and formation of apoptotic 
bodies. In contrast, necrosis is passive and associated with ATP depletion, rupture of the 
plasma membrane and spilling of the cellular content eliciting inflammation (6). 
Heme oxygenase-1 (HO-1) catalyzes the oxidation of heme to form equimolar amounts of 
ferrous iron, biliverdin and carbon monoxide (CO). Biliverdin is rapidly converted into bilirubin 
by NAD(P)H:biliverdin reductase. HO-1 is induced by a variety of stimuli, most of them 
associated with oxidative stress (8). Many studies have suggested that HO-1 acts as an 
inducible defense against oxidative stress, e.g. in models of inflammation, 
ischemia/reperfusion, hypoxia and hyperoxia-mediated injury (9). In the liver, HO-1 induction 
protected against ischemia/reperfusion injury (10, 11) and endotoxemia (12, 13). In addition, 
overexpression of HO-1 by gene transfer has been shown to protect against hyperoxia 
induced lung injury (14), immune-mediated apoptotic liver damage in mice (15) and against 
CYP2E1-dependent toxicity in HepG2 cells (16). However, the mechanisms by which HO-1 
mediates cytoprotection are not elucidated yet. Protective effects of both biliverdin and CO 
have been reported and several papers suggest that biliverdin protects against oxidative 
stress by acting as an antioxidant in different models of liver injury (17, 18). Less is known 
about the biological actions of CO. Although CO is known to be toxic and lethal at high 
doses, interest has recently emerged for the role of CO as a signaling and regulatory 
molecule in cellular processes (19, 20). A cytoprotective effect of CO has been 
demonstrated in several conditions associated with apoptosis. 
In the present study, our aim was to investigate the regulation of HO-1 in vivo (model of 
acute inflammation and chronic cholestasis) and in vitro in primary cultures of rat 
hepatocytes. In addition, we investigate whether CO contributes to the protective effect of 
HO-1 against oxidative stress-induced apoptosis in primary hepatocytes, and the 
mechanisms involved in the process. 
5.3 Materials and Methods 
Animals 
Specified pathogen-free male Wistar rats (220-250 g) were purchased from Harlan (Zeist, 
The Netherlands). They were housed under standard laboratory conditions with free access 
to standard laboratory chow and water. Experiments were performed following the guidelines 
of the local Committee for Care and Use of laboratory animals. 
Animal models 
Bile Duct ligation 
Male Wistar rats were anaesthetized and subjected to bile duct ligation (BDL) as a model of 
chronic cholestasis (21). At the indicated time points after BDL, rats (n=4 per group) were 
sacrificed, livers were perfused with saline and removed. Control rats (n=4) received a sham 
operation (SHAM) or not (control). 
Model of acute inflammation 
Rats were injected intraperitoneally (IP) with 5 mg/kg body weight lipopolysaccharide (LPS 
serotype 0127:88; Sigma-Aldrich, St. Louis, MO) or the same volume of phosphate-buffered 
saline (PBS, control group, n=4 for each experimental group), with or without diethylmaleate 
(DEM: 4 mmol/kg bodyweight, Sigma-Aldrich) 30 minutes prior to LPS or PBS injection. LPS 
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and DEM were dissolved in sterile PBS. Rats were sacrificed 6 hrs after LPS injection. Livers 
were perfused with saline and snap-frozen in liquid nitrogen until further use. 
Rat hepatocyte isolation 
Hepatocytes were isolated as described previously (22) and cultured in William's E medium 
(lnvitrogen; Breda, The Netherlands) supplemented with 50 µg/ml gentamycin (lnvitrogen) 
without the addition of hormones or growth factors. During the attachment period (4 hrs), 50 
nmol/L dexamethasone (Sigma-Aldrich) and 5% fetal calf serum (lnvitrogen) were added to 
the medium. Cells were cultured in a humidified incubator at 37°C and 5% CO2. Hepatocyte 
viability was always more than 90% and purity more than 95% as determined by trypan blue 
staining. 
Experimental design 
Experiments were started 24 hrs after the isolation of hepatocytes. Cells were exposed to 
the intracellular superoxide anion-donor menadione (2-methyl-1,4-naphthoquinone, 50 
µmolll, Sigma-Aldrich; 23), hydrogen peroxide (H2O2, 1 mmol/L, MERCK, Haarlem, The 
Netherlands) or a cytokine mixture (24) composed of 20 ng/ml murine TNFa (R&D Systems, 
Abingdon, United Kingdom), 10 ng/ml human interleukin-113 (R&D Systems) and 10 ng/ml rat 
interferon-y (R&D Systems) for the indicated time. Activation of ERK1/2 mitogen-activated 
protein kinase (MAPK) was inhibited using the MEK inhibitor U0126 at 10 µmol/L (Promega, 
Madison, WI, USA). 1 H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ, 50 µmol/L, Sigma­
Aldrich) was used to inhibit soluble guanylate cyclase (sGC). Depletion of intracellular 
reduced glutathione was achieved using L-buthionine-(S, R)-sulfoximine (BSO, 200 µmol/L, 
Sigma-Aldrich) and 1 mmolll DEM (Sigma-Aldrich). In some experiments, caspase activity 
was inhibited using a cocktail of caspase inhibitors, composed of 5 µmol/L Z-DEVD-FMK 
(caspase-3 inhibitor; R&D Systems), 5 µmol/L Z-IETD-FMK (caspase-8 inhibitor; R&D 
Systems), 5 µmol/L Z-VEID-FMK (caspase-6 inhibitor; R&D Systems) and 5 µmol/L Z-LEHD­
FMK (caspase-9 inhibitor; R&D Systems). 
Hepatocytes were exposed to the adenoviruses Ad5HO-1, Ad51KBAA or Ad5LacZ 
(multiplicity of infection of 10) 15 hours before exposure to the superoxide anion-donor 
menadione or cytokine mixture. 
Parallel experiments were performed in a normal and a carbon monoxide containing culture 
atmosphere. Hepatocytes were placed in the carbon monoxide containing atmosphere after 
attachment, approximately 15 hrs before the start of the experiments. Each experimental 
condition was performed in triplicate wells. Each experiment was performed, at least three 
times, using hepatocytes from different isolations. 
Carbon monoxide exposure 
CO at a concentration of 1 % (10000 parts per million, ppm) in compressed air was mixed 
with compressed air containing 5% CO2 before being delivered into the culture incubator, 
yielding a final concentration of 400 ppm CO. The incubator was humidified and maintained 
at 37°C. A CO analyzer was used to determine CO levels in the chamber. After the chamber 
had stabilized, no oscillations were measured in the CO concentration. 
Caspase enzyme activity assay 
Caspase-3 enzyme activity was assayed as described previously (25). 
Sytox green nuclear staining 
Rupture of the plasma membrane distinguishes necrotic from apoptotic cell death (26). To 
determine necrosis, hepatocytes were incubated 1 5  minutes with Sytox green (lnvitrogen) 
nucleic acid stain, which only penetrates cells with compromised plasma membranes but 
does not cross the membranes of viable cells or apoptotic bodies. Fluorescent nuclei were 
visualized using an Olympus CKX41 microscope at 450-490 nm. 
66 
Carbon monoxide blocks oxidative stress-induced apoptosis via inhibition of the p54 JNK isoform 
RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) 
RNA was isolated using Tri-reagent (Sigma-Aldrich) according to the manufacturer's 
instructions. Reverse transcription was performed on 5µg of total RNA using random primers 
in a final volume of 75µ1 according to the manufacturer's instruction (Sigma-Aldrich). 
Quantitative PCR 
Reverse transcription was performed on 2.5µg of total RNA using random primers in a final 
volume of 50µ1. Real time detection was performed on the ABI PRISM 7700 (Applied 
Biosystems, Nieuwerkerk aid IJssel, The Netherlands). Samples were heated for 10 min at 
95°C, followed by 40 cycles of 15 sec at 95°C, and 1 min at 60°C. Each sample was 
analyzed in duplicate. 18S mRNA levels were used as an endogenous control. Primers and 
probes are listed in table 1. 
Table 1 Sequences of primers and probes used for quantitative PCR analysis 
18S Sense 5'-CGG CTA CCA CAT CCA AGG A-3' 
rat Antisense 5'-CCA ATT ACA GGG CCT CGA AA-3' 
Probe 5'FAM-CGCGCAAA TT ACCCACTCCCGA-TAMRA3' 
H0-1 Sense 5'-CAC AGG GTG ACA GAA GAG GCT AA-3' 
rat Antisense 5'-CTG GTC TTT GTG TTC CTC TGT CAG-3' 
Probe 5'FAM-CAG CTC CTC AAA GAG CTC AAT GTT GAG C-TAMRA3' 
Western blot analysis 
Western blot analysis of cell lysates was performed by SOS-PAGE followed by transfer to 
Hybond ECL nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA). An 
antibody against GAPDH (glyceraldehyde 3-phosphate dehydrogenase, Calbiochem, La 
Jolla, CA, USA) and Ponceau S (Sigma-Aldrich) staining were used to ensure equal protein 
loading and electrophoretic transfer. 
Caspase cleavage was detected using polyclonal rabbit antibodies recognizing only cleaved 
caspase-9, -6, and -3. A monoclonal antibody was used to detect HO-1 (Stressgen, Sanbio 
BV, Uden, The Netherlands). Poly{ADP-ribose) polymerase (PARP) cleavage was detected 
using a rabbit anti-PARP polyclonal antibody. PARP (116 kDa) is a substrate of caspase-3 
yielding a product of 89 kDa and it is considered a late marker for apoptosis. After Western 
blot analysis for phosphorylated ERK1/2 and -JNK using monoclonal antibodies (Santa Cruz 
Biotechnology, Inc, Heidelberg, Germany), blots were stripped using 0.1 % SDS in 
PBS/Tween-20 at 65°C for 30 minutes and incubated with antibodies against, total-ERK1/2 
or total-JNK. All antibodies were obtained from Cell Signaling Technology, Inc (Danvers, MA, 
USA), unless indicated otherwise, and used at 1: 1000 dilution. The blots were analyzed in a 
ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA). Protein band intensities were 
quantified by Quantity One software (Bio-Rad). 
Adenoviral constructs 
Recombinant, replication-deficient adenovirus Ad5IKBAA was used to inhibit NF-KB 
activation as previously described (27). Functionality of the Ad5IKBAA virus was 
demonstrated by its ability to sensitize hepatocytes to cytokine-induced hepatocyte 
apoptosis. Ad5LacZ containing the E.coli 13-galactosidase gene, was used as a control virus. 
The Ad5HO-1 adenovirus was a kind gift of prof. Augustine Choi, University of Pittsburg, 
Pittsburg, USA and has been described before (28, 29). 
Statistical analysis 
All data are expressed as the mean of at least 3 independent experiments ± standard 
deviation. Statistical significance was determined by the Mann-Whitney U test; p<0.05 was 




Regulation of H0-1 in vivo 
To investigate the regulation of HO-1 in vivo, models of chronic cholestatic liver disease 
(BDL) and acute inflammation were used. Chronic cholestasis increased HO-1 mRNA level 
about 6-fold compared to controls in a time dependent manner (Fig 1 ). 
A 1 week 2 weeks 4 weeks Figure 1. HO-1 expression is nduced in 
Con Sham BOl Sham SOL Con Sham BOl chronic cholestasis. Rats were subjected to 
ilill!!!a- I H0-1 
bile duct ligat-on as a model of cholestasis. - - At Indicated t me points after BDL, rats (n=4 B per group) were sacrificed, bvers were 
perfused with saline and removed Control 
! rats received a sham operation (SHAM) or 
I 
5 not (Con). H0-1 expression is induced in 
• BDL at prote·n leve (A) and at mRNA level 
� (B) GAPDH was used as a protein oadlng 
J control ,n Western blots and 1 BS mRNA E 
;; 
2 
levels were used as an endogenous control 
:z: 
� ,n qPCR. Statistical analysis p<0 05 
1 compared to control in each group # 
p<O 05 compared to BDL 1 week group. 
a 
Control Shem BOl Sham BDL Conlrol Sham BDL 
1 week 2 weeks 4 weeks 
In contrast, acute inflammation does not increase HO-1 expression, although iNOS 
expression was highly elevated in the same livers at protein and at mRNA level as 
00 
CON lPS • OEM OEM 
previously demonstrated (30). DEM-induced 
oxidative stress, superposed on acute 
inflammation, strongly increases HO-1 mRNA 
level in acute inflammation in vivo. Induction of 
oxidative stress with DEM alone also increases 
HO-1 mRNA in the liver (Fig 2). The induction of 
HO-1 by DEM alone or in combination with LPS 
correlates with results obtained in rat intestine in 
the same model (31 ). 
Figure 2. Acute inflammation does not induce HO-1 expression ,n lhe liver. 
However OEM-induced oxtdal ve stress, superposed on acute inflammation, strongly increases HO-1 mRNA evel in acute inflammation ,n vivo. 
qPCR analys s of cONA from rats ( ,ver) exposed to LPS or the same volume of PBS (contro group Con) with or without DEM. In the figure, a 
representative set of a group (n-4) is shown Statistica analysis: · p<0.05 compared to control. # p<0.05 compared to LPS group. 
Regulation of H0-1 in vitro 
To confirm our in vivo data we investigated the regulation of HO-1 expression in vitro in 
primary rat hepatocytes. The superoxide anion-donor menadione induces HO-1 expression 
in a time (Fig 3A) and concentration dependent manner (Fig 38). 
Figure 3.  The 1r1tracellular superoxide an on­
donor menad1one induces HO-1 expression in a 
lime- and concentration-dependent manner in 
vitro. Cells were exposed to menadione (Men, 50 
µmol/L) and harvested at different time points (A) 
or exposed to different concentrations of 
menadione for 9 hrs (B) HO-1 expression was 
detenmined at A) protein level by Western b ot. 
GAPDH was used as a protein loading control 
and at B) mRNA level by qPCR (9 hrs). 1BS 
mRNA levels were used as an endogenous 
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Carbon monoxide blocks oxidative stress-induced apoptosis via 1nh1b1t1on of the p54 JNK isoform 
Exposure of hepatocytes to H2O2 does not induce HO-1 expression in hepatocytes (Fig 4A). 
In contrast, cytokine mixture only slightly induces HO-1 expression in vitro (Fig 5), although 
iNOS expression was highly induced under the same circumstances as shown previously 
(30). Depletion of glutathione using BSO, an inhibitor of glutamate cysteine ligase the rate 
limiting step in GSH biosynthesis, or DEM, further enhances the induction of HO-1 mRNA 
and HO-1 protein level in vivo (Fig 2) and in vitro (Fig 4, 5) in all tested conditions. 
e Con Men Men •SSO eso kDa 
1-.- ;;;;;;;;-
-- ;;;;;;;;;1 32 - H0-1 
Figure 4. H0-1 expression is not increased by hydrogen 
peroxkfe in vitro. Cells were exposed to hydrogen peroxtde or I 
.... _ 35  - GAPDH 
• I menadione with or without BSD or OEM. H0-1 mRNA level was - - _ increased by menadione, BSD and OEM but not by hydrogen 
HPi H • .O: • BSO  Hi'J: • OE.M ..., Meri • BSO  Men • DEM peroxide as determined by qPCR (A) and H0-1 expression is CON 
induced by menadione and BSO as determined by Western blot 
(B). Statistical analysis: • p<0.05 compared lo control. # p<0.05 compared to H202 group. ,:, P< 0.05 compared to menadione treated cells. 
Figure 5. Cylokines slightly induce H0-1 expression in primary 
hepatocytes in vitro. Cells were exposed to cytoklne mixture (10 
hrs) with or without BSD or OEM. H0-1 mRNA level was 
increased by B50 and DEM but only a minor increase was 
observed after exposure Jo CM as determined by qPCR. Slalislical 
analysis: • p<0.05 compared lo control group. # p<0.05 compared 
lo CM treated group. 
Heme Oxygenase-1 overexpression protects against oxidative stress 
To investigate whether HO-1 plays a role in the protection against oxidative stress, HO-1 
was overexpressed in primary rat hepatocytes by transfection with Ad5HO-1 15 hrs before 
exposure to menadione. Although metalloporphyrins like hemin or chromium mesoporphyrin 
are widely used to induce or reduce expression of HO-1 respectively, in our hands it showed 
serious toxic side-effects. This confirms recent reports that metalloporphyrins induce 
oxidative stress themselves and therefore cannot be used in combination with menadione 
(32). In addition, it has recently been reported that metalloporphyrins interfere with caspase 
activity, independent of its HO-1 inducing effect (33). To avoid these confounding side 
effects, we opted to use an adenoviral construct to achieve overexpression of HO-1. 
As shown in Fig 6A, Ad5HO-1 infection dose dependently increased HO-1 expression at 
mRNA and protein level in hepatocytes at the time of menadione exposure. Overexpression 
of HO-1 protected against menadione-induced caspase-3 activity and processing compared 
with control and Ad5LacZ infected hepatocytes (Fig 6B). Hepatocytes infected with only the 
Ad5LacZ virus or Ad5HO-1 virus and not exposed to menadione did not display elevated 
caspase-3 activity (Fig 6B). 
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Figure 6. Overexpression of HO-1 , using the adenovirus AdSHO-1,  leads to protectk>n of primary hepatocytes against oxidative stress-induced 
apoptosis Cells were exposed to Ad5H0-1 or Ad5LacZ (virus control) 15 hrs before the addition of menadione (50 µmoVL, 9 hrs) A) Ad5H0-1 
highly Induces H0-1 expression dose dependent y at protein level (upper panels) and at mRNA level (up to 70-fold as delermined by qPCR, lower 
graph) compared with Ad5LacZ and conlrol B) Overexpression of H0-1 prevenls capase-3 aclivily (graph) and processing (Western biol, upper 
panel) Statistical analys s • p<O 05 compared to control. # p<0.05 compared to menadione treated cells. 
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Carbon monoxide protects primary rat hepatocytes against oxidative stress-induced 
apoptosis 
Since HO-1 overexpression protects primary rat hepatocytes against superoxide anion­
induced apoptosis, we investigated whether CO contributes to the protective effect of HO-1 
expression. CO suppresses menadione-induced PARP-cleavage and apoptosis in primary 
hepatocytes, indicating that CO has a protective role against superoxide anion-induced 
apoptosis (Fig 7A, B). 
A B -
Con Men Con Men kOa � 
1� -�- 7 ":o } PARP f 
- � ·- 38 - GAPDH $ 
:!. 






Nonna! almosphe•e CO atmos:inllre 
Figure 7. Carbon mono,dde prevents 
O)(idative stress-induced apoptosis in 
hepatocytes. Cells were incubated with 
menadione or not (control) in the 
presence and absence of carbon 
monoxide A) Western blot analysis: CO 
Inhibits PARP-cleavage induced by 
menadlone. GAPOH was used as a 
protein loading control. B) Caspase-3 
activity assay: Carbon monoxide blocks 
menadtone-induced apoptos s (expressed as capase 3 aclivaty) Statistic-a[ analysis. • p<0.01 compared to control. # p<0.01 compared to 
menadione treated cells in a normal atmosphere. 
In addition, CO also inhibits menadione-induced caspase-9, -6 and -3 activation (Fig 8), 
which is in accordance with our previous finding that menadione-induced apoptosis is 
con �� con � •o• dependent on caspase activation in primary hepatocytes (27). CO did not induce necrosis 
in primary rat hepatocytes (data not shown), 
suggesting that CO is really protective 
against oxidative stress-induced apoptosis 
and does not switch the balance between 
apoptosis and necrosis. 
I = I � I: =�:: :::::: :--=:::::::w!::�:::::::::l'iiii::::;_: : ::: ··· .... 3 == =-===== 
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Figure 8 Carbon monoxide prevents menad10ne induced caspase activation in hepatocytes Celis were incubated w th menadione (50 µmoJ/L, 9 
hrs) and without (control) in the presence and absence of carbon monoxide Western blot CO inhibits caspase-9, -6 and -3 cleavage induced by 
menadione. GAPDH was used as a protein fOading control. 
The protective effect of CO is not dependent on soluble guanylate cyclase 
To investigate whether soluble guanylate cyclase (sGC) is involved in the protective effect of 
CO against menadione-induced apoptosis in primary hepatocytes, cells were exposed to the 
sGC inhibitor ODQ with or without menadione in the presence of carbon monoxide. The 
ability of CO to inhibit menadione-induced apoptosis was not reversed by ODQ (Fig 9), 
indicating that the anti-apoptotic effect of CO is not dependent on the activation of sGC or 











ODO Con Men 
SO.,M 
Men + ODO 
ODO 
Normal atmosphere 
Figure 9. The protective effect of carbon monoxide is not dependent on the act1VaUon of sGC. Cells were exposed to ODO with or without 
menad10ne (50 µmol/L, 9hrs) in the presence of carbon monoxide Caspase�3 activ ty assay The abi'.ity of CO to nhibit menadione-induced 
apoptos1s was not reversed by ODO Statistical analysis • p<0 05 compared to control. # p<0.05 compared to menadione treated cells in a 
normal atmosphere 
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Carbon monoxide blocks oxidative stress-induced apoptosis via inhibition of the p54 JNK isoform 
NF-KB pathway is not involved in the protective effect of CO against menadione­
induced apoptosis 
In our study, inhibition of the NF-KB pathway by recombinant adenovirus expressing 
dominant negative IKB did not reverse the protective effect of CO against superoxide anion­
induced apoptosis (Fig1 0A). Functionality of the virus was demonstrated by sensitizing 
hepatocytes to cytokine-induced apoptosis (Fig 108). 
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CO atmosphere Normal atmosphere 
Figura 10. NF-KB pathway is not involved in the protective effect of CO against oxidative stress-induced apoptoslS A) Caspase-3 activity assay 
inhibition of the NF-KB pathway, using the AdSdnlKB 1 5  hrs before menad1one addition, did not reverse the protective effect of carbon monoxide 
against menadione-induced apoptosis. B) Functionality of the Ad5IKBAA virus was demonstrated by its abi ity to sensitize hepatocytes to 
cytokine-induced hepatocyte apoptosis. Statistical analysis • p<0 05 compared to control. # p<0.05 compared to menadione treated cells in a 
normal atmosphere. 
Carbon monoxide blocks phosphorylation of the pro-apoptotic MAP-kinase JNK 
Menadione-induced caspase activation and apoptosis are dependent on J NK activity in 
primary rat hepatocytes (27). Since CO prevents caspase-9, -6 and -3 activation, we also 
investigated the effect of CO on MAPK-phosphorylation. 
As shown in figure 11A, CO induces ERK-phosphorylation at 2hrs. To investigate the role of 
ERK in the protective effect of CO against menadione-induced apoptosis, hepatocytes were 
exposed to CO in the presence of the ERK1/2 inhibitor U0126. Inhibition of ERK1/2 did not 
reverse the protective effect of CO (Fig 11 B). The functionality of U0126 was shown by its 
ability to reduce ERK1/2 phosphorylation as shown by Western blot (Fig 11 C). On the other 
hand, CO inhibits predominantly the menadione-induced phosphorylation of the p54 JNK 
isoform (Fig 11A). Since inhibition of JNK activity, using the inhibitor SP6001 25, prevents 
menadione-induced caspase activation and apoptosis (27), our results indicate that the 
protective effect of CO against superoxide anion-induced apoptosis is at least partly due to 
inhibition of JNK activation. To distinguish between the possibility that JNK activation is the 
cause of apoptosis and the possibility that J NK activation is the result of apoptosis, we 
determined JNK phosphorylation in response to menadione in the presence of a cocktail of 
caspase inhibitors (caspase-3,6,8,9 inhibitors). Inhibition of apoptosis did not change 
menadione-induced JNK phosphorylation (data not shown). 
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Figure 1 1 .  Carbon monoxide Induces ERK1/2- and inhibits JNK-
phosphorylalion. Cells were exposed to menadione (1·2 hrs, A) or 9hrs 
(B) in the presence and absence of carbon monoxide. A) Western blot analysis against phosphorylaled and total JNK, phosphorylated and total 
ERK1/2 CO induces ERK112 phosphorylalton and prevents menadione-induced p54 JNK phosphorylation. Western blots were quantified and 
band intensities of phosphorylated protein were expressed as ratio of the intensity of the corresponding total protein (lower graphs) B) Caspase-3 
activity assay Cells were exposed lo U0126 before and during Iha incubation with menadione in the presence of CO. Inhibition of ERK1/2 
activation does nol prevent the protective effect of CO. C) Inhibition of ERK1/2 aclivation by lhe specific inhibitor U0126. Statistical analysis • 




In this study, we demonstrate that HO-1 expression is induced in different models of 
oxidative stress in the liver both in vitro and in vivo, including chronic cholestasis. 
Interestingly, acute inflammation, induced by endotoxin administration, is a very weak 
inducer of H O-1, although in this model NF- KB-regulated genes like iNOS are highly 
induced as shown previously (30). A similar reciprocal regulation of AP-1 responsive genes 
like HO-1 and NF-KB responsive genes like iNOS was observed in intestinal epithelial cells 
(31) and is in accordance with other reports (39). We have demonstrated that this switch 
from an NF-KB regulated stress response to an AP-1 regulated stress response in hepatic 
inflammation is controlled by the extent of oxidative stress. An important regulator of this 
switch might be the content of reduced glutathione (GSH) in the cell: GSH depletion inhibits 
NF-KB-mediated cytokine-inducible iNOS expression and at the same time increases 
oxidative stress and the expression of oxidative stress inducible genes like HO-1 (30, 31 ). 
These results suggest that TNFa or CM (in vitro) or LPS exposure (in vivo) in the presence 
of sufficient GSH-levels do not induce important oxidative stress and hence no AP-1 
activation and HO-1 induction. This switch might be an adaptation to the type of stress. NF­
KB regulated protective genes include antl-apoptotic genes, for example iNOS, which protect 
against pro-apoptotic inflammatory cytokines like TNFa, whereas AP-1 regulated genes, 
such as HO-1, are involved in the protection against various forms of oxidative stress. In 
vitro, in primary cultures of rat hepatocytes, HO-1 expression is induced by the superoxide 
anion donor menadione, but not by H2O2• Hepatocytes have a high capacity to detoxify H2O2 
(27), and it is likely that this molecule is hardly sensed by hepatocytes. This also correlates 
with our previous finding that 1 mmol/L H2O2 does not induce cell death. The induction of 
HO-1, both in vivo and in vitro, was much more pronounced after depletion of the antioxidant 
glutathione. This correlates with our in vivo model of acute inflammation demonstrating that 
acute inflammation is not accompanied by extensive oxidative stress and depletion of 
antioxidants. 
Numerous studies have shown the cytoprotective and anti-apoptotic properties of HO-1 
against oxidative stress (34). Although, the superoxide anion-donor menadione induces HO-
1 expression in primary hepatocytes, this induction does not prevent apoptosis, probably 
because HO-1 induction is not high and/or rapid enough. In support of this we observed that 
overexpression of HO-1 prior to menadione protects against oxidative stress-induced 
apoptosis. Metalloporphyrins like hemin or chromium mesoporphyrin are widely used as 
inducers or inhibitors of HO-1,  respectively. In our hands these compounds showed serious 
side-effects, confirming recent reports that describe aspecific effects of these compounds, in 
particular when studying phenomena related to oxidative stress and apoptosis (32, 33). 
In this study we provide evidence that carbon monoxide (CO), one of the products of HO-1, 
protects against superoxide anion-induced apoptosis. Previously, we showed that 
superoxide anion-induced apoptosis is dependent on caspase activation (27). In accordance 
with these findings, we demonstrate that CO is a potent inhibitor of caspase activation, 
PARP cleavage and apoptosis in primary hepatocytes exposed to the superoxide anion­
donor menadione. Since CO inhibits caspase-9 activation, we speculate that CO prevents 
disruption of mitochondria and subsequent apoptosis. Indeed, it has been shown that CO 
blocks mitochondrial cytochrome c release (35, 36). We also show that CO does not shift the 
balance from apoptotic cell death to necrotic cell death. This is not a trivial finding as we 
have shown previously (27). Therefore, CO really protects hepatocytes against superoxide 
anion-induced cell death. Our findings are in accordance with studies using different 
inducers of hepatocyte cell death, including glucose-deprivation in BNL CL.2 hepatoma cells 
or by Fas (37) and TNFa in hepatocytes (38). In addition, a protective effect of CO has been 
demonstrated in a wide range of different cell types (35, 39, 40). In contrast, a pro-apoptotic 
effect of CO has been observed for murine thymocytes and bovine pulmonary arterial 
endothelial cells (41, 42). These data indicate that CO may regulate apoptosis and 
cytotoxicity in a cell-specific manner. 
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It has been suggested that the cytoprotective effect of CO is due to activation of soluble 
guanylate cyclase, however we saw no effect of sGC inhibition on the protective effect of 
CO. Previous studies are contradictory concerning the role of sGC in the anti-apoptotic effect 
of CO, both confirming (40) and contradicting (35) our findings. Again, different signaling 
pathways may be involved in the protective effect of CO in different cell types. NF-KB 
inhibition did not influence the protective effect of CO against superoxide anion-induced 
apoptosis in hepatocytes, although it was reported that the protective effect of CO was 
dependent on NF-KB activation in hepatocytes exposed to TNFa (38). 
In this study we demonstrate that CO inhibits JNK activation, in particular the p54 isoform of 
JNK. A similar inhibitory effect of CO on JNK-phosphorylation has been described in a model 
of sepsis in vivo (43). In a previous study, we demonstrated that superoxide anion-induced 
apoptosis is dependent on J NK activity, since inhibition of J NK activity prevents menadione­
induced caspase activation and apoptosis in primary hepatocytes (27). However, we cannot 
conclude beyond any doubt that the inhibitory effect of CO on J NK activity is responsible for 
the protective effect of CO, since CO appears to inhibit mainly the phosphorylation of the 
p54 isoform of J NK, whereas the pharmacological inhibitor SP600125 inhibits both the p54 
and p46 isoforms of JNK. 
Menadione-induced JNK activation was not changed in the presence of a cocktail of 
caspase inhibitors. Together with our previous finding (27) that inhibition of JNK activity 
using SP600125 abolishes menadione-induced caspase activation and apoptosis and that 
JNK activation precedes caspase activation and apoptosis by at least 6-8 hours, these 
results indicate that reduced JNK activation is the cause of reduced apoptosis and not the 
result of reduced apoptosis. 
The mechanisms by which J NK exerts its pro-apoptotic properties are probably diverse and 
not completely elucidated yet. Many studies suggest that JNK triggers the mitochondrial 
death pathway, including phosphorylation and activation of pro-apoptotic bcl-2 family 
members (44-50). Recently, a role for JNK in the degradation of the anti-apoptotic protein c­
FLIP has been reported (51 ). 
Another finding of the present study is that CO induces ERK 1/2 MAPK-phosphorylation. 
ERK1/2-activity is anti-apoptotic in hepatocytes and its activation attenuates cell death. 
However, although significant, the magnitude of the protective effect of ERK1/2 activity 
against superoxide anion-induced apoptosis is moderate (27). Apparently, the anti-apoptotic 
action of CO is mainly due to its inhibitory effect on J NK activation and not to its stimulatory 
action on ERK1/2 activation. Regulation of MAPK signaling pathways by CO in a variety of 
cell types has been reported in other studies (36, 52). In addition, it has been reported that 
CO mediates protection against CYP2E1-dependent cytotoxicity in part via inhibition of 
CYP2E1 activity (16). 
In this study, we focus on the mechanism of the protective action of CO. It has been 
described that biliverdin, another product of HO-1, is also protective against oxidative stress­
induce injury in part due to its antioxidant properties (17). Indeed, a cooperative protective 
effect of biliverdin and carbon monoxide has been shown in immune-mediated liver injury in 
mice (18). 
In conclusion, HO-1 is induced by oxidative stress in primary hepatocytes in vivo and in vitro. 
HO-1 protects primary hepatocytes against superoxide anion-induced apoptosis, and this 
protection may be mediated in part via CO production. CO inhibits the activity of the pro­
apoptotic JNK MAPK and, in addition, induces ERK1/2 MAPK anti-apoptotic activity. 
Modulation of HO-1 expression, or the levels of its product CO, may become an important 
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Background: Cholestasis or impaired bile flow is characterized by increased serum levels of 
bile acids, hepatocyte injury and loss of hepatocytes. Prolonged cholestasis may induce 
adaptive changes in hepatocytes which might affect the hepatocellular response to toxic 
compounds and to drugs. Therefore, detailed knowledge of these adaptive changes and 
altered responsiveness are required, but are limited by the lack of a suitable in vitro model to 
study cholestatic hepatocytes. Aim: to develop and characterize a cell culture model to study 
cholestatic hepatocytes in vitro. 
Methods: Primary rat hepatocytes were isolated from 1 week bile duct ligated (BDL) and 
sham operated rats. mRNA levels of bile acid transporters were analyzed by qPCR. 
Cholestatic and sham hepatocytes were exposed to bile acids. Apoptosis and necrosis were 
quantified by caspase-3 activity assay and acridine orange staining and Sytox green 
staining, respectively. 
Results: Compared to sham hepatocytes, cholestatic hepatocytes show decreased mRNA 
levels of Ntcp and Mrp2, and increased mRNA levels of Mrp3 immediately after isolation and 
during culture. The toxic bile acid glycochenodeoxycholic acid (GCDCA) induces apoptosis 
in sham hepatocytes, but not in cholestatic hepatocytes. The anti-apoptotic bile acid 
tauroursodeoxycholic acid (TUDCA) is only effective in sham hepatocytes. 
Conclusion: We have developed a representative in vitro model for cholestatic hepatocytes, 
which can be used to study signaling pathways in these hepatocytes. Our preliminary data 
show that cholestatic hepatocytes maintain their in vivo phenotype during culture, and 
respond differently to hydrophobic bile acids than sham hepatocytes. 
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6.2 Introduction 
Cholestasis or impaired bile flow occurs in many acute and chronic liver diseases. 
Cholestasis can be caused by a genetic defect (e.g. progressive familial intrahepatic 
cholestasis (PFIC) type 1 to 3), drugs (such as cyclosporine A, oral contraceptives, anabolic 
steroids) or an immunologic (e.g. viral infection, sepsis) or mechanical (gall stones, tumors) 
insult to the bile ducts (1-5). In some cholestatic disorders, the cause of bile duct injury 
remains unknown. Many of these diseases, like biliary atresia, occur in children (5). 
Cholestasis progresses via hepatocyte damage and activation of inflammatory cells and 
hepatic stellate cells. Cholestatic disorders develop via fibrosis, the increased deposition of 
extracellular matrix (1, 6-8), into cirrhosis and eventually end-stage liver failure (1 ). 
In cholestatic patients and animal models of cholestasis like bile duct ligation (BDL), 
endotoxemia (lipopolysaccharide (LPS) administration) or chelate-feeding, the bile acid 
retention in hepatocytes affects several transporters involved in the enterohepatic circulation 
(2-4, 9, 10). The transporters involved in the uptake of bile acids and organic anions at the 
basolateral membrane, Na•/taurocholate cotransporting polypeptide (Ntcp) and organic 
anion transporting polypeptide (Oatp), are down-regulated. Multidrug resistance-associated 
protein (Mrp) 2, responsible for the secretion of bile acids and glutathione conjugates across 
the canalicular membrane into bile, is also down-regulated (3, 4, 9, 10), while Mrp3, which 
secretes bile acids and organic anions across the basolateral membrane of hepatocytes into 
the sinusoids (reverse transport) is up-regulated (3). 
The glycine-conjugates of hydrophobic primary and secondary bile acids trigger hepatocyte 
apoptosis and necrosis in cholestasis (1 , 2, 1 1 , 1 2). Apoptosis or programmed cell death is a 
tightly regulated process, involving the caspase-family of cysteine proteases (1 3, 14). The 
energy-dependent apoptotic pathway results in cell shrinkage and formation of apoptotic 
bodies, which are cleared very efficiently by surrounding phagocytosing cells (13, 15, 16). 
Necrosis, a passive mode of cell death, leads to plasma membrane rupture, and subsequent 
release of cellular content in the extracellular environment and circulation and hence an 
increased inflammatory response (17-1 9). 
Ursodeoxycholic acid (UDCA) is a dihydroxy bile salt which is used in the treatment of 
chronic cholestatic liver diseases (2, 20). In patients with primary biliary cirrhosis (PBC), 
primary sclerosing cholangitis (PSC) and PFIC, UDCA therapy improved liver function and 
histology (20). The progression of PBC was also delayed by U DCA treatment (20). The 
hepatoprotective mechanism of UDCA is accomplished via upregulation of the bile acid 
transporters and hence stimulation of bile acid secretion of hepatocytes, and via the 
protection of hepatocytes against bile acid induced cell death (2, 10, 20, 21). Inhibitory 
effects of UDCA on the mitochondrial permeability transition (MPT) and cytochrome c 
release from the mitochondria in in vivo and in vitro animal studies have been described 
(20). In addition, activation of anti-apoptotic signaling pathways including phosphoinositide-3 
kinase (Pl3K) and the mitogen-activated protein kinase (MAPK) member extracellular signal 
regulated kinase (ERK) 1/2 by UDCA have been described (20, 22-25). Cholestatic 
disorders do not always respond to UDCA therapy, and surgery is often required to drain or 
eliminate the obstruction. Often, a liver transplantation is indicated when complications occur 
(1 ). Because of the limited therapeutic options for cholestatic disorders, there is an 
immediate need for novel therapies. Therefore, signaling pathways involved in cholestatic 
liver injury and the identification of potential drug targets are the focus of many studies. 
In recent years, some of these pathways have been identified. Hepatocyte apoptosis, 
stellate cell activation and fibrogenesis were reduced in Fas-deficient (6) and cathepsin B­
deficient (26) mice subjected to BDL for 3 days compared to wild type mice. Livers of bile 
duct ligated mice were resistant to tumor necrosis factor (TNF) a-induced apoptosis via the 
Pl3K-effector, Akt. (27). Furthermore, cholestatic livers were more resistant to 
ischemia/reperfusion injury (28), and mitochondria isolated from cholestatic livers were less 
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susceptible to the MPT induced by bile acids (11 ). Other signaling molecules that have been 
reported to exert anti-cholestatic effects are calcium ions (25, 29), protein kinase C (PKC; 
30) and hepatocyte growth factor (HGF; 31 ). In addition to cholestatic livers, cirrhotic livers 
were resistant to apoptosis induced by various stimuli (cytokines, transforming growth factor 
(TGF) 13 and UV irradiation). This resistance was dependent on an increased generation of 
reactive oxygen species (ROS), since these cirrhotic hepatocytes were again susceptible to 
apoptosis after exposure to antioxidants (32). 
The different response of cholestatic livers to toxic compounds is clinically relevant and 
prompted us to examine in detail the underlying mechanism(s) of this altered 
responsiveness. For this purpose, an in vitro system of cholestatic hepatocytes that 
maintains its in vivo phenotype in culture is obliged. In this study, we describe a method to 
isolate, culture and analyze cholestatic hepatocytes in vitro. Hepatocytes were isolated from 
bile duct ligated rats and compared with hepatocytes from sham operated rats, immediately 
after isolation (to hepatocytes) and in primary culture. Both cholestatic and sham 
hepatocytes maintain in culture their in vivo phenotype. Our preliminary results show that the 
toxic bile acid glycochenodeoxycholic acid (GCDCA) induces cell death in sham 
hepatocytes, but not in cholestatic hepatocytes. In addition, the anti-apoptotic bile acid 
tauroursodeoxycholic acid (TUDCA) is only protective against apoptosis in sham 
hepatocytes. In conclusion, we report a functional in vitro approach to study hepatocytes in 
cholestatic liver diseases, and the preliminary results indicate that cholestatic hepatocytes 
are resistant to GCDCA-induced cell death. 
6.3 Materials and Methods 
Animals 
Specified pathogen-free male Wistar rats (200-250 g) were purchased from Charles River 
Laboratories Inc (Wilmington, MA, USA). Rats were housed under standard laboratory 
conditions with free access to standard laboratory chow and water. Experiments were 
performed following the guidelines of the local Committee for Care and Use of laboratory 
animals. 
Animal model of cholestasis 
Rats were anaesthetised with 02/N20 and subjected to common bile duct ligation or sham 
operation (SHAM) as described perviously (33). Hepatocytes were isolated from BDL 
(cholestatic hepatocytes) and SHAM (sham hepatocytes) rats at day 7 and 14 after surgery. 
Rats were weighed before and after surgery (at least three times a week) as indicator of their 
welfare. Blood was taken from the tail vein immediately prior to the hepatocyte isolation. 
Blood samples were analyzed for markers of liver damage and cholestasis. 
Rat hepatocyte isolation 
Hepatocytes were isolated from overnight fasted rats by a two step coflagenase perfusion as 
described before (34). Cell viability as determined by trypan blue exclusion was greater than 
84% for sham hepatocytes and greater than 68% for cholestatic hepatocytes. Aliquots of 
approximately 1 million cells were snap-frozen in liquid nitrogen immediately after isolation 
(to hepatocytes) and 112,500 cells per cm2 were plated on Vitrogen® (Cohesion 
Technologies Inc., Palo Alto, CA, USA) coated plates in William's E medium (lnvitrogen, 
Breda, The Netherlands) supplemented with 50 µg/mL gentamycin (lnvitrogen) and 
penicillin-streptomycin-fungizone (Lonza, Verviers, Belgium). During the attachment period 
(4 hrs) 50 nmol/L dexamethasone (Dept. of Pharmacy, UMCG, Groningen, The Netherlands) 
and 5% fetal calf serum (lnvitrogen) were added to the medium. Cells were cultured in a 
humidified incubator at 37°C and 5% CO2• 
Experimental design 
Experiments were started after the attachment period of 4 hrs. Monolayer cultures of 
hepatocytes were exposed to 50 µmol/L GCDCA (Calbiochem, La Jolla, CA, USA) or 50 
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µmol/L TUDCA (Calbiochem) for 4 hrs. Each experimental condition was performed in 
triplicate. 
Cells were harvested at the indicated time points, and washed three times with ice cold 
phosphate-buffered saline (PBS) before the addition of hypotonic cell lysis buffer (protein 
analysis, caspase-3 assay) or Tri-reagent (RNA isolation, Sigma-Aldrich) as described 
previously (24 ). 
Hepatocytes were isolated from different SHAM (n=4) and BDL (n-=2) animals. 
Caspase enzyme activity assay 
Caspase-3 like activity was assayed as described previously (24). The arbitrary fluorescence 
unit (AFU) was corrected for the amount of protein in the cell lysate. 
Sytox Green and acridine orange nuclear staining 
To determine necrotic cell death, hepatocytes were incubated with Sytox green (lnvitrogen, 
1 :40,000) nucleic acid stain. Apoptotic nuclei were visualized using acridine orange (Sigma­
Aldrich, 1 :5,000). Fluorescent nuclei were visualized using an Olympus CKX41 microscope 
at 450-490 nm as described previously (34 ). Necrosis and apoptosis were quantified by 
counting fluorescent nuclei (necrotic or apoptotic cells) and the total number of cells in 3 
randomly chosen high power fields. 
RNA isolation and quantitative Polymerase Chain Reaction (qPCR) 
RNA isolation, reverse transcription (RT) PCR and qPCR were performed as described 
previously (35). Details of primers and probes are listed in Table 1. Each sample was 
analyzed in duplicate. 18S mRNA levels were used as endogenous control. 
Table 1. Sequences of primers and probes used for quantitative PCR analysis 
Sense 5'-CGG CTA CCA CAT CCA AGG A-3' 
1BS 
Antisense 5'-CCA ATT ACA GGG CCT CGA AA-3' 
rat 
Probe 5'FAM-CGCGCAAA TT ACCCACTCCCGA-TAMRA3' 
Sense 5'-GAC GAC GAT GAT GGG CTG AT-3' 
Mrp2 
Antisense 5'-CTT CTC ATG GCC AAG GAA GCT-3' 
rat 
Probe S'FAM-CCC ACC ATG GAG GAA ATC CCT GAG G-TAMRA3' 
Mrp3 Sense 5'-TCC CAC TTC TCG GAG ACA GTA ACT-3' 
rat Antisense 5'-CTT AGC ATC ACT GAG GAC CTT GAA-3' 
Probe 5'FAM-CAG TGT CAT TCG GGC CTA CGG CC-TAMRA3' 
Ntcp Sense 5'-ATG ACC ACC TGC TCC AGC TT-3' 
rat Antisense 5'-GCC TTT GTA GGG ACC TTG T-3' 
Probe 5'FAM-CCT TGG GCA TGA TGC CAC TCC TC-TAMRA3' 
6.4 Results 
Characterization of cholestatic hepatocytes isolated from bile duct ligated rats 
Rats were weighed before and after surgery to monitor their welfare. Sham-operated 
animals lost weight in the first day after surgery, but within three days body weight was back 
to pre-surgery levels (Fig 1A). BDL resulted in a weight loss that continued for 6 days post­
surgery. Thereafter, body weight increased again with a slope comparable to the sham 
group (Fig 1A). Aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and 
alkaline phosphatase (AP) levels were increased 1 week after bile duct ligation, and these 
enzymes were further enhanced during the second week of BDL (Fig 1 B). Gamma 
glutamyltransferase (GGT) levels were comparable in all three groups (Fig 1 B). As expected, 
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Figure 1 .  Body weight and plasma analysis or rats after sham operation (SHAM) or bile duct ligation (BDL). (A) Up to 1 week after BDL, body 
weigh! is still decreased compared to pre-surgery level, while lhe weight loss caused by the surgery itself (SHAM) is recovered w·thin 3 days. (B) 
Plasma levels ol markers for liver damage (ASAT, ALAT, alkal ine phosphatase and gamma-GT) and cholestasis (total b lirubin). 
Hepatocytes were isolated from sham and bile duct ligated-rats. After one week BDL, 
hepatocytes were isolated that were less viable then hepatocytes from sham-operated rats 
(average 70.0% and 86.9% resp.), and also fewer in number (69 vs 353 million cells). We 
were unable to isolate viable hepatocytes after 2 weeks BDL (data not shown), therefore we 
only studied hepatocytes isolated 1 week after BDL. 
Expression of bile acid transporters in cholestatic hepatocytes 
First, we examined the effects of bile duct ligation on bile acid transporters. BDL caused 
down-regulation of Mrp2 and Ntcp mRNA expression both in t0 hepatocytes and primary 
cultures, while Mrp3 mRNA levels were increased compared to sham (Fig 2A). Next, we 
studied the effect of culturing (4 hrs attachment followed by 4 hrs experiment) on the 
expression of these transporters. In culture, Mrp2 and Mrp3 mRNA levels increased 
compared to t0 hepatocytes: 5.4 and 3.0 fold respectively for sham hepatocytes and 2.9 and 
2.6 times for cholestatic hepatocytes (Fig 2B). Ntcp mRNA expression was enhanced in 
culture 1.5 times in sham hepatocytes, while in cholestatic hepatocytes the Ntcp mRNA level 
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Cholestatic hepatocytes are resistant to GCDCA-induced apoptosis 
The toxic bile acid GCDCA induced caspase-3 activity in primary sham hepatocytes, which 
is reduced by the anti-apoptotic bile acid TUDCA by 66% (Fig 3A) as described previously 
(24). In contrast, cholestatic hepatocytes exposed to GCDCA or GCDCA in combination with 
TUDCA resulted in caspase-3 activities similar to control cholestatic hepatocytes (Fig 3A). 
TUDCA alone did not induce caspase-3 activity in sham or cholestatic hepatocytes (Fig 3A). 
The results from the caspase-3 activity assay (Fig 3A) were confirmed by acridine orange 
staining, visualizing condensed apoptotic nuclei. Sham hepatocytes exposed to GCDCA for 
4 hrs demonstrate apoptotic nuclei in 36% of the cells (Fig 3B), and in combination with 
TUDCA the percentage of condensed nuclei was reduced to 13%. In control hepatocytes or 
cells exposed to TUDCA only, apoptotic cells were hardly present (Fig 3B). Cholestatic 
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hepatocytes exposed to GCDCA displayed apoptotic nuclei in 41 % of the cells (Fig 3B), 
while in combination with TUDCA the percentage of condensed nuclei remained at 41 %. 
Apoptosis was observed in 32% of the cells treated with only TUDCA, while 23% of 
cholestatic control hepatocytes showed nuclear condensation (Fig 3B). 
A 30 B SHAM hepatocytes OSHAM --.. • BDL 1 wk  f! ,. ? jj 
h 10 
" J  
control GCDCA501,,1M GCDCA + TUOCA TUDCA !S01,,1M "' 38% 13% 0% 
BOL hopatocytes 
'""'"" GCDCA GCDCA+ TUDCA TUOCA 
Figure 3. GCDCA does not induce apoptosis in primary 
cholestatic hepatocytes. Primary rat hepatocytes from 
BDL or sham operated animals were exposed for 4 hrs 
to GCDCA (50 µmoUL), TUDCA (50 µmol/L) or GCDCA control GCDCA &01,,1M GCDCA + TUOCA TUDCA 50µM 
in combination with TUDCA. (A) Caspase-3 like activity 23% '1% '1% 32% 
was measured, and is shown as fold induction compared to control values of the corresponding group, control values were set at one. (B) Nuclear 
condensation upon GCDCA exposure was reduced by TUDCA in sham hepatocytes, but not in cholestatic hepatocytes. Primary rat hepatocytes 
were exposed to GCDCA, TUDCA, both bile acids or left untreated (control) Apoptot1c nuclei were determined by acridine orange staining 4 hrs 
after bile acid-exposure and expressed as % of total nuclei. Representative images are shown. Magnification 20X 
Since control hepatocytes isolated from BDL rats displayed a marked number of apoptotic 
nuclei (Fig 3B), we decided to express caspase-3 activity in cholestatic hepatocytes relative 
to sham control hepatocytes (Fig 4). Caspase-3 activity of cholestatic control hepatocytes 
was 8-times higher than sham control hepatocytes, and GCDCA only slightly enhanced 
caspase-3 activity in cholestatic hepatocytes (Fig 4). Again, TUDCA alone resulted in 
caspase-3 activities similar to cholestatic control hepatocytes. 
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Figure 4. Cholestatic control hepatocytes display high levels of apoptosis 
compared to control hepatocytes from sham animals Primary hepatocytes from 
BDL or sham operated rats were exposed for 4 hrs to GCDCA (50 µmol/L), 
TUDCA (50 µmoUL) or the combination of GCDCA and TUDCA Caspase-3 like 
activity was measured, and is shown as fold induction compared to control 
hepatocytes from sham animals; sham control values were set at one 
control GCDCA GCDCA + TUDCA TUOCA 
Bile acid-induced necrosis in cholestatic hepatocytes 
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Figure 5. GCDCA-induced necrosis is not significantly affected by 
TUDCA. Primary rat hepatocytes were treated without (control) or with 
GCDCA, TUDCA or the combination of GCDCA and TUDCA. Sytox 
green nuclear staining was used to visualize necrotic cell death after 4 
hrs exposure. Representative images are shown. Upper panel 
combined phase contrast and fluorescence. Lower panel: 
fluorescence. Magnification 20X. 
bile acid exposure in hepatocytes isolated 
from BDL and sham operated rats. In sham 
hepatocytes, necrosis was observed in 9% 
of the cells treated for 4 hrs with GCDCA 
(Fig 5) and this percentage was not 
significantly changed by TUDCA (8% 
necrotic cells). Control hepatocytes or 
hepatocytes exposed to TUDCA displayed 
low levels (<5%) of necrosis (Fig 5). In 
cholestatic hepatocytes, control cells 
showed relative high levels of necrosis 
(12%) compared to control sham 
hepatocytes (3%). Treatment with GCDCA 
resulted in 23% of necrotic cells, while the 
combination of GCDCA and TUDCA or 
TUDCA alone resulted in a slightly higher 
percentage of necrotic cells than control 




The aim of this study was to develop an in vitro model for the study of cholestatic 
hepatocytes. Although some studies described the use of primary cholestatic hepatocytes 
(11, 29), a comprehensive comparison of sham and bile duct ligated rat hepatocytes in 
culture was never reported. We demonstrate the functionality of primary cholestatic 
hepatocytes both immediately after isolation and after an 8 hr culture period (4 hr attachment 
and 4 hr experiment). Our preliminary results suggest that cholestatic hepatocytes maintain 
their in vivo phenotype during the in vitro experiments and that, in contrast to sham 
hepatocytes, cholestatic hepatocytes are resistant to bile acid induced cell death. However, 
it should be noted that control hepatocytes from BDL rats already exhibit elevated levels of 
apoptosis and necrosis. This new approach to study the signaling pathways in hepatocyte 
cell death in cholestatic livers will provide more insight in possible targets for intervention. 
The increases in serum ALAT, ASAT, alkaline phosphatase and bilirubin after bile duct 
ligation are in accordance with previous results (33) and indicate hepatocyte damage, 
damage to the biliary tract and cholestasis. Weight loss of bile duct ligated animals was 
more severe and prolonged than of sham operated rats, but after 1 week weight gain was 
similar in both groups. Reduced mRNA expression of Mrp2 and Ntcp and increased 
expression of Mrp3 mRNA has been reported in bile duct ligated rat livers in vivo (3, 4, 9, 
10). These changes in mRNA expression can be explained by adaptation of the liver to 
increased serum bile acid levels and decreased bile flow. The down-regulation of Ntcp and 
Mrp2 results in reduced bile acid uptake and excretion into the canalicular lumen, while 
increased Mrp3 expression stimulates bile acid excretion across the basolateral membrane 
into the blood. In addition, the shift in mRNA expression of transporters during culture is 
similar in sham hepatocytes and cholestatic hepatocytes: mRNA expression of Mrp2 and 
Mrp3 tend to increase during culture in both sham and cholestatic hepatocytes, whereas 
Ntcp expression is not affected or increases slightly during culture. In this study, we 
demonstrate that the observed changes in transporter mRNA levels are maintained 
immediately after isolation of hepatocytes and during the experiments. These observations 
validate our in vitro model, since we demonstrates that the in vivo phenotype is preserved in 
vitro, and phenotypic alterations due to the culturing process do not differ between normal 
and cholestatic hepatocytes. 
As described previously (24), GCDCA strongly induced caspase-3 activity and nuclear 
condensation in sham hepatocytes, which were partially inhibited by TUDCA. In contrast, 
caspase-3 activity in cholestatic hepatocytes did not respond to GCDCA, even though 
nuclear condensation upon GCDCA exposure was equal in sham and cholestatic 
hepatocytes (Fig 3). This apparent paradox is due to the high amount of apoptotic cells 
present in cholestatic control hepatocytes: 22% of these cells already display nuclear 
condensation. In fact, when we express caspase-3 activity in cholestatic hepatocytes relative 
to sham hepatocytes, the cholestatic hepatocytes already show significantly induced levels 
of caspase-3 activity (Fig 4 ). Surprisingly, despite the lower starting viability of cholestatic 
hepatocytes the exposure to the hydrophobic bile acid GCDCA did not induce additional 
caspase-3 activity. The percentage of necrotic cells was also elevated in cholestatic control 
hepatocytes and GCDCA treatment did not significantly change necrosis (Fig 5). In contrast, 
bile acid exposure to sham hepatocytes increased necrosis as reported previously 
(unpublished data), however TUDCA is not protective against GCDCA-induced necrosis. 
In summary, our preliminary data show that in cholestatic hepatocytes the response to 
GCDCA is very limited relative to control hepatocytes. We can only speculate about possible 
explanations. One important reason could be that conjugated bile acids are no longer able to 
enter the hepatocytes. The down-regulation of Ntcp, the transporter involved in the 
basolateral uptake of conjugated bile acids, by 82% implies that Ntcp is almost absent at the 
plasma membrane and therefore, a minimal bile acid import into the cholestatic hepatocyte 
compared to sham hepatocytes. In addition to the altered expression of bile acid 
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transporters, other mechanisms may be operative in the altered responsiveness of 
cholestatic hepatocytes to bile acids. Recently, increased resistance of cirrhotic hepatocytes 
to TGFl3 was reported. This increased resistance was due to sustained generation of ROS in 
cirrhotic hepatocytes. The addition of antioxidants to cirrhotic hepatocytes completely 
abolished the increased resistance to TGFl3. ROS are known to activate numerous signal 
transduction pathways and genes such as heme oxygenase-1 (HO-1) involved in the 
regulation of cell survival. Our in vitro model provides the opportunity to study these 
mechanisms in cholestasis in detail. 
Therapy of chronic liver diseases usually starts when the disease is already advanced. 
Therefore, therapy should be effective in 'chronically diseased' hepatocytes, e.g. cholestatic 
or cirrhotic hepatocytes. Hence, an in vitro model which represents 'diseased' livers is 
obliged. Our study provides the first steps towards a representative in vitro model for 
cholestatic hepatocytes, which can be used to study adaptive changes in these hepatocytes 
and to examine the effects of drugs in cholestatic liver diseases. Our preliminary data imply 
that cholestatic hepatocytes respond different to hydrophobic bile acids than sham 
hepatocytes. 
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Chapter 7 
In many liver diseases, hepatocyte damage occurs upon exposure to toxic bile acids, 
inflammatory cytokines and increased levels of reactive oxygen species (ROS). Detailed 
information of the signaling pathways involved in hepatocyte damage will facilitate the 
discovery of new targets for intervention. Therefore, in this thesis the modulation of signaling 
pathways involved in three models of hepatocyte cell death was studied: 1) 
glycochenodeoxycholic acid (GCDCA), as a model for acute bile acid toxicity, 2) the cytokine 
tumor necrosis factor (TNF) a in combination with the transcriptional inhibitor actinomycin D 
(ActD, to inhibit nuclear factor-KB (NF-KB) activation), as a model for acute liver failure and 
3) the superoxide anion donor menadione as a model for oxidative stress-induced apoptosis. 
These models are clinically relevant, because bile acids, cytokines and reactive oxygen 
species are present at increased levels in most liver diseases. In addition to a detailed 
investigation of the mechanisms of cell death in these models, the effects of potential drugs 
for the treatment of liver diseases were studied. 
Chapter 2 describes the hepatoprotective mechanism of metformin against bile acid-induced 
apoptosis. Metformin, a drug used in the treatment of Diabetes Mellitus type II disease, was 
shown to improve liver function (lower plasma levels for alanine aminotransferase {ALAT) 
and aspartate aminotransferase (ASAT)) in patients and animal models with non-alcoholic 
fatty liver disease (NAFLD; 1-5). Furthermore, metformin and its downstream target AMP­
activated protein kinase (AMPK) have been implicated in both anti-apoptotic (6, 7) and pro­
apoptotic (8, 9) actions. Considering this controversy, we examined the effects of metformin 
in bile acid- and cytokine-induced cell death in primary rat hepatocytes. We demonstrate a 
protective effect of metformin against bile acid-induced apoptosis (caspase-3 activation and 
nuclear fragmentation). Our results are in contrast to previous reports describing pro­
apoptotic effects of activated AMPK in liver cells In contrast, anti-apoptotic effects of 
activated AMPK were observed in astrocytes and endothelial cells (10). Apparently, the 
protective effect of metformin is restricted to specific death stimuli and cell types. Previously, 
we have demonstrated that metformin protects against superoxide anion-induced apoptosis 
(Conde de la Rosa L et al: unpublished data), while metformin does not protect against 
TNFa/ActD-mediated apoptosis. Ark5, another AMPK family member, did protect against 
Fas-induced apoptosis in colon carcinoma cells (6). This selectivity of metformin is probably 
due to the use of different signaling pathways by these death stimuli. Similar to Ark5 (6), the 
hepatoprotective effect of metformin requires an intact phosphoinositide-3 kinase (Pl3K)/Akt 
signaling pathway. The important role of Pl3K/Akt signaling In cell survival has been 
demonstrated before in models of apoptosis induced by UV radiation, DNA damage and 
cytokines (11 ). In addition, inhibition of the Pl3K/Akt pathway completely abolished the 
protective effect of tauroursodeoxycholic acid (TUDCA) against GCDCA-induced apoptosis 
(12). The metformin-mediated increased expression of Bel-xi might also be regulated via the 
Pl3K/Akt pathway. Collectively, these data identify the Pl3K/Akt pathway as a key player in 
the regulation of cell survival and hence, an important target for therapeutic intervention. 
Although many papers (13-18) reported downstream effects of metformin on the 
AMPK/mammalian target of rapamycin (mTOR) pathway, in our study, this signaling 
pathway appears to be not involved in the anti-apoptotic actions of metformin. In line with 
this, we observed that metformin only moderately increased AMPK activity, compared to 5-
aminoimidazole-4-carboxamide 1-13-D-ribofuranoside (AICAR), a known potent activator of 
AMPK. 
Important in our study is the observation that metformin does not inhibit NF-KB activity. 
Again, our data are in contrast to several reports describing inhibition of NF-KB by metformin 
via AMPK activation (19, 20). However, these studies also demonstrated the involvement of 
AMPK in metformin signaling, while in our experiments the anti-apoptotic actions of 
metformin are independent of AMPK activity. Since metformin does not affect NF-KB activity, 
and does not sensitize hepatocytes to TNFa-induced cell death, metformin might be a 
promising drug for the treatment of chronic liver diseases accompanied by inflammation 
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(TNFa). In vivo studies, validating the observed in vitro effects of metformin in models 
without insulin-sensitivity, e.g. bile duct ligation (BDL) would help to elucidate the 
hepatoprotective mechanism of metformin and its possible therapeutic applications. 
In chapter 3 of this thesis the protective effect of leflunomide and its active metabolite (A77 
1 726) against bile acid-induced cell death of hepatocytes is described, and we speculate 
about the mechanisms involved in this hepatoprotective effect. Leflunomide is used in the 
treatment of autoimmune diseases, particularly rheumatoid arthritis, because of its anti­
inflammatory, anti-proliferative and immunosuppressive properties (21 -26). In vivo and in 
vitro studies have demonstrated beneficial effects of leflunomide in several models of liver 
damage, including acetaminophen (21 ,  27), concanavalin A (22), bile duct ligation (28) and 
ischemia/reperfusion (1/R) injury (23). In contrast, pro-apoptotic effects of leflunomide have 
been reported in rat thymocytes (29) and breast cancer cells (30). We describe the reduction 
in bile acid-induced apoptosis (caspase-3 and -6 activation, nuclear condensation) and 
necrosis by A77 1 726, while the prodrug leflunomide - used at similar concentrations - had 
no effect. Thus, we confirm previous observations (21 ) demonstrating a 1 00-fold higher 
activity of A 77 1 726 than leflunomide. Although hepatocytes can convert the inactive 
prodrug into the active metabolite, the short duration of the experiments probably precluded 
the generation of sufficient amounts of the active metabolite. A77 1 726 was even protective 
when added after the bile acid, a mechanism described before for TUDCA ( 1 2) and 
indicating a rapid activation of survival pathways by leflunomide. However, our results do not 
support a key role for the anti-apoptotic mitogen-activated protein kinases (MAPK) p38 and 
extracellular signal regulated kinase (ERK) 1 /2 or the Pl3K/Akt survival pathway in the 
hepatoprotective actions of A77 1726. These observations are in contrast to other studies, 
describing inhibitory effects of A77 1 726 on p38 activation (22, 3 1 ,  32) and stimulation of 
ERK1 /2 and Akt activity (32). Furthermore, we did not observe an inhibition of the pro­
apoptotic MAPK member, JNK, by A77 1 726 as has been reported by others (21 , 26, 27, 3 1 , 
32). 
Finally, we show that NF-KB activity is not affected by A77 1 726, which is in line with some 
studies (31 ,  32), but in contrast to others (22, 33, 34). These conflicting results appear to be 
cell type specific. Because A77 1 726 does not inhibit NF-KB activity and hepatocytes are not 
sensitized to TNFa-induced apoptosis by A77 1 726, our results imply that A77 1726 could 
be valuable as therapy for chronic cholestatic liver diseases in the presence of inflammation. 
Since none of the major signaling pathways involved in hepatocyte survival and death is 
implicated in the protective mechanism of leflunomide, we can only speculate about possible 
targets of leflunomide. Recently, members of the Src family of kinases were identified as 
important proteins in hepatocyte death (35, 36). Moreover, leflunomide was shown to block 
the activity of some specific Src family members in T-cells (34, 37, 38). In chapter 4, we 
describe a similar effect of a specific Src-inhibitor on bile acid-induced cell death as 
observed with A77 1 726 in this study. Therefore, we speculate that the Src kinases can be a 
potential target for A77 1 726. Additional experiments are required to study this hypothesis in 
more detail. 
Although reports have described effects of leflunomide in acute and chronic liver injury (21 -
23, 27, 28), in our study A77 1 726 was ineffective in the protection against menadione or 
TNFa/ActD-induced apoptosis of hepatocytes. Again, this could be related to the activation 
of different signaling pathways by these death stimuli. 
Chapter 4 examines the role of reactive oxygen species in bile acid-induced cell death. 
Previous studies have reported contradictory information concerning the role of reactive 
oxygen species (ROS) in bile acid-induced hepatocyte death. The majority of studies have 
described increased ROS production in response to bile acid exposure (39-43). However, it 
is not clear whether bile acid-induced ROS generation contributes to hepatocyte cell death. 
Although ROS generation is diminished by antioxidants, the correlation with bile acid-
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induced cell injury is not always observed (39-41, 44-46). According to Reinehr et al (36, 4 7), 
bile acids activate the membrane-associated enzyme nicotinamide adenine dinucleotide 
phosphate (NADPH)-oxidase, which generates ROS. Subsequently, ROS activate the Src 
kinase family member Yes. Activated Yes facilitates the activation of Fas, death inducing 
signaling complex (DISC) formation and apoptosis. 
We demonstrate that ROS are not critical for bile acid induced cell death. Bile acid exposure 
neither depletes glutathione nor induces the oxidative stress responsive gene heme­
oxygenase-1 (HO-1 ). Secondly, ROS scavengers and various antioxidants do not reduce 
bile acid-induced apoptosis. Finally, although inhibition of NADPH-oxidase reduces GCDCA­
induced apoptosis, necrosis is strongly induced. In addition, the involvement of the Src 
kinase family member Yes in bile acid-induced cell death was confirmed using the Src­
inhibitor SU6656. 
Our results strongly argue against a role for reactive oxygen species in bile acid-induced 
hepatocyte apoptosis. Our observations are in agreement with a recent study (41) describing 
complete abrogation of GCDCA-induced apoptosis by caspase-8 inhibition, while ROS 
generation was only partially reduced. This indicates a weak or no correlation between ROS 
generation and cell death. A possible explanation for these contradictory results is that bile 
acids at concentrations below 100 µmol/L generate low levels of ROS, as has been shown in 
many studies, which are insufficient to induce oxidative stress accompanied by HO-1 
induction and glutathione depletion. Thus ROS are not causally involved in apoptotic cell 
death. Higher concentrations of bile acids (above 200 µmol/L) might generate high levels of 
ROS, which are accompanied by oxidative stress and necrotic rather than apoptotic cell 
death. 
Hence, future experiments should focus on the role of ROS in the toxicity of high 
concentrations of bile acids and the involvement of ROS generation in cholestatic liver 
diseases. These studies are also important to establish the value of antioxidant therapy in 
cholestatic liver diseases. 
In chapter 5 we study the protective effects of HO-1 and carbon monoxide (CO) against 
oxidative stress-induced apoptosis. ROS are key players in many liver diseases like non­
alcoholic steatohepatitis (NASH). We demonstrate the induction of HO-1 in an in vivo model 
of cholestatic liver injury, but not in acute inflammation. The lack of HO-1 induction in acute 
inflammation might be the result of sufficient levels of reduced glutathione. Indeed, the 
glutathione level controls the balance between the NF-KB (inflammation) and AP-1 (oxidative 
stress) regulated stress-response (48-50). Glutathione depletion in the model of acute 
inflammation leads to a shift from the NF-KB response (iNOS induction) to the AP-1 
response (HO-1 induction). Superoxide anions, but not hydrogen peroxide, induce HO-1 
induction and overexpression of HO-1 protects hepatocytes against superoxide anion­
induced apoptosis. The anti-apoptotic action of HO-1 is, at least in part, due to one of the 
products of HO-1, CO. These observations are in line with previous studies describing 
cytoprotective effects of CO both in hepatocytes (51, 52) and in other cell types (50, 53, 54), 
although pro-apoptotic actions of CO have also been observed (55, 56). In our study, the 
anti-apoptotic effects of CO are the result of direct inhibition of the pro-apoptotic MAPK 
member JNK, similar as described in a model of sepsis (57). CO did not modulate NF-KB 
activation, as has been described before (52). Our data demonstrate protection of HO-1 and 
one of its products, CO, against superoxide anion-induced apoptosis. These compounds, as 
well as other HO-1 products (e.g. biliverdin), might be potential therapeutic targets in 
oxidative stress-related liver injury. 
In chapter 6 a novel approach to study cholestasis in vitro is described. Most patients with 
chronic liver injury, including cholestatic liver diseases, start treatment when the disease 
becomes clinically manifest and is already well advanced. Therefore any therapeutic 
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intervention should be aimed at 'diseased' (e.g. cholestatic) hepatocytes and not normal 
'healthy' hepatocytes. Likewise, mechanisms of cell death should be studied in 'diseased' 
hepatocytes. Thus, studying the signaling pathways involved in hepatocyte death in 
cholestatic liver injury is crucial. Only a few papers described the use of primary hepatocytes 
isolated from cholestatic rats (58, 59). In this study, we compare the phenotype of primary 
hepatocytes isolated from bile duct ligated rats and sham-operated rats. The cholestatic 
phenotype observed in vivo after BDL, i.e. decreased expression of Na+/taurocholate 
cotransporting polypeptide (Ntcp) the basolateral transporter involved in the uptake of bile 
acids and multidrug resistance-associated protein (Mrp) 2, responsible for the bile acid 
secretion into bile at the canalicular membrane and increased expression of Mrp3, which 
secretes bile acids and organic anions from the hepatocytes into the sinusoids (reverse 
transport), is maintained in hepatocytes both directly after isolation and during the time of 
culture. The effects on transporters in our primary cholestatic hepatocytes are in agreement 
with previous reports (60-63) describing similar transporter regulation in patients and animals 
with cholestatic disorders. Hence, we demonstrate that hepatocytes retain the cholestatic 
phenotype during the timeframe of our experiments. Furthermore, our preliminary results 
suggest that cholestatic hepatocytes are less sensitive to bile acid-induced apoptosis. 
Although cholestatic control hepatocytes demonstrate increased levels of apoptosis and 
necrosis, no additional induction of cell death by bile acids was observed. Increased 
resistance of cholestatic and cirrhotic livers to apoptosis induced by different stimuli, 
including 1/R injury, TNFa and transforming growth factor (TGF) 13 has been described (64, 
65) and is in accordance with our observations. A possible explanation for the observed 
resistance to bile acid-induced apoptosis is the diminished uptake of conjugated bile acids 
into the cholestatic hepatocyte due to the absence of Ntcp at the plasma membrane. 
Our preliminary data demonstrate the validity of our in vitro system to study cholestasis in 
primary hepatocytes. Future experiments will focus on the signaling mechanisms in 
cholestatic hepatocytes and the response of these cells to therapeutic drugs. 
Conclusions 
New therapies for liver diseases can only be discovered via firm knowledge of the signaling 
mechanisms contributing to the death and survival of hepatocytes during liver damage. This 
thesis describes the protective mechanism of metformin and leflunomide against bile acid­
induced cell death. Our analysis and modulation of pathways involved in bile acid signaling 
has provided more insight in the role of oxidative stress in bile acid-induced apoptosis. In 
addition, we have examined a novel approach to study signaling pathways in cholestatic 
hepatocytes in vitro. In the future, this new technique will provide a better understanding of 
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De lever is verantwoordelijk voor verschillende functies, waaronder het metabolisme van 
(toxische) stoffen en geneesmiddelen, de productie en secretie van gal, de synthese van 
eiwitten en vetten, het metabolisme van koolhydraten (b.v. gluconeogenese) en de opslag 
van metabolieten. De meeste functies warden uitgevoerd door de parenchymcellen of 
hepatocyten. Hepatocyten hebben onderling contact nodig voor het optimaal vervullen van 
hun taken, en zijn daarom gerangschikt in zogeheten platen. Naast de hepatocyten vinden 
we in de lever endotheelcellen, die de sinusorden vormen, Kupffer cellen en stellaatcellen. 
Endotheelcellen zijn betrokken bij de immuunresponse en de uitwisseling van stoffen tussen 
bloed en lever. De Kupffer cellen zijn leverspecifieke macrofagen, die deel uitmaken van het 
afweersysteem en de stellaatcellen zorgen voor de opslag van vitamine A en voor de 
productie van extracel lulaire matrix. Tussen de hepatocyten bevinden zich de galkanaaltjes. 
Deze vertakken zich via de kanalen van Hering en eindigen in de galgangen. Dit netwerk 
van vertakkende galkanalen heet het galgangstelsel of galwegsysteem. 
Gal bestaat voor het grootste deel uit water. Daarnaast bevat gal galzouten, fosfolipiden, 
cholesterol, glutathion (conjugaten) en metabolieten. Galzouten warden gesynthetiseerd in 
de lever, waarna actieve secretie van galzouten in de galkanaaltjes plaatsvindt. In de lever 
warden galzouten geconjugeerd met glycine of taurine, zodat ze efficient getransporteerd 
kunnen warden in de enterohepatische kringloop. De meerderheid van galzouten (90%) 
wordt na passage in de dunne darm gereabsorbeerd in het terminale ileum. Het resterende 
deel gaat verloren via de faeces, hetgeen gecompenseerd wordt middels de novo synthese 
van galzouten (primaire galzouten) uit cholesterol in hepatocyten. Twee routes voor galzout 
synthese zijn bekend, de 'neutrale' of klassieke route (meest voorkomend) en de 'zure' of 
alternatieve weg. Beide routes resulteren in de productie van cholzuur en 
chenodeoxycholzuur en specifieke leden van de cytochrome P450 enzym familie zijn nodig 
voor de galzoutsynthese. In de darm warden de primaire galzouten omgezet in de 
secundaire galzouten deoxycholzuur en lithocholzuur door bacterien. 
De enterohepatische kringloop is het permanente transport van galzouten tussen de lever 
en de darm. Galzouten hebben meerdere functies, cholesterol wordt verwijderd uit de lever 
via de de novo synthese van galzouten in hepatocyten en via de inbouw in micellen. In de 
darm zorgt gal voor de absorptie van vetten, cholesterol en vet-oplosbare vitamines. 
Daarnaast activeren galzouten verschillende signaal transductie routes in de darmen (en 
lever). De enterohepatische kringloop is dan oak een belangrijk proces voor de vorming van 
gal en de homeostase van gal, vetten en cholesterol. De enterohepatische kringloop begint 
bij de hepatocyten. Aan het basolaterale membraaan nemen hepatocyten galzouten op uit 
het bloed via de transport eiwitten Ntcp en Oatp's. Na intracellulair transport warden de 
galzouten aan het canaliculaire membraan in de gal uitgescheiden via de transport eiwitten 
Bsep en Mrp2. Andere transport eiwitten zorgen ervoor dat cholesterol en fosfolipiden in de 
gal terechtkomen, waarna micellen uit galzouten, cholesterol en fosfolipiden warden 
gevormd. Na passage door het galgangstelsel, waar een deel van de galzouten 
geabsorbeerd wordt, vindt opslag van gal plaats in de galblaas. De galblaas contraheert in 
respons op voedsel, waardoor gal in de dunne darm wordt gepompt. In het ileum warden 
eveneens galzouten geabsorbeerd, die via verschillende transporters naar het bloed warden 
vervoerd. Via het bloed komen de galzouten terug in de lever waar ze weer over het 
basolaterale membraan van de hepatocyten getransporteerd warden door Ntcp en Oatp's. 
Veel leveraandoeningen warden veroorzaakt door verstoringen in de enterohepatische 
kringloop, welke resulteren in celdood en leverschade. Twee vormen van celdood warden 
beschreven in dit proefschrift, apoptose en necrose. Apoptose of geprogrammeerde celdood 
is een energie afhankelijk proces, waarbij bepaalde enzymen, de caspases, betrokken zijn. 
Apoptotische cellen warden gekenmerkt door condenserende kernen en verschrompeling en 
fragmentatie van de eel tot apoptotische lichamen, waarbij de plasmamembranen intact 
blijven. Deze celfragmenten warden efficient verwijderd door fagocyterende cellen. Hierdoor 
treedt minimale ontsteking op. Caspases warden verdeeld in twee categorieen: caspases 
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die een rol spelen bij het 'starten' van de apoptotische route (caspases 8, 9 en 1 0) en 
caspases die betrokken zijn bij het eind van het apoptotische proces (caspases 3, 6 en 7). 
Er bestaan twee apoptotische routes, de extrensieke en de intrinsieke route. De extrensieke 
weg wordt ge"initieerd door de binding van een ligand aan receptoren op de celmembraan 
(b.v. tumor necrose factor, TNF) en de intrinsieke route wordt ge"induceerd door een 
stressprikkel in de eel (b.v. oxidatieve stress) en begint in een celorganel (b.v. 
mitochondrien, kern of endoplasmatisch reticulum). Seide routes leiden tot de activatie van 
caspases. Verschillende factoren zoals cytokines, oxidatieve stress en DNA schade kunnen 
apoptose induceren. 
Necrose is een passieve vorm van celdood. Mitochondriele en cellulaire zwelling 
veroorzaakt lekkage van het plasma membraan, waarna de cellulaire inhoud vrijkomt in de 
circulatie. Hierdoor wordt een ontstekingsrespons uitgelokt. In tegenstelling tot apoptose is 
necrose een veel minder gestructureerde vorm van celdood. Bij de meeste 
leveraandoeningen wordt celschade gekenmerkt door een combinatie van apoptose en 
necrose. 
Tijdens cellulaire stress neemt de productie van vrije zuurstof radicalen (o.a. waterstof 
peroxide en superoxide anionen) dusdanig toe, dat de eel niet meer in staat is om deze vrije 
zuurstof radicalen te ontgiften. Dit verschijnsel wordt oxidatieve stress genoemd. Condities 
die gepaard gaan met oxidatieve stress zijn o.a. veroudering, alcohol metabolisme en 
ontsteking. Hepatocyten beschikken over verschillende afweermechanismen tegen 
oxidatieve stress: de superoxide dismutase enzym familie, catalase, glutathion-peroxidases, 
gereduceerd glutathion en vitamines. Ook pro-oxidatie systemen zijn aanwezig zoals 
NADPH oxidase (generatie van superoxide anionen) en xanthine oxidase. Vrije zuurstof 
radicalen worden gegenereerd in zowel acute als chronische leveraandoeningen. Een 
voorbeeld van een leverziekte die gepaard gaat met oxidatieve stress is niet-alcoholische 
steatohepatitis (NASH). 
Verschillende signaal transductie routes die betrokken zijn bij celdood en eel overleving zijn 
in dit proefschrift bestudeerd, waaronder fosfoinositide-3 kinase (Pl3K), mitogeen­
geactiveerde proteine kinases (MAPK), de Src tyrosine kinase familie en de transcriptie 
factor NF-KB. De Pl3K route is een bekende overlevingsroute in cellen vooral via effecten op 
het prote"ine kinase B (PKB)/Akt. De bescherming van het anti-apoptotische galzout 
tauroursodeoxycholzuur (TUDCA) tegen glycochenodeoxycholzuur (GCDCA)-ge"induceerde 
apoptose bleek veroorzaakt te zijn door effecten van TUDCA op Pl3K. De MAPK familie is 
onderverdeeld in pro- en anti-apoptotische eiwitten. Het pro-apoptotische JNK is belangrijk 
voor de inductie van apoptose, terwijl ERK1 /2 en p38 bekend staan als anti-apoptotische 
eiwitten. Remming van JNK resulteert in vermindering van apoptose door galzouten en 
oxidatieve stress. Terwijl remming van ERK1 /2 en p38 zorgde voor een afname van het 
beschermend effect van het anti-apoptotische galzout TUDCA. Recent is aangetoond dat 
specifieke leden van de Src familie een belangrijke rol spelen bij celdood veroorzaakt door 
cytokines en galzouten. In dit proefschrift is de rol van het Src kinase familielid Yes 
beschreven in galzout-ge"induceerde celdood. De transcriptie factor NF-KB reguleert zowel 
pro- als anti-apoptotische genen. NF-KB-gereguleerde genen zijn onder andere cytokines, 
superoxide dismutases en anti-apoptotische leden van de Bcl-2 familie. NF-KB activatie 
wordt bepaald door veel factoren waaronder JNK en Pl3K/Akt. 
Dit proefschrift beschrijft de mechanismen van celdood tijdens leverziekten en de 
mogelijkheden voor preventie van deze celdood. In leveraandoeningen spelen galzouten, 
oxidatieve stress en cytokines een belangrijke rol bij celschade en celdood van hepatocyten. 
Galzouten spelen een cruciale rol bij acute en chronische cholestase, een aandoening die 
beschreven wordt als een verstoorde enterohepatische kringloop waardoor accumulatie van 
galzouten in bloed en lever optreedt. Dit kan veroorzaakt worden door een genetisch defect, 
geneesmiddelen, immunologische of mechanische schade (obstructie a.g.v. tumor of 
galstenen). Vrije zuurstof radicalen zijn belangrijk bij alcohol-gerelateerde leverschade en 
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NASH. Cytokines spelen een rol bij vrijwel elke vorm van leverschade, maar zijn specifieke 
veroorzakers van acuut leverfalen en acute hepatitis. De meeste chronische leverziekten 
verlopen van fibrose via cirrose en eindigen in leverfalen. De enige effectieve remedie bij 
leverfalen is een levertransplantatie. Geneesmiddelen die warden toegepast bij 
leveraandoeningen zijn onder andere ursodeoxycholzuur (UDCA, cholestase) en insuline­
gevoeligheid verhogende middelen als metformine (NASH). Helaas zijn deze middelen niet 
altijd effectief, waardoor de ziekte zich verder kan ontwikkelen en uiteindelijk een 
transplantatie nodig is. Het is dan oak van zeer groat belang om kennis te hebben van de 
mechanismen die de leveraandoening veroorzaken, zodat nieuwe mogelijkheden voor 
ingrijpen en potentiele geneesmiddelen bestudeerd kunnen warden. 
In dit proefschrift is onderzoek gedaan naar drie verschillende in vitro modellen van 
leverschade. Ten eerste het toxische galzout GCDCA als model voor acute galzout schade. 
GCDCA induceert zowel apoptose als necrose in hepatocyten. Ten tweede het cytokine 
TNF, een model voor acuut leverfalen gekenmerkt door apoptose. Als derde is de 
superoxide anion donor menadione gebruikt als model voor oxidatieve stress-ge"induceerde 
apoptose. 
In hoofdstuk 2 wordt de beschermende werking van het anti-diabetische geneesmiddel 
metformine in galzout-ge"induceerde celdood beschreven. Naast de positieve effecten van 
metformine op de insuline-gevoeligheid in patienten met Diabetes type I I ,  heeft metformine 
oak gunstige effecten op merkers voor leverschade bij patienten en diermodellen voor 
steatotische leverziekten. Een bekende effector van metformine is AMP-geactiveerd 
prote"ine kinase (AMPK), de energie sensor van de cellen. AMPK wordt geactiveerd door 
veranderingen in de energie huishouding (AMP:ATP ratio), maar oak door bijvoorbeeld 
farmacologische middelen of tijdens condities van cellulaire stress. AMPK veroorzaakt zijn 
effecten a.a. via mTOR (mammalian target of rapamycin), een kinase dat betrokken is bij 
transcriptie, translatie en eiwit synthese. 
Onze studie toont aan dat metformine dosis-afhankelijk beschermt tegen GCDCA· 
ge"induceerde apoptose in ge"isoleerde rat hepatocyten, zonder een effect te hebben op 
necrotische celdood. Metformine biedt geen bescherming in ons model voor acuut leverfalen 
(TNFa in combinatie met de transcriptie remmer actinomycine D). Metformine is in staat om 
apoptose le remmen tot 2 uur na toevoeging van het galzout. De bescherming van 
metformine is niet het gevolg van een verminderde galzout opname in de hepatocyten door 
transporter eiwitten. De bescherming van metformine moet daarom afhankelijk zijn van een 
snelle activatie van signaaltransductie routes, zoals de Pl3K/Akt overlevingsroute: het 
beschermend effect van metformine is afhankelijk van een functionerende PI3K/Akt 
overlevingsroute. De bescherming is onafhankelijk van de bekende effector route van 
metformine, A MPK/mTOR. De verschillende leden van de MAPK familie, zowel pro- als anti­
apoptotisch, zijn eveneens niet betrokken bij het beschermend effect van metformine. 
Metformine heeft oak geen remmend effect op de transcriptie factor NF-KB. Dit laatste 
resultaat is erg belangrijk, omdat metformine hierdoor mogelijk toepasbaar is in 
cholestatische leverziekten die gepaard gaan met ontsteking. 
Hoofdstuk 3 beschrijft de bescherming van leflunomide tegen galzout-ge"induceerde 
celdood in ge"isoleerde rat hepatocyten. Leflunomide is een geneesmiddel voor de 
behandeling van auto-immuunziekten, o.a. rheumato"ide artritis. Daarnaast wordt leflunomide 
toegepast als therapie bij de ziekte van Crohn en kanker. Leflunomide is een zogeheten 
'prodrug':  in het lichaam wordt leflunomide voor ongeveer 95% omgezet in de actieve 
metaboliet A77 1726. Verscheidene effecten van leflunomide en de actieve metaboliet zijn 
beschreven in de literatuur waaronder remmende effecten op tyrosine kinases, pro­
apoptotische MAPK leden en cytokine productie via effecten op NF-KB. Bovendien is van 
beide stoffen bekend dat ze in experimentele modellen levercellen beschermen tegen 
schade veroorzaakt door onder andere paracetamol, concanavalin A (model voor immuun­
gemedieerde hepatitis) en galgang ligatie (model voor cholestase, BDL). Er zijn echter oak 
celdood stimulerende effecten voor beide stoffen beschreven, echter wel in andere celtypes. 
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Ons onderzoek toont aan dat de actieve metaboliet, A77 1726, primaire rat hepatocyten 
beschermt tegen GCDCA-ge"induceerde apoptose en necrose, maar geen bescherming 
biedt tegen apoptose ge"induceerd door cytokines of oxidatieve stress. Het mechanisme 
achter de anti-apoptotische effecten van leflunomide blijft onbekend. Onze resultaten laten 
duidelijk zien dat de bescherming niet veroorzaakt wordt via de anti-apoptotische MAP 
kinases p38 en ERK1/2 of via de Pl3K/Akt signaal transductie route. Aangezien A77 1726 
eenzelfde resultaat veroorzaakt op galzout-ge"induceerde celdood als een farmacologische 
remmer van de Src-kinases, impliceren onze resultaten dat A77 1726 mogelijk een Src­
kinase remmer is. Vervolgonderzoeken zijn nodig om deze suggestie te kunnen 
onderbouwen. Het feit dat leflunomide geen remmend effect heeft op NF-KB impliceert dat 
deze stof toepasbaar is bij leverziekten waarbij ontsteking een rol speelt. In vivo studies zijn 
nodig om onze in vitro resultaten te onderbouwen. 
In hoofdstuk 4 van dit proefschrift word! de rot van vrije zuurstof radicalen in galzout­
ge"induceerde celdood van hepatocyten nader onderzocht. Verschillende studies beschrijven 
een rot voor oxidatieve stress in galzout-ge"induceerde celdood en de bescherming 
hiertegen middels anti-oxidanten. Andere publicaties tonen echter aan dat er een gering of 
zelfs geen verband bestaat tussen galzout-ge"induceerde productie van vrije zuurstof 
radicalen en celdood. In ons onderzoek zijn de mechanismen van twee verschillende 
toxische galzouten, GCDCA en taurolithocholzuur 3-sulfaat {TLCS), bestudeerd. 
Verschillende anti-oxidanten en 'wegvangers' van vrije zuurstof radicalen veroorzaakten 
geen afname in celdood ge"induceerd door deze galzouten. GCDCA en TLCS zorgden ook 
niet voor een inductie van het oxidatieve stress gevoelige gen HO-1 of een reductie van de 
totale glutathion spiegels in de hepatocyten. Tezamen suggereren deze bevindingen dat 
oxidatieve stress niet noodzakelijk is voor galzout-ge"induceerde celdood. De specifieke Src­
remmer SU6656 bood wel bescherming tegen GCDCA-ge"induceerde celdood, zowel tegen 
apoptose als necrose. Oak remming van het enzym NADPH oxidase, welke vrije zuurstof 
radicalen vormt, resulteerde in een sterke afname van galzout-ge"induceerde apoptose. 
Deze reductie ging echter gepaard met een significante toename van necrose in 
hepatocyten. Een vergelijkbaar fenomeen -de verschuiving van apoptose naar necrose- is 
eerder waargenomen met de stikstofmonoxide donor SNAP in combinatie met de 
superoxide anion donor menadione. Onze resultaten suggereren dat de generatie van vrije 
zuurstof radicalen door galzouten geen essentiele rot speelt in galzout-ge"induceerde 
apoptose, maar dat de Src-kinases, met name Yes, hierbij wel een cruciale rot spelen. 
Hoofdstuk 5 beschrijft de beschermende rol van het enzym HO- 1 en een van de producten 
van dit enzym, koolstofmonoxide (CO), in verschillende in vivo en in vitro modellen van 
leverschade. Het oxidatieve stress-gevoelige gen HO-1 is ge"induceerd na galgang ligatie, 
een in vivo model voor chronische cholestase, terwijl er geen effect op HO-1 waarneembaar 
is in een in vivo model voor acute ontsteking. In in vitro experimenten induceerde de 
superoxide anion donor menadione HO-1, terwijl waterstof peroxide en cytokines niet 
resulteerden in verhoogde HO-1 expressie in hepatocyten. Overexpressie van HO-1 
vermindert menadione-ge"induceerde apoptose, hetgeen deels veroorzaakt wordt door 
koolstofmonoxide. De anti-apoptotische werking van koolstofmonoxide is het gevolg van een 
directe remming van de pro-apoptotische MAP kinase JNK. Een vergelijkbaar effect van 
koolstofmonoxide op JNK activatie is beschreven in een model voor sepsis. Uit dit 
onderzoek kunnen we concluderen dat HO-1 en koolstofmonoxide, maar mogelijk ook 
andere HO-1 producten zoals biliverdine, potentiele therapeutische opties zijn voor de 
behandeling van oxidatieve stress-gerelateerde leverschade. 
Patienten met leveraandoeningen beginnen meestal met een therapie als de symptomen 
merkbaar worden, terwijl de ziekte dan vaak al langere tijd aanwezig is. Het is dan ook 
belangrijk om onderzoek te doen naar reeds beschadigde levercellen en de 
werkingsmechanismen in deze cellen te bestuderen. Aangezien nog veel onderzoek naar 
leverschade wordt uitgevoerd met normale 'gezonde' cellen beschrijft hoofdstuk 6 van dit 
proefschrift de toepassing van cholestatische hepatocyten in in vitro experimenten. 
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Hepatocyten werden geTsoleerd uit proefdieren die een galgang ligatie (1 week) hadden 
ondergaan. Ten opzichte van hepatocyten ge"isoleerd uit controle proefdieren hadden de 
cholestatische hepatocyten een verminderde vitaliteit en was de opbrengst van de cellen 
verlaagd. Direct na isolatie en tijdens experimenten werd het fenotype van de cholestatische 
hepatocyten vergeleken met de normale hepatocyten. Zoals beschreven in de literatuur, is 
de expressie van de transporter eiwitten Ntcp en Mrp2 verlaagd in cholestatische 
hepatocyten, terwijl de expressie van Mrp3 juist verhoogd is. Deze expressie patronen 
blijven gehandhaafd gedurende de experimenten (8 uur). De cholestatische hepatocyten 
behouden dus hun fenotype. Preliminaire resultaten suggereren dat cholestatische 
hepatocyten minder gevoelig zijn voor galzout-ge"induceerde celdood. GCDCA induceert 
apoptose en necrose in normale hepatocyten, maar in cholestatische hepatocyten is, 
ondanks de lagere vitaliteit van de cellen, geen verschil met de ongestimuleerde cellen waar 
te nemen. Een verklaring h iervoor zou kunnen zijn dat cholestatische hepatocyten -door de 
verlaagde expressie van Ntcp- niet meer in staat zijn om galzouten op te nemen. Uitgebreid 
onderzoek is vereist om deze ongevoeligheid en het mechanisme hiervan in cholestatische 
hepatocyten in detail te bestuderen. Het hier beschreven en gevalideerde in vitro model voor 
cholestase is een belangrijk middel voor deze toekomstige studies. 
Conclusie 
Het ophelderen van de rol van de verschillende signaal transductie routes die betrokken zijn 
bij de dood van hepatocyten bij verschillende leverziekten is noodzakelijk voor de 
ontwikkeling van nieuwe therapieen voor de behandeling van deze ziekten. In dit proefschrift 
worden de beschermende effecten van metformine en leflunomide tegen galzout­
ge"induceerde celdood in vitro beschreven. Met deze onderzoeken is een begin gemaakt 
aan de mogelijke toepassing van metformine en leflunomide bij cholestatische leverziekten. 
Daarnaast heeft ons onderzoek naar de mechanismen van galzout-ge"induceerde celdood 
meer kennis opgeleverd over de rol van oxidatieve stress in dit proces. Als laatste hebben 
we een nieuwe opzet voor het bestuderen van cholestatische hepatocyten in vitro 
beschreven. Deze techniek zal in de toekomst bijdragen aan de kennis over de 
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Het is al weer even geleden dat ik vanuit het bacterie onderzoek bij Farmaceutische Biologie 
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het lab Maag Darm en Leverziekten (MDL), hetgeen zonder mijn collega's niet gelukt was. 
Han, eerst als begeleider en later als promotor ben je altijd erg betrokken geweest bij mijn 
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proefschrift gezorgd. lk heb de afgelopen jaren veel van je kunnen leren, en waardeer je 
wetenschappelijke inzichten enorm. Ook jouw 'maffe' feitenkennis en bizarre verhalen, 
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stand altijd voor me open. 
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Uwe, Vincent, Wietze, Yan en iedereen die ik nog vergeten ben heel erg bedankt voor de 
gezellige jaren op het lab. 
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